Semi-synthetic proteins for catalytic and analytical applications by Huettinger, Karl



























In Partial Fulfillment 
of the Requirements for the Degree 



























Dr. Christoph J. Fahrni, Advisor   Dr. Andreas S. Bommarius 
School of Chemistry and Biochemistry School of Chemical and Biomolecular 
Engineering  
Georgia Institute of Technology  Georgia Institute of Technology 
 
 
Dr. Angus P. Wilkinson   Dr. Z. John Zhang 
School of Chemistry and Biochemistry School of Chemistry and Biochemistry 
Georgia Institute of Technology  Georgia Institute of Technology 
 
Dr. James A. Mulholland 
School of Civil & Environmental Engineering 
Georgia Institute of Technology 
       
      Date Approved: January 23, 2009 





 I would like to thank Dr. Christoph J. Fahrni for his guidance during my graduate 
studies at Georgia Tech. I would also like to thank Reagan McRae for her help on 
biological experiments but especially for her moral support and friendship. Moreover, I 
would like to thank Dr. Subrata Mandal, Dr. Yonggang Wu, Dr. John Cody and all others 
who worked in this group. Sybille Krause helped me to get into Georgia Tech and the 
importance of her support cannot be underestimated. I am very grateful for the constant 
support and trust of my family despite being separated by the Atlantic Ocean. Through 
my experiences in graduate school, I have finally learned to understand the true 
meaning of the following Latin saying that I memorized a long time ago: 
 









TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................. iii 
LIST OF TABLES ......................................................................................................... xiv 
LIST OF FIGURES ........................................................................................................ xv 
LIST OF SYMBOLS AND ABBREVIATIONS ............................................................... xxv 
Chapter I 
INTRODUCTION .............................................................................................................1 
1.1 Semi-Synthetic Proteins for Catalytic Applications .................................................1 
1.1.1 Green Chemistry and Its Importance ...............................................................1 
1.1.2 Reactions in Aqueous Media ...........................................................................2 
1.1.3 Organometallic Reactions in Water by Small Molecule Catalysts.....................6 
1.1.4 Enantioselective Organometallic Reactions in Water by Small Molecule 
Catalysts ..................................................................................................................8 
1.1.5 Enzymes and Enzyme Mimics .........................................................................9 
1.1.6 Semi-Synthetic Proteins for Catalysis ............................................................11 
1.2 Semi-Synthetic Proteins for Analytical Applications ..............................................20 
1.2.1 Copper, Iron and Zinc in Biology ....................................................................20 
v 
 
1.2.2 Homeostasis of Copper, Iron an Zinc .............................................................20 
1.2.3 Labile Pools of Copper, Iron and Zinc ............................................................21 
1.2.4 Chemical Sensing of Metal Ions with Small Molecule Fluorescent Probes .....22 
1.2.5 Green Fluorescent Protein – A Vital Tool for Cell Imaging Applications .........25 
1.2.6 Signal Peptides..............................................................................................27 
1.2.7 Cell Imaging by FRET and FLIM ....................................................................28 
1.2.8 Protein Labeling for In Vivo Cell Studies ........................................................30 
1.2.8.1 Biarsenical Tetracysteine System ...........................................................31 
1.2.8.2 Protein Splicing and Trans-Splicing .........................................................32 
1.2.8.3 Expressed Protein Ligation .....................................................................34 
1.2.8.4 Human Alkylguanine Transferase ...........................................................35 
1.2.8.5 Other Labeling Methods for In Vivo Cell Imaging Applications.................35 
1.3 Thesis Objective ..................................................................................................36 
1.4 References ..........................................................................................................38 
Chapter II 
CHARACTERIZATION OF RUTHENIUM PORPHYRINS AS WATER-SOLUBLE 
ORGANOMETALLIC CATALYSTS ...............................................................................54 
2.1 Introduction and Concept .....................................................................................54 
vi 
 
2.1.1 Semi-Synthetic Protein Designs Based on Incorporation of Cofactors ...........55 
2.1.2 Selection of Platinum Metal in Cofactor .........................................................57 
2.1.3 Selection of Model Reaction ..........................................................................57 
2.1.4 Selection of a Suitable Ruthenium Porphyrin for Aqueous Cyclopropanation 
Model Reactions .....................................................................................................59 
2.2 Synthesis .............................................................................................................60 
2.3 Model Cyclopropanation Reactions in Aqueous Medium ......................................62 
2.3.1 Selection of Reaction Conditions ...................................................................62 
2.3.2 Analysis of the Model Cyclopropanation by GC-MS .......................................63 
2.3.3 Quantitation by GC-FID .................................................................................65 
2.3.4 Influence of the pH on the Cyclopropanation Reaction in Aqueous Medium ..68 
2.3.4.1 Mass Balance of Reaction .......................................................................73 
2.3.4.2 Stereoselectivity of Reaction ...................................................................74 
2.3.5 Phase Transfer Catalysis ...............................................................................76 
2.3.6 Reagent Addition Time Studies .....................................................................77 
2.3.7 Concentration Dependent Turnover Numbers ...............................................78 
2.4 Reaction Kinetics .................................................................................................80 
2.4.1 Catalytic Cycle ...............................................................................................80 
vii 
 
2.4.2 Kinetics of Carbene Formation ......................................................................81 
2.4.3 Kinetics of Reaction of Carbene-Complex with Styrene .................................83 
2.4.4 Kinetics of Decomposition of EDA in water ....................................................83 
2.5 Examination of Reaction Mechanism ...................................................................86 
2.5.1 Generation of Carbene-Complex in D2O ........................................................86 
2.5.2 Generation of carbene complex in C6D6.........................................................91 
2.5.3 Influence of Axial Ligands on Carbene Formation ..........................................94 
2.5.4 Examination of the Reaction of Lewis Bases with Ruthenium Carbonyl 
Porphyrins ..............................................................................................................99 
2.6 Conclusion ......................................................................................................... 102 
2.7 Experimental Section ......................................................................................... 103 
2.7.1 Materials and Reagents ............................................................................... 103 
2.7.2 Synthesis ..................................................................................................... 103 
2.7.3 GC-FID and GC-MS .................................................................................... 105 
2.7.4 Model Cyclopropanation Reaction for Analysis by GC ................................. 105 
2.7.5 Standardization of Analytes with Internal Standard by GC-FID and 
Quantitation .......................................................................................................... 105 
2.7.6 Influence of pH on Cyclopropanation Reactions .......................................... 106 
viii 
 
2.7.7 Phase Transfer Catalysis ............................................................................. 106 
2.7.8 Reagent Addition Time Studies ................................................................... 107 
2.7.9 Concentration Dependent Turnover Numbers ............................................. 107 
2.7.10 Kinetics of Carbene Formation .................................................................. 107 
2.7.11 Kinetics of Decomposition of EDA in water ................................................ 107 
2.7.12 Generation of Carbene Complex in D2O .................................................... 108 
2.7.13 Generation of Carbene Complex in C6D6 ................................................... 108 
2.7.14 Influence of Axial Ligands on Carbene Formation ...................................... 108 
2.7.15 Examination of the Reaction of Lewis Bases with Ruthenium Carbonyl 
Porphyrins ............................................................................................................ 109 
2.8 References ........................................................................................................ 110 
Chapter III 
CHARACTERIZATION OF RECONSTITUTED SEMI-SYNTHETIC PROTEINS AS 
CYCLOPROPANATION CATALYSTS......................................................................... 116 
3.1 Introduction ........................................................................................................ 116 
3.1.1 Selection of Heme Protein ........................................................................... 116 
3.1.2 Selection of Synthetic Cofactor .................................................................... 120 
3.2 Synthesis of Cofactor ......................................................................................... 120 
ix 
 
3.3 Characterization of Native Myoglobin Reconstituted with Ru(CO)MPIX ............. 123 
3.3.1 Reconstitution of Native Myoglobin .............................................................. 123 
3.3.2 Cyclopropanation Using Myoglobin Reconstituted with Ru(CO)MPIX as 
Catalyst ................................................................................................................ 126 
3.3.3 The Influence of Imidazole on the Catalyst Activity of Ru(CO)MPIX ............ 127 
3.3.3.1 Analysis by UV-vis Spectroscopy .......................................................... 127 
3.3.3.2 Analysis by Gas Chromatography ......................................................... 129 
3.4 Cobalt Porphyrins as Alternatives to Ruthenium Porphyrins ............................... 130 
3.4.1 Selection of Cobalt Porphyrins as Cyclopropanation Catalysts .................... 130 
3.4.2 Synthesis of a Water-Soluble Cobalt Porphyrin ........................................... 131 
3.4.3 Cyclopropanation of Styrene by Cobalt Porphyrins in the Presence of 
Imidazole .............................................................................................................. 133 
3.5 Characterization of Myoglobin Mutants Reconstituted with Ru(CO)MPIX ........... 134 
3.5.1 Generation of Myoglobin Mutants ................................................................ 134 
3.5.2 Properties of Myoglobin Mutants ................................................................. 135 
3.5.3 Cyclopropanation with Myoglobin H64G/H93G Reconstituted with 
Ru(CO)MPIX ........................................................................................................ 137 
3.5.4 Cyclopropanation with Myoglobin H64G/H93G Reconstituted with RuMPIX 139 
x 
 
3.6 Non-Specific Binding of Synthetic Prosthetic Group ........................................... 141 
3.7 Cyclopropanation by Cytochrome P450 154C1 .................................................. 142 
3.8 Cyclopropanation by Anchored Ruthenium Porphyrin - BSA Conjugates ........... 143 
3.9 Conclusion ......................................................................................................... 144 
3.10 Experimental Section ....................................................................................... 146 
3.10.1 Materials and Reagents and General Techniques ..................................... 146 
3.10.2 Synthesis ................................................................................................... 146 
3.10.3 Reconstitution of Heme Proteins................................................................ 149 
3.10.4 Reconstitution of Wild Type Myoglobin Monitored by UV-vis Spectroscopy
 ............................................................................................................................. 149 
3.10.5 Attempted Cyclopropanation with Myoglobin and Myoglobin Mutants 
Reconstituted with Ru(CO)MPIX .......................................................................... 149 
3.10.6 The Influence of Imidazole on the Catalyst Activity of Ru(CO)MPIX .......... 150 
3.10.7 Cyclopropanation by Cobalt Porphyrins ..................................................... 150 
3.10.8 Construction of Expression Plasmids of Horse Heart Myoglobin ................ 150 
3.10.9 Expression of Myoglobin and Cytochrome P450 ........................................ 152 
3.10.10 Reactions of Myoglobin H64G/H93G Reconstituted with Ru(CO)MPIX 
Monitored by UV-Vis Spectroscopy ...................................................................... 152 
xi 
 
3.10.11 Purification of Myoglobin Reconstituted with 3-6 ...................................... 153 
3.10.12 Examination of Non-Specific Binding by ATR-IR ...................................... 153 
3.11 Literature .......................................................................................................... 155 
Chapter IV 
DESIGN OF SEMI-SYNTHETIC PROTEINS FOR THE STUDY OF LABILE POOLS OF 
COPPER, IRON AND ZINC IN INTRACELLULAR COMPARTMENTS ....................... 159 
4.1 Introduction and Concept ................................................................................... 159 
4.1.1 Mechanism of Fluorescence Quenching by Charge Transfer States ............ 166 
4.2 Design and Generation of Fusion Proteins ......................................................... 168 
4.2.1 Plasmids for Eukaryotic Expression Targeting Mitochondria Based on Labeling 
by AGT ................................................................................................................. 168 
4.2.2 Plasmids for Eukaryotic Expression Targeting the Nucleus Based on Labeling 
by AGT ................................................................................................................. 170 
4.2.3 Plasmids for Eukaryotic Expression Targeting the Trans-Golgi Network ...... 171 
4.2.4 Plasmids for Prokaryotic Expression ............................................................ 175 
4.3 In Vitro Studies of Labeling Expressed Fusion Proteins with Model Compounds177 
4.3.1 Labeling of AGT Based Fusion Proteins ...................................................... 177 
4.3.1.1 Expression and Isolation of AGT Based Fusion Proteins....................... 177 
xii 
 
4.3.1.2 Synthesis of Model Compound.............................................................. 180 
4.3.1.3 Labeling of AGT Based Proteins with Rhodamine Derivatives .............. 181 
4.3.2 Labeling of Split-Intein Based Fusion Proteins ............................................. 185 
4.3.2.1 Expression and Isolation of Split-Intein Based Fusion Proteins ............. 185 
4.3.2.2 Design and Synthesis of Split-InteinN Containing Model Compound ...... 186 
4.3.2.3 Labeling of Split-Intein Based Fusion Proteins with Rhodamine Derivatives
 ......................................................................................................................... 189 
4.4 Labeling of Proteins with Zinc Chelators ............................................................ 190 
4.4.1 Synthesis of Benzyl Guanine Zinquin .......................................................... 191 
4.4.2 Labeling of Proteins with Benzyl Guanine Zinquin ....................................... 191 
4.4.3 Labeling of Proteins with Alternative Zinc Chelators .................................... 192 
4.5 Labeling of Proteins with Iron Chelators ............................................................. 196 
4.6 Labeling of Proteins with Copper Chelators ....................................................... 197 
4.6.1 Synthesis of Bicinchoninic Acid Based Derivatives ...................................... 198 
4.6.2 Synthesis of Bathocuproine Based Derivatives ............................................ 203 
4.7 Conclusion ......................................................................................................... 205 
4.8 Experimental Section ......................................................................................... 207 
4.8.1 Materials and Reagents and General Techniques ....................................... 207 
xiii 
 
4.8.2 Generation of Plasmids ............................................................................... 207 
4.8.3 Synthesis ..................................................................................................... 213 
4.8.4 Analysis of FRET Pair MTS-AcGFP-AGT-Rhodamine ................................. 219 
4.9 Literature ............................................................................................................ 222 
CHAPTER V 















LIST OF TABLES 
 
Table 2-1.  Yields of the cyclopropanation reaction of styrene with EDA catalyzed by 2-5 
and unreacted starting material. ....................................................................................68 
















LIST OF FIGURES 
 
 
Figure 1-1.  Cartoon rendering of X-ray structure of sperm whale myoglobin including 
heme group that is depicted as ball and stick structure (PDB entry 1mbo).....................12 
Figure 1-2.  The native heme group of Myoglobin. .........................................................13 
Figure 1-3.  Reconstitution of Myoglobin with synthetic prosthetic cofactor based on 
previous removal of native heme. ..................................................................................14 
Figure 1-4.  Synthetic prosthetic group for generation of an interface. ..........................14 
Figure 1-5.  Salen and Salophen derivatives utilized for sulfoxidation reactions. ............15 
Figure 1-6.  (a) Active site structure of Mn(III)-3,3’-Dimethylsalophen A71G apo-
myoglobin. (b) Crystal structure of Mn(III)-3,3’-Dimethylsalophen A71G apo-myoglobin.
 ......................................................................................................................................16 
Figure 1-7.  (a) Computer model of Mn-salen complex covalently bound to myoglobin 
backbone. (b) Unbound Mn-salen complex....................................................................16 
Figure 1-8.   Whitesides and Ward design of supramolecular anchoring with 
(strept)avidin (purple), biotin (green), spacer (blue) and a Rhodium(I) hydrogenation 
catalyst (red and black)..................................................................................................18 
Figure 1-16.  Sulfoxidation by semi-synthetic serum albumin conjugates. ......................19 
xvi 
 
Figure 1-17.   Fluorescent calcium probes. A. Fura-2 (ratiometric probe). B. Calcium 
Green (“turn-on” probe). ................................................................................................23 
Figure 1-18.   Chemical structures of fluorescent copper(I) and zinc(II) probes. A. Zinquin 
(ratiometric Zn(II)-probe).163 B. ZnAF-1(ratiometric Zn(II)-probe).164 C. CS1 (“turn-on” 
Cu(I)-probe).165 D. CTAP-1 (ratiometric Cu(I)-probe).166 ................................................24 
Figure 1-19.   Chemical structures of iron probes based on fluorescence quenching of 
the fluorophore moiety upon binding of iron to the metal chelating moiety  A. Fl-Phen. B. 
NBD-DFO. 161,162 ............................................................................................................25 
Figure 1-20.   Cartoon rendering of X-ray structure of green fluorescent protein (PDB 
entry 1EMA) ..................................................................................................................26 
Figure 1-21.   San Diego beach scene drawn with E. coli expressing 8 differently colored 
fluorescent proteins (created in Tsien lab). ....................................................................27 
Figure 1-22.   Fluorescence emission spectra of FRET pair Fluorescein-Rhodamine in 
high density lipids (with permission of J. R. Lakowicz, “Principles of Fluorescence 
Spectroscopy”, 3rd edition).160 ........................................................................................29 
Figure 1-23.   Protein localization using FRET-FLIM microscopy of CFP-YFP couple. A. 
Fluorescence lifetime distribution in cell. B. Two-dimensional lifetime distribution within 
specified area. C. Three-dimensional plot of lifetime distribution.175 ...............................30 
Figure 2-1.   Heme catalyzed peroxidation and ruthenium porphyrin catalyzed 
cyclopropanation reaction. .............................................................................................58 
xvii 
 
Figure 2-2.    GC-MS chromatogram of cyclopropanation reaction. An HP-5 column was 
used ((5%-Phenyl)-methylpolysiloxane); temperature ramp 50 °C to 200 °C (4 minutes; 
15 minutes total run time). .............................................................................................64 
Figure 2-6.   Molar fractions of quantitated educts and products. ...................................74 
Figure 2-7.   Stereoselectivity of cyclopropanation of styrene in aqueous medium with 
varying pH. ....................................................................................................................75 
Figure 2-8.   Influence of solvents on trans/cis ratios of the cyclopropanation of styrene.
 ......................................................................................................................................75 
Figure 2-9.   Yields of 2-6b of the cyclopropanation reaction of styrene with EDA 
catalyzed by 2-5 in comparison with the yields of diethyl maleate. The respective yields 
were obtained with varying addition times of EDA. ........................................................78 
Figure 2-10.   Yield dependence of 2-6b on catalyst load (2-5) of the cyclopropanation of 
styrene. .........................................................................................................................79 
Figure 2-11.   Dependence of turnover number on catalyst load (2-5) of the 
cyclopropanation of styrene ...........................................................................................79 
Figure 2-12.   UV-vis traces at the beginning (t=0) and after 2 h of the reaction of 2-5 (40 
µM) with EDA. The reaction was carried out at room temperature in PIPES buffer at pH 
7.0. ................................................................................................................................82 
Figure 2-13.   Absorbance change at 530 nm as a function of time and added 
equivalents of EDA. The reaction of 2-5 (40 µM) with EDA was carried out at room 
temperature in PIPES buffer at pH 7.0...........................................................................82 
xviii 
 
Figure 2-14 .  UV-vis spectrum of EDA decomposition in water. ....................................85 
Figure 2-15.  1H-NMR spectra of reaction of EDA with 2-5. A + B. 2-5 with EDA (1 
equiv.). C. ethyl glycolate. D. diethyl maleate. E. EDA. Formed signals by the reaction 
and the expected signals of the terminal carbene-complex (c) are depicted with arrows.
 ......................................................................................................................................89 
Figure 2-16.  Possible complexes formed by the reaction of 2-5 with EDA. A. lone pair of 
terminal nitrogen of the diazo group of EDA coordinating to the ruthenium porphyrin 
metal center. B. side-on coordination of the nitrogens of the diazo group to the 
ruthenium center. C. reversible isomerization of terminal carbene to its N-bridged form.
 ......................................................................................................................................90 
Figure 2-17.  1H-NMR spectrum of carbene formation in C6D6. A. Ru(CO)TPP (2-7) B. 2-
7 + EDA (0.5 equiv.) C. 2-7 + EDA (1 equiv.). D. 2-7 + EDA (3 equiv.). The formed 
signals of the carbene complex are depicted with arrows. .............................................92 
Figure 2-18.  1H-NMR spectrum of carbene formation in C6D6. A. 2-7 + EDA (1 equiv) B. 
EDA C. diethyl maleate D. diethyl fumarate. Signals that could not be assigned to any 
likely compound, such as starting material or known side-products, were depicted with 
arrows. ..........................................................................................................................93 
Figure 2-19.   1H-NMR spectrum of carbene formation with pyridine as axial ligand. A. 
Ru(CO)TPP (2-7) B. 2-7 + pyridine (4 equiv.) C. pyridine D + E. 2-7 + pyridine + EDA (1 
equiv.) F. EDA ...............................................................................................................96 
xix 
 
Figure 2-20.   1H-NMR spectrum of carbene formation with DMAP as axial ligand. A. 
Ru(CO)TPP (2-7) B. 2-7 + DMAP (4 equiv.) C. DMAP D + E. 2-7 + DMAP + EDA (1 
equiv.) F. EDA ...............................................................................................................97 
Figure 2-21.   1H-NMR spectrum of carbene formation with mercaptoethanol as axial 
ligand. A. Ru(CO)TPP (2-7) B. 2-7 + mercaptoethanol (3 equiv.) C. mercaptoethanol D + 
E. 2-7 + mercaptoethanol + EDA (1 equiv.) F. EDA G. diethyl maleate..........................98 
Figure 2-22.   MS spectrum of 2-7 reacted with excess of pyridine. A,B and C represent 
the structures of the most abundant signals................................................................. 101 
Figure 3-1.  Active site topology of myoglobin (protein crystallographic database entry 
1AZI) ........................................................................................................................... 119 
Figure 3-2.  Active site topology of cytochrome P450 BM3 (protein crystallographic 
database entry 1BU7) .................................................................................................. 119 
Figure 3-3.   A. heme b B. Ru(CO)PPIX ...................................................................... 120 
Figure 3-4.  Reconstitution of Myoglobin with synthetic cofactor ................................. 124 
Figure 3-5.  UV-vis spectra of myoglobin reconstituted with 3-6 (lilac) in comparison with 
wild-type myoglobin (yellow) and free cofactor 3-6 (blue) (spectra normalized to soret 
band). .......................................................................................................................... 125 
Figure 3-6.   UV-vis spectra of myoglobin reconstituted with 3-6 (lilac) in comparison with 
wild-type myoglobin (yellow) and free cofactor 3-6 (blue) with focus on the visible range 
(spectra normalized to soret band). ............................................................................. 125 
xx 
 
Figure 3-7.  Cartoon representation of active site of horse heart myoglobin (entry 1AZI 
from protein crystallographic database) ....................................................................... 127 
Figure 3-8.   UV-vis spectrum of the reaction of 3-6 with EDA in PIPES buffer at pH 7.0
 .................................................................................................................................... 128 
Figure 3-9.   UV-vis spectrum of the reaction of 3-6 with EDA in presence of imidazole 
(30 mM) in PIPES buffer at pH 7.0 .............................................................................. 129 
Figure 3-10.   Analysis (GC-FID) of cyclopropanation of styrene by 3-6 with or without 
imidazole ..................................................................................................................... 130 
Figure 3-11.   Analysis (GC-FID) of cyclopropanation of styrene by 3-6 compared to 3-9 
with or without imidazole.............................................................................................. 134 
Figure 3-12.   Normalized UV-vis spectra of expressed horse-heart myoglobin mutants
 .................................................................................................................................... 136 
Figure 3-13.   The relative level of heme incorporation of myoglobin mutants. ............. 137 
Figure 3-14.   UV-vis spectra of reaction of Ru(CO)Mb 64/93G with EDA .................... 138 
Figure 3-15.   UV-vis spectra of reaction of Ru(CO)Mb 64/93G with EDA .................... 138 
Figure 3-16.   Cyclopropanation of styrene by 3-6 and RuMb. (A). 3-6 (B). 3-6 + EDA + 
styrene t = 1 h (C). B + apomyoglobin 64/93G t = 0 (D). C t = 1 h. .............................. 140 
Figure 3-17.  Cyclopropanation of styrene by 3-6 and RuMb. (A). 3-6 (B). 3-6 + EDA + 
styrene t = 1 h (C). B + apomyoglobin 64/93G t = 0 (D). C t = 1 h. .............................. 140 
Figure 3-18.   ATR-IR spectra of mixtures of 3-6 with myoglobin and GFP. ................. 142 
xxi 
 
Figure 3-19.   Generation of ruthenium porphyrin – BSA attachment. (A) 2-5. (B) A + 
BSA (1 equiv). (C) B + 2-5 (1 equiv) t = 0. (D) C t = 2 h. .............................................. 144 
Figure 4-1.   Strongly colored metal charge transfer complexes of copper and iron. A. 
free ligands. B. metal complexes, which almost exclusively exhibit 2:1 or 3:1 binding 
behavior (ligand : metal). ............................................................................................. 163 
Figure 4-2.   Design concept of a genetically encoded, semi-synthetic metal sensor. .. 164 
Figure 4-3.  Target organelles (with permission of Michael W. Davidson and Florida 
State University). ......................................................................................................... 165 
Figure 4-4.   Jablonski diagram of fluorescence quenching by FRET ........................... 167 
Figure 4-5.  Circular and linear representation of plasmids for eukaryotic expression 
targeting mitochondria. ................................................................................................ 169 
Figure 4-6.  Light micrographs of 3T3 cells transfected with plasmid A expressing MTS-
AcGFP-AGT. Localization in the mitochondria was observed (left panel) and confirmed 
by staining with mitochondria specific antibodies (center panel) and overlay of the 
resulting images (right panel). ..................................................................................... 170 
Figure 4-7.   Linear representation of plasmids for eukaryotic expression targeting the 
nucleus. ....................................................................................................................... 170 
Figure 4-8.  Light micrographs of 3T3 cells transfected with plasmid E expressing 
AcGFP-AGT-NLS. Localization in the mitochondria was observed. ............................. 171 
Figure 4-9.   Linear representation of plasmids encoding AcGFP with 11 amino acid TGN 
localization sequences. ............................................................................................... 172 
xxii 
 
Figure 4-10.  Light micrographs of 3T3 cells transfected with F expressing AcGFP. 
Localization in the TGN was not observed. .................................................................. 172 
Figure 4-11.   Linear representation of plasmid encoding AcGFP with TGN localization 
sequences. .................................................................................................................. 173 
Figure 4-12.  Linear representation of split-intein based plasmids targeting TGN......... 175 
Figure 4-13.   Linear representation of AGT based plasmids targeting TGN. ............... 175 
Figure 4-14.  Light micrographs of 3T3 cells transfected with plasmids encoding AcGFP-
TGN38. Localization in the TGN was observed. .......................................................... 175 
Figure 4-15.   Linear representation of bacterial expression plasmids based on labeling 
by AGT. ....................................................................................................................... 176 
Figure 4-16.  Linear representation of bacterial expression plasmids based on labeling 
by split-inteins. ............................................................................................................. 176 
Figure 4-17.  Linear representation of bacterial expression plasmids based on labeling 
by split-inteins. ............................................................................................................. 177 
Figure 4-18.  SDS-PAGE gel of expression of AGT based fusion proteins (cell lysates). 
The expressed fusion proteins only appeared in the insoluble fractions. ...................... 178 
Figure 4-19.   SDS-PAGE gel of purified protein MTS-AcGFP-AGT. ............................ 179 
Figure 4-20.   Thrombin cleavage of His-tag of MTS-AcGFP-AGT. All utilized 
concentrations led to complete cleavage. .................................................................... 179 
Figure 4-21.   Labeling of MTS-AcGFP-AGT with rhodamine. ...................................... 182 
xxiii 
 
Figure 4-22.  Fluorescence spectrum of unreacted MTS-AcGFP-AGT (0.29 µM in 50 
mM phosphate buffer, pH 8.0). A. [M] MTS-AcGFP-AGT (exc.: 475 nm). B. [X] MTS-
AcGFP-AGT (emm.: 505 nm). C. [X] MTS-AcGFP-AGT (emm.: 470 nm). ................... 183 
Figure 4-23.  Fluorescence spectrum of the labeling reaction of MTS-AcGFP-AGT with 
BGRH (0.29 µM each in 50 mM phosphate buffer, pH 8.0). D. [M] MTS-AcGFP-AGT + 
BGRH (exc.: 475 nm). E. [X] MTS-AcGFP-AGT + BGRH (emm.: 505 nm). ................. 183 
Figure 4-24.   Fluorescence spectrum of the labeling reaction of MTS-AcGFP-AGT with 
BGRH (0.29 µM each in 50 mM phosphate buffer, pH 8.0). F. [X] MTS-AcGFP-AGT + 
BGRH (emm.: 600 nm). G. [M] MTS-AcGFP-AGT + BGRH (exc.: 554 nm). ................ 184 
Figure 4-25.  Fluorescence decay of labeled and unlabeled MTS-AcGFP-AGT. .......... 185 
Figure 4-26.  Labeling of AcGFP with rhodamine by trans splicing with split-inteins. The 
splicing reaction is induced by recombination of the split-inteins and yields labeled 
protein and the excised split-inteins. ............................................................................ 189 
Figure 4-27.  SDS-PAGE gel of the trans-splicing reaction with split inteins. InteinC-
AcGFP can be seen at 47 kDa and an impurity at 32 KDa that is most likely His-tagged 
AcGFP. No band of excised inteinC was observed at 17 kDa suggesting that trans-
splicing did not occur. .................................................................................................. 190 
Figure 4-28.  Emission ratiometric Zn(II) sensor. The sensor contains a tris(picolyl) 
metal-chelating unit with an anisole donor connected by a rigid oxazole core.24 .......... 192 
Figure 4-29.  Benzyl guanine modified Zn(II) emission ratiometric sensor (see Figure 4-
25). 24 .......................................................................................................................... 193 
xxiv 
 
Figure 4-30.  Fluorescence emission spectra (excitation at 350 nm) of 4-19 (4 µM) in 
methanol or aqueous buffered solution (10 mM PIPES, 10 mM HEDTA, pH 7.06, 0.1 M 
KCl). A. 4-19 + TPEN in MeOH. B. 4-19 + Zn2+ in MeOH. C. 4-19 in aqueous buffer. D. 
4-19 + Zn2+ in aqueous buffer. ..................................................................................... 195 
Figure 4-31.  Fluorescence emission spectra (excitation at 350 nm) of 4-19 (6 µM) 
reacted with MTS-AGT (6 µM) in aqueous buffered solution (10 mM PIPES, 10 mM 
HEDTA, pH 7.06, 0.1 M KCl, 1 mM DTT). E. reaction time = 5 min. F. reaction time = 1 
h. G. F + Zn2+. ............................................................................................................. 195 
Figure 4-32.  Tetrahedral 2:1 Cu(I) complexes of bicinchoninic acid (A) and 
bathocuproine (B). Both metal complexes are colored (A = purple; B = red). .............. 197 
Figure 4-33.  Structures of Cu(I) complexes of bicinchoninic acid and bathocuproine 
(generated by molecular modeling with MM2 force field calculations).28 A. 
Dimethylbicinchoninic acid complex with 2:1 ligand-metal stochiometry. B. 
Dimethylbicinchoninic acid complex connected by a linker with 1:1 ligand-metal 
stochiometry. C. Bathocuproine complex connected by a linker with 1:1 ligand-metal 








LIST OF SYMBOLS AND ABBREVIATIONS 
 
Ǻ  Angstrom 
AAS  atomic absorption spectroscopy 
AGT  O6-alkylguanine-DNA alkyltransferase 
b  broad signal 
C  Celsius 
Cer  Cerulean 
cm  centimeter 
CD  circular dichroism 
CT  charge transfer 
D  doublet 
deg  Degree 
DNA  Deoxyribonucleic acid 
E.coli  Escherichia coli 
EI  electron ionization 
ESI  electrospray ionization 
FID  Flame Ionization Detector 
xxvi 
 
FP  Fluorescent Protein 
FRET  Förester Resonance Energy Transfer 
HOMO  highest occupied molecular orbital 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
Hz  Hertz 
ICPMS  inductively coupled mass spectrometry 
IR  infrared 
K  Kelvin 
Λ  Wavelength 
LUMO  lowest unoccupied molecular orbital 
m  multiplet 
MHz  Megahertz 
mm  millimeter 
MS  mass spectrometry 
nm  nanometer 
NMR  nuclear magnetic resonance 
ppm  part per million 
xxvii 
 
q  quartet 
s  singlet 
TGN  trans-Golgi network 
t  triplet 
THF  tetrahydrofuran 















 Proteins have evolved over millions of years to serve a plethora of highly 
specialized functions in biological systems. Given the enormous diversity in structure 
and function, it is truly surprising that only 20 different amino acids are utilized as the 
building blocks of proteins. Furthermore, only a small set of metal cations that are 
biologically available are used as structural or catalytically active cofactors in proteins, 
whereas rare metal cations such as platinum, ruthenium or rhodium remain absent. In 
the 20th century myriad catalysts, based on non-biological transition metals, emerged 
that can facilitate numerous organic transformations. The goal of my thesis was to 
introduce new functions into proteins by attaching platinum metals and fluorescent metal 
sensors. Thus, semi-synthetic proteins for catalytic and analytical applications were 
generated. 
Chapter I provides the background for the generation and development of semi-
synthetic proteins for catalytic and analytical applications. This chapter also provides 
background about challenges in sustainable chemistry, water as a reaction medium for 
organic reactions and catalysis, the role of copper, iron, and zinc ions in biology, small 
molecule fluorescent probes for visualization of biologically relevant metals and 
fluorescent proteins as tools for cellular imaging. Chapter II and III focus on semi-
synthetic proteins for catalytic applications while chapter IV focuses on their analytical 
applications. 
 The replacement of organic solvents by environmentally benign solvents such as 
water is an imperative step towards achieving “green chemistry”. The combination of 
small molecule catalysts with proteins may introduce new functions and take advantage 
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of the benefits of “both worlds” while avoiding their potential drawbacks. Therefore semi-
synthetic catalysts were developed for enantioselective organic reactions in aqueous 
medium. 
 Chapter II discusses the design, development and characterization of a suitable 
reaction, reaction conditions and catalytic system for later utilization in a semi-synthetic 
protein. Ruthenium porphyrins catalyzed cyclopropanation reactions with fair yields and 
high stereoselectivity in aqueous medium. The successful reaction in water was a crucial 
requirement for a catalytically active semi-synthetic protein. Mechanistic studies did not 
elucidate the actual catalytic species for the formation of the cyclopropanation product 
and the side-product diethyl maleate; however, new insights were gained from the 
analysis of potential reaction pathways. Moreover, studies of the influence of axial 
ligands, resembling likely residues coordinating to the ruthenium metal center in the 
active site of a semi-synthetic protein, on the carbene formation of ruthenium porphyrins 
illustrated that coordination of axial ligands may inhibit the catalytic activity. 
 In chapter III, the generation of ruthenium porphyrin based semi-synthetic 
proteins and their subsequent catalysis of cyclopropanation reactions is discussed. 
Myoglobin and myoglobin mutants were successfully reconstituted with a heme-like 
ruthenium carbonyl porphyrin; however, none of the formed semi-synthetic proteins 
catalyzed the enantioselective cyclopropanation of styrene. Efforts to determine the 
reconstitution efficiency of the generated semi-synthetic were hampered by problems to 
purify the generated semi-synthetic proteins that are probably due to non-specific 
binding of the ruthenium porphyrin to the protein surface. 
xxx 
 
 The exploration of labile metal pools of the biologically relevant transition metals 
copper, iron and zinc in cells was the goal of developing semi-synthetic proteins for 
analytical applications. Combining fluorescent proteins with colored or fluorescent metal 
chelators by forming semi-synthetic proteins allows taking advantage of their beneficial 
properties while avoiding their downsides. This design offers an attractive platform for in 
vivo metal sensing. 
 Chapter IV discusses the design and generation of semi-synthetic proteins for 
analytical applications. Plasmids encoding fluorescent proteins, targeting sequences and 
AGT or intein fusion domains (necessary for labeling) for eukaryotic and prokaryotic 
expression were generated. The targeting of intracellular compartments (mitochondria, 
nucleus and TGN) was successful (confirmed by light microscopy experiments with 
transfected mammalian cells). In vitro labeling experiments of expressed and purified 
fusion proteins with rhodamine derivatives succeeded with AGT based fusion proteins; 
however, labeling of fusion proteins by trans-splicing with split-inteins failed. A zinc(II)-
chelator was attached to an AGT based protein and the resulting semi-synthetic protein 
exhibited strong changes of fluorescence in the presence of zinc(II). This represents an 
important step towards the goal of in vivo cell imaging of labile zinc(II) pools. Iron 
chelators suitable for protein-labeling could not be synthesized. Despite extensive 
efforts, all attempts failed to generate a chelator that forms Cu(I)-complexes with the 1:1 








1.1 Semi-Synthetic Proteins for Catalytic Applicati ons 
1.1.1 Green Chemistry and Its Importance 
In 1990 the Pollution Prevention Act was passed in the United States, representing 
the beginning of Green Chemistry.1,2  Since then the Environmental Protection Agency 
(EPA) has promoted Green Chemistry by  grants, education, partnerships, research, and 
the notable Presidential Green Chemistry Challenge Awards.3 Green Chemistry, also 
called sustainable chemistry, is based on a set of principles that reduces or eliminates 
the use or generation of hazardous substances in the design, manufacture and 
application of chemical products.4  The expenditure on environmental protection has 
risen in western industrialized countries because of increasingly stringent environmental 
protection regulations.5  Therefore it is possible to get a competitive advantage by 
applying green chemistry technologies.6  The significance of green chemistry was 
recognized by awarding Richard R. Schrock, Robert H. Grubbs, and Yves Chauvin with 
the Nobel Prize in Chemistry in 2005 for the development of the metathesis method in 
organic synthesis. The Nobel Prize Committee stated “this represents a great step 
forward for ‘green chemistry’, reducing potentially hazardous waste through smarter 
production. Metathesis is an example of how important basic science has been applied 
for the benefit of man, society and the environment.”7   
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There are several principles of green chemistry, stating for example that “catalytic 
reagents are superior to stoichiometric reagents.” or that auxiliary substances like 
solvents should be “innocuous when used”.4 Catalysis in aqueous medium fulfills these 
criteria and therefore represents an attractive way to develop methods for sustainable 
chemistry.  
 
1.1.2 Reactions in Aqueous Media 
Water is a highly polar solvent with a high dielectric constant (εr = 78.30) compared 
to common organic solvents like ethanol (εr = 24.55), diethyl ether (εr = 4.20), or n-
hexane (εr = 1.88). It is unique among solvents because of its exceptionally small 
molecular volume and its ability to form a three dimensional hydrogen bonding network 
with a dominant tetrahedral coordination.8 Due to these properties most organic 
compounds show only limited solubility in water. Moreover, water can deactivate many 
reactions. A classic text book example is the deactivation of the reactive magnesium 
surface for the formation of the Grignard reagent (Scheme 1-1).9 Besides, water has a 
deleterious effect on many reagents and organic compounds. In the McMurry reaction 




Scheme 1-1. 10,11 
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Therefore it is no surprise that water as a solvent was ignored for a long time or even 
considered a contaminant in organic reactions.12   
Nevertheless, water has several properties that make it attractive for synthetic 
applications. First, water is the cheapest solvent and readily available. Consequently, the 
utilization of water can make many chemical processes more economic. Besides, the 
large heat capacity of water, which is one of the largest ones of all substances, allows 
easier control of the reaction temperature.13  Moreover, in certain large scale industrial 
processes isolation of the organic products can be achieved by simple phase 
separation.14  The innocuous water has crucial advantages with regards to safety, 
because many organic solvents constitute health hazards by being inflammable, 
potentially explosive, mutagenic, and/or carcinogenic.15  The chemical industry is a 
major producer of environmental pollution. The development of nonhazardous solvent 
alternatives like water is of great importance in order to respond to increasing regulatory 
pressure focusing on organic solvents.16 Water’s high polarity and ability to form a 
hydrogen-bonding network can lead to a significant increase of the reaction rate.17-19 
These properties can also result in beneficial effects on organic reactions regarding 
selectivity.20  Lengthy protection-deprotection steps can also be reduced in case of the 
presence of acidic moieties or by using water-soluble compounds without derivatization 
with hydrophobic moieties.12  Thus, the possible benefits of water as a reaction medium 
has prompted the reevaluation of reactions that were optimized for common solvents like 
dichloromethane, dimethylsulfoxide or hexanes.     
The discoveries made in the early 1980s by the research groups of Breslow21-23 
and Grieco24-26 on the dramatic effect of water on the reaction rates and 
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stereoselectivities of the Diels-Alder reaction (Scheme 1-2) triggered a broad interest in 





Scheme 1-2. 23 
 
The strong enhancement of the reaction rate in water, compared to solvents like 
acetonitrile, is a phenomenon that cannot be simply explained by the higher polarity of 
the aqueous media. Addition of lithium chloride, a “salting-out” agent, decreases the 
solubility of hydrocarbons in water. The lowered solubility resulted in an even higher rate 
enhancement compared to plain water. On the other hand salts like guanidinium 
chloride, which are known to solubilize hydrocarbons in water, decreased the reaction 
rate. These findings can only be explained by the hydrophobic effect (Scheme 1-3).  The 
hydrophobic effect is based on hydrophobic interactions27,28 between nonpolar moieties 
molecules. This process, in which water forces nonpolar molecules to associate, is 
crucial for biological systems29,30 (e.g. protein folding) but was mostly ignored for 
synthetic applications. The driving force of the aggregation of hydrophobic molecules is 
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a combination of van der Waals interactions and the increase of entropy by the release 
of water molecules.  
 
 Scheme 1-3.  31 
 
The great impact of hydrophobic effects on simple organic model reactions like the 
benzoin condensation in water has been studied in detail since the discovery of rate 
enhanced Diels-Alder reactions.32,33  
 Poor solubilities of substrates in aqueous media do not necessarily present 
obstacles for organic synthesis if the hydrophobic effects are strong enough to enable 
the reaction. The Wittig reaction was carried out in water utilizing poorly water-soluble 
stabilized ylides to produce enoates that are instrumental templates for the synthesis of 
macrolide antibiotics (Scheme 1-4).17 
 
 




Despite the reactants and the product being poorly water-soluble the reaction proceeded 
with nearly the same yield as in CH2Cl2. However, the reaction time was only two hours 
in water, in contrast to four weeks in CH2Cl2. 
Sharpless and coworkers demonstrated that water is an ideal medium for many 
organic transformations, like “click chemistry” or the preparation of substituted tetrazoles, 
despite poorly soluble starting materials and products.34,35 Hence, poor solubility in water 
is not simply an obstacle but, contradictory to previous assumptions in the scientific 
literature, can even be beneficial.  
 
1.1.3 Organometallic Reactions in Water by Small Mo lecule Catalysts 
 A plethora of chemical reactions can be facilitated utilizing small molecule 
organometallic catalysts;36-40 however, the vast majority of reactions is conducted in 
organic solvents. Apart from the general difficulties of aqueous organic chemistry 
(Chapter 1.2), the challenges of organometallic reagents lie in the thermodynamic 
































 Scheme 1-5. 41 
Moreover, water can act as a ligand itself and replace ligands that are bound to the 
metal center. Hydrolysis reactions do not always deactivate or destroy the catalyst. In 
some reactions (e.g. Wacker-Hoechst acetaldehyde process) water may even form the 
catalytically active species.42 
 In spite of these difficulties many organometallic reactions in aqueous media 
have already been developed.43-53 Faster reaction to the desired products than 
decomposition or deactivation by water allows these reactions to be carried out in 
aqueous medium (kinetic control). The most important industrial reaction utilizing 
aqueous organometallic catalysis is the hydroformylation reaction of alkenes.54 Rhodium 





1.1.4 Enantioselective Organometallic Reactions in Water by Small Molecule 
Catalysts 
 The development of methods to produce enantiomerically pure molecules is of 
critical importance, especially in the pharmaceutical industry. Thalidomide is a racemic 
drug that was sold in nearly 50 countries from 1957 to 1961 as a sleeping aid and to 
combat morning sickness of pregnant women. The R(+) enantiomer had a sedative 
effect while the S(-) enantiomer is teratogenic and caused serious birth defects.56 Hence, 
the enantiopurity of drugs has become a crucial property. 
 Myriad small molecule organometallic catalysts have been developed for 
enantioselective transformations of compounds in organic solvents;36-40 however, with a 
few notable exceptions, the development of chiral ligands and asymmetric catalysts was 
conducted almost exclusively in organic solvents.  By the recent focus on aqueous 
organometallic catalysis several reactions with high stereoselectivity and yield have 
been developed.12,46,51,53,57 A notable example is the rhodium catalyzed asymmetric 
transfer reaction of alkyl and aryl ketones in aqueous media by Adolfsson and coworkers 





 Scheme 1-6. 58   
The rhodium catalyst is a modified catalyst that was originally developed by Noyori and 
coworkers and is formed in situ.59 The reduction to the corresponding alcohol was 
facilitated with sodium formate as hydride donor and SDS as surfactant. Several alkyl 
and aryl ketones were reduced with an enantiomeric excess of up to 97% at a 
conversion of up to 99%. 
 
1.1.5 Enzymes and Enzyme Mimics 
 The synthesis of enantiomerically pure compounds necessitates chiral 
organometallic catalysts, which require often multi-step preparations and are therefore 
too expensive for large scale industrial applications.60,61 An alternative to small molecule 
organometallic catalysts for enantioselective organic transformations is the utilization of 
enzymes. Enzymes are biological, protein-based catalysts that use water as their natural 
solvents. Myriad enzymatic reactions and their corresponding enzymes have been 
characterized.62 These biocatalysts usually catalyze reactions with very large turnover 
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numbers and high regio- and stereoselectivity.31 Enzymes are typically easy to handle 
due to their stability under ambient conditions, unlike small molecule organometallic 
catalysts that tend to decompose in air, by moisture, and by light. Moreover, the 
biodegradability of enzymes can help to reduce the amount of produced toxic waste. 
Besides, properties like stereospecificity and turnover numbers for a particular substrate 
can be enhanced by mutations of the active site. Due to their lack of stability in organic 
solvents and high temperatures enzymes are often only used in industry for reactions 
that require highly selective catalysts. In particular enzymes are utilized for 
enantioselective transformations in the synthesis of drugs.63-69  Baclofen for instance is 
an antispastic drug, which was sold as a racemate despite significantly different 
pharmacological and toxicological properties of the enantiomers.69,70 The 
chemoenzymatic synthesis of both enantiomers was carried out in order to solve this 
problem (Scheme 1-7).71  
 




The key step for the synthesis of the enantiomers was the enantioselective hydrolysis of 
the prochiral dimethyl 3-(p-chlorophenyl)glutarate to its half-ester by the enzyme 
chymotrypsin.  
 
1.1.6 Semi-Synthetic Proteins for Catalysis 
 Most enzymes used in organic synthesis offer large turnover number and high 
stereoselectivity but exhibit a narrow substrate tolerance while small molecule 
organometallic catalysts usually accept a much broader range of substrates.72 A viable 
approach to combine the benefits of “both worlds” lies in the design of semi-synthetic 
proteins. Semi-synthetic proteins consist of a protein and an incorporated synthetic 
prosthetic group.  
 Several research groups have focused on the incorporation of organometallic 
cofactors into proteins and the characterization of the resulting semi-synthetic proteins. 
The prosthetic groups of many heme proteins were successfully removed and 
reconstituted with either the native or modified heme group.73 Hayashi, Lu, and 
Watanabe and coworkers have utilized the heme-protein Myoglobin as their model-
protein for the introduction of prosthetic groups.74-113 Myoglobin plays an essential role in 
the storage of oxygen during periods of rest until required for oxidative phosphorylation. 
It is a small single-chain globular protein with a molecular weight of about 18 kDa and 
contains the porphyrin cofactor iron protoporphyrin IX (Figure 1-1 and Figure 1-2). Most 
commonly used are horse heart myoglobin and sperm whale myoglobin, which amino 
acid sequence differs only in 18 positions from each other. These differences appear 





Figure 1-1.  Cartoon rendering of X-ray structure of sperm whale myoglobin 






Figure 1-2.  The native heme group of Myoglobin. 
  
Non-native metal-containing cofactors can be integrated into proteins by non-
covalent, single-point and dual-point attachment. Non-covalent attachment is based on 
hydrogen-bonding interactions, hydrophobic interactions and coordinative bonds to the 
metal center of the cofactor. The non-native prosthetic groups incorporated by this 
method include metal complexes for electron-transfer studies, artificial receptors for 
modulation of heme protein activities and binding domains for protein-protein and 
protein-small molecule recognition.76,116  Hayashi and coworkers utilized non-convalent 
attachment in order to incorporate heme-groups containing artificial interfaces into 
myoglobin (Figure 1-3 and Figure 1-4).76 The resulting semi-synthetic proteins show a 
much higher activity in the sulfoxidation reaction of 2-methoxyphenol than native 




Figure 1-3.  Reconstitution of Myoglobin with synthetic prosthetic cofactor based 
on previous removal of native heme. 76 
 




Both the Lu and the Watanabe research group have focused on the incorporation 
of metal-salen and salophen derivatives into myoglobin (Figure 1-5). 
 
Figure 1-5.  Salen and Salophen derivatives utilized for sulfoxidation 
reactions.84,100,109 
 
 However, they applied different designs and methods to incorporate these types 
of organometallic complexes in myoglobin. The Watanabe group utilized non-covalent 
attachment (Figure 1-6) while Lu and coworkers preferred single-point and dual-point 
attachment (Figure 1-7).84,109 The sulfoxidation of thioanisole yielded only low 
enantiomeric excess (up to 32%) with Watanabe’s salen and salophen based modified 
myoglobin (optimized by H64D/A71G mutation). On the other hand, Lu and coworker’s 
approach to covalently attach salen derivatives to myoglobin (M72C/Y103C) in two 
positions by disulfur bonds yielded a more stable and rigid attachment and resulted in 




Figure 1-6.  (a) Active site structure of Mn(III)-3,3’-Dimethylsalophen A71G apo-




Figure 1-7.  (a) Computer model of Mn-salen complex covalently bound to myoglobin 






 Whitesides pioneered the concept of anchoring a homogenous catalyst within a 
protein environment by non-covalent interactions in order to induce enantioselectivity. A 
biotinylated diphosphinerhodium(I) complex was incorporated into avidin and enabled 
the asymmetric hydrogenation of α-acetamidoacrylic acid with up to 44% ee (Figure 1-
8).117 Efficient attachment of the organometallic species is facilitated by the extreme 
binding affinity of the protein streptavidin to biotin (Kd around 10
-15), which is the 
strongest known non-covalent interaction.118 This type of supramolecular anchoring 
approach was optimized by Ward and coworkers. Combinatorial modification of the 
rhodium organometallic catalyst, the spacer to the biotin moiety and site-directed 
mutations of streptavidin led to the successful asymmetric hydrogenation of 
acetamidoacrylic acid with up to 96% ee in favor of the (R) configuration.119 Remarkably, 
by applying the same kind of combinatorial modification strategy the enantioselectivity 
was reversed to 88% ee in favor of the (S) configuration.120 Recently, new types of 
reactions (i.e. allylic alkylation and sulfoxidation) were successfully catalyzed by the 





Figure 1-8.   Whitesides and Ward design of supramolecular anchoring with 
(strept)avidin (purple), biotin (green), spacer (blue) and a Rhodium(I) 
hydrogenation catalyst (red and black). 117,118 
 
 The transport proteins serum albumin, in particular bovine serum albumin (BSA), 
can be useful for supramolecular anchoring strategies of metal cofactors within a host 
protein. These exhibit the ability to strongly bind a wide range of hydrophobic guests, 
including fatty acids, steroids, thyroxine, porphyrins, etc.118 Several enantioselective 
transformations were performed with these proteins, including sulfoxidation, epoxidation, 
reduction, and Diels-Alder reactions, without the presence of an organometallic 
catalyst.123-128 Gross and coworkers successfully incorporated amphiphilic bis-sulfonated 
iron and manganese corroles into various serum albumins through supramolecular 
anchoring. The in situ formed semi-synthetic protein facilitated the enantioselective 
sulfoxidation of thioanisole derivatives with up to 74% ee (Figure 1-16).129 The Mn(III)-
corrole conjugate shows a 1:1 conjugate with a Kd in the high nanomolar range. The 
presence of an induced circular dichroism signal suggests that the metal complex is 
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integrated into a well-defined chiral environment.130 This finding is consistent with the X-
ray structure of a hemin human serum albumin conjugate. Reetz and coworkers applied 
the same approach in order to incorporate a water-soluble copper(II)-phtalocyanine into 
BSA and HSA. The resulting conjugate catalyzed the Diels-Alder reaction of multiple 
substrates in a highly enantioselective fashion.131  
 
Figure 1-16.  Sulfoxidation by semi-synthetic serum albumin conjugates. 
  
Other notable contributions to the field of semi-synthetic proteins include covalent 
anchoring of Cu-phenanthroline to adipocyte lipid binding protein,132 covalent anchoring 
of Mn-Schiff bases to papain,133 or supramolecular anchoring of Cu-pyridoxamine to 





1.2 Semi-Synthetic Proteins for Analytical Applicat ions 
1.2.1 Copper, Iron and Zinc in Biology 
 Copper, iron and zinc are essential trace elements in all organisms and are 
crucial for the function of numerous enzymes.135  Iron ranks first in intracellular 
abundance, followed by zinc and copper.136 Copper is found in various enzymes as 
catalytic cofactor, most notably cytochrome c oxidase and superoxide dismutase. It is 
involved in many cellular processes such as iron uptake, mitochondrial respiration and a 
range of enzymatic redox processes.137 Iron is found in myriad enzymes, often 
incorporated into heme groups. Most notably are cytochrome proteins (redox reactions) 
and oxygen binding proteins such as hemoglobin and myoglobin. Non-heme iron 
containing proteins include ribonucleotide reductase (DNA synthesis) and purple acid 
phosphatase (hydrolysis of phosphate esters).138 Zinc is essential for growth and 
development,139,140 prostate gland function,141 reproduction,142,143 olfactory sensing,144 the 
immune system,145-147 and can be found in numerous enzymes. 
 
1.2.2 Homeostasis of Copper, Iron an Zinc 
 The free intracellular concentrations of copper, iron, and zinc are low compared 
to the total cellular level presumably because these free metals can generate deleterious 
reactive oxygen species (ROS). The transition metals copper, iron and zinc are 
distributed to numerous proteins while maintaining low free metal concentrations, 
indicating the presence of a sophisticated uptake, transport and recycling 
system.138,148,149 Defects of these complex regulatory systems can lead to serious clinical 
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conditions, e.g. immune system dysfunction (zinc deficiency),147 Menkes’ disease 
(copper deficiency),150 and hemochromatosis (iron overload).151  The elucidation of 
copper, zinc and iron homeostasis at a molecular level is crucial for understanding the 
mechanisms of these diseases. 
 
1.2.3 Labile Pools of Copper, Iron and Zinc 
 High binding affinities of native metal binding proteins are the cause of the low 
intracellular concentrations of free copper, iron and zinc. It has been shown by uptake 
studies with radioactive 64Cu(II) that copper uptake occurred rapidly and reached a 
steady state concentration after about 40-60 minutes.152 However, upon reaching the 
steady state level, fast efflux of copper was detected after incubation with copper 
deficient media within the first 15 minutes. These data contradict the high binding 
affinities of the native cellular metal binding proteins. Therefore, based on similar results 
for iron and zinc, a kinetically labile pool was suggested that allows rapid uptake and 
release of these metal ions.153,154 This accessible labile pool could be due to a metal 
exchange between two ligands according to an associative mechanism, which has been 
shown for the dynamic exchange of zinc.155 Another possibility is that various weakly 
binding ligands (in comparison to the native binding proteins) in the cytoplasm such as 
organic anions (phosphates and carboxylates), surface components of membranes 
(phospholipid head groups), etc. could act as metal buffers.156 Storage of copper, iron 
and zinc in intracellular compartments would also prevent deleterious effects by 
generation of ROS.157,158 In case of higher concentration of these metals inside of the 
compartments than in the cytosol an active transport system against the concentration 
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gradient must be present. Despite the wealth of information available about labile metal 
pools in cells many questions remain unanswered especially about the exact nature and 
subcellular location of labile pools of copper, iron, and zinc. 
 
1.2.4 Chemical Sensing of Metal Ions with Small Mol ecule Fluorescent Probes 
 Metal ions can be detected by small molecule metal chelators that emit 
fluorescence or change the fluorescent properties upon binding. There are usually two 
types of fluorescent probes for metal ions, “turn on” or ratiometric. “Turn on”-type 
sensors such as Calcium Green (Ca(II)-sensor) exhibit strong fluorescence or 
fluorescence enhancement upon binding without a shift (Figure 1-17). Probes such as 
Fura-2 (Ca(II)-sensor) display spectral shifts upon binding.159 These kinds of probes are 
called wavelength-ratiometric because the analyte concentration can be determined by 
the ratio of fluorescence intensities at different excitation or emission wavelengths.160 
There are many more fluorescent zinc sensors than iron and copper sensors because 
the presence of copper and iron tends to quench the fluorescence emission of most 
fluorophores. Of the few examples of copper selective fluorescent probes most are 
selective for Cu(II). Unfortunately, copper will be present as Cu(I) in the reductive 
intracellular environment, thus rendering Cu(II) probes unsuitable for cell imaging 
applications. Various fluorescent small molecule metal probes for zinc and copper are 
depicted in Figure 1-18. Iron is present in the cell in its +2 and +3 oxidation state. Due to 
the fluorescence quenching iron is usually measured indirectly by linking an iron 
selective chelator with a fluorophore (Figure 1-19).156 The analyte concentration can be 
determined from the fluorescence quenching of the fluorophore-chelator conjugate such 
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as FL-Phen (fluorescein-phenantroline) and NBD-DFO (nitrobezodiazole-































Figure 1-17.   Fluorescent calcium probes. A. Fura-2 (ratiometric probe). B. 











Figure 1-18.   Chemical structures of fluorescent copper(I) and zinc(II) probes. A. 
Zinquin (ratiometric Zn(II)-probe).163 B. ZnAF-1(ratiometric Zn(II)-probe).164 C. 





Figure 1-19.   Chemical structures of iron probes based on fluorescence 
quenching of the fluorophore moiety upon binding of iron to the metal chelating 
moiety  A. Fl-Phen. B. NBD-DFO. 161,162 
 
1.2.5 Green Fluorescent Protein – A Vital Tool for Cell Imaging Applications 
 Fluorescence has long been used for cell imaging applications.167 Originally, 
fluorescence imaging of biological systems was carried out with small molecule 
fluorescent dyes attached to the protein of interest through antibodies. This usually 
necessitates cell fixation and permeabilization. Moreover, fluorescent dyes were also 
developed that can recognize certain organelles and molecules in the cell. Green 
Fluorescent Protein (GFP) offers a non-invasive alternative for imaging of living cells and 
organisms (Figure 1-20). Many mutants, fluorescing in different colors, have been 
created (Figure 1-21).168 The genetically encoded fluorescent proteins, which can be 
expressed as fusion proteins with the protein of interest, have revealed the location and 
functions of numerous proteins. The significance of fluorescent proteins was recognized 
by awarding Martin Chalfie, Osamu Shimomura and Roger Y. Tsien the 2008 Nobel 







Figure 1-20.   Cartoon rendering of X-ray structure of green fluorescent protein 







Figure 1-21.   San Diego beach scene drawn with E. coli expressing 8 differently 
colored fluorescent proteins (created in Tsien lab). 
 
 
1.2.6 Signal Peptides 
 Genetically encoded proteins (e.g. GFP) can be directed to subcellular locations, 
such as organelles and compartments, via signal peptides. These type of localization 
signals are short peptide sequences (around 3 - 60 amino acids) that direct the post-
translational transport of a protein. Typical targets are peroxisomes (AKL; C-terminal),170 
the nucleus (DPKKKRKV; N or C-terminal),171 the endoplasmatic reticulum (KDEL; C-
terminal)172 and mitochondria (MSVLTPLLLRGLTGSARRLPVPRAKIHSL; N-terminal).173 




1.2.7 Cell Imaging by FRET and FLIM 
 Förster Resonance Energy Transfer (FRET) occurs between a donor molecule in 
the excited state and an acceptor molecule in the ground state.160 The donor emits at 
shorter wavelengths (higher energy) and overlaps with the acceptor spectrum. The 
acceptor is either another fluorophore or colored species. Energy transfer occurs in a 
nonradiative fashion as a result of dipole-dipole interactions between donor and 
acceptor. Consequently, the fluorescence emission of the donor decreases upon energy 
transfer (Figure 1-22). FRET efficiency decays with the sixth power of distance between 
donor and acceptor. Thus, high FRET efficiency is obtained with sufficiently large 
spectral overlap, favorable dipole-dipole orientation and close proximity. The strong 
distance dependence renders FRET a valuable tool for studying protein-protein 
interactions and changes of protein conformations.  The genetically encoded CFP-YFP 
(cyan fluorescent protein – yellow fluorescent protein) FRET-pair offers good FRET 
efficiency (if FRET requirements are met) and is widely used for cell imaging 




Figure 1-22.   Fluorescence emission spectra of FRET pair Fluorescein-
Rhodamine in high density lipids.160 
 
 FRET can also be measured based on the rate of decay of the fluorescence 
signal rather than fluorescence emission (FLIM = Fluorescence Lifetime Imaging) 
(Figure 1-23). The advantage of this method is that fluorescence lifetime is unaffected by 






Figure 1-23.   Protein localization using FRET-FLIM microscopy of CFP-YFP 
couple. A. Fluorescence lifetime distribution in cell. B. Two-dimensional lifetime 
distribution within specified area. C. Three-dimensional plot of lifetime 
distribution.175 
 
1.2.8 Protein Labeling for In Vivo Cell Studies 
 In vitro studies in clearly defined and simplified systems have improved the 
understanding of many biological aspects and systems. However, the insights gained by 
in vitro studies are limited because an artificial system cannot simulate all physiological 
characteristics of a cell such as localization, dosage, timing and intermolecular 
interactions.176 Utilizing cysteine moieties (naturally occurring or introduced by point-
mutations) within the peptide chain of a protein has been a common method to 
functionalize proteins in vitro (usually by formation of a disulfide-bond) but is not suitable 
for in vivo applications due to the abundance of soluble thiols in the intracellular 
environment. The requirements for successful in vivo labeling of proteins are efficient 
reactivity in aqueous solution, inertness of the label to the surrounding cellular 
environment, high selectivity or even specificity to the protein of interest and high 
stability of the formed protein-label adduct.177 Several methods, which meet the 
requirements for in vivo labeling of proteins, have been developed (Scheme 1-8). All of 
the illustrated methods are based on the expression of the protein of interest with a 
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fusion portion that allows reaction with the desired label and will be explained in detail in 
the following chapters. 
 
 
 Scheme 1-8.  
 
1.2.8.1 Biarsenical Tetracysteine System 
 In the biarsenical tetracysteine protein labeling approach the label contains two 
trivalent arsenic ethanedisulfide moieties that bind to a tetracysteine motif of the protein 
of interest (Cys-Cys-Xaa-Xaa-Cys-Cys; Xaa = non-cysteine amino acid) (Scheme 1-
8).178-180 This method is a particularly useful alternative if the size of GFP (≈ 25 kDa) 
leads to perturbation of the protein function. Therefore most of the utilized labels are cell-
permeable fluorescein and rhodamine derivatives (≈ 0.5 kDa). One of the drawbacks of 
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this method is the higher fluorescence detection threshold compared to GFP due to 
background labeling. 
 
1.2.8.2 Protein Splicing and Trans-Splicing  
 Protein splicing is an autocatalytic posttranslational process in which an 
intervening polypeptide sequence (intein) is excised while the flanking sequences 
(exteins) are joined by a peptide bond.181,182 The intein domain (≈150 amino acids) 
cannot be excised by itself. Cysteine or serine at the N-terminus and the triad His-
(Asn/Gln)-(Ser/Thr/Cys) at the N-terminus of the splicing junction are required for the 
splicing reaction. The splicing mechanism consists of four major steps (Scheme 1-9). 
First there is an N-S shift (or N-O shift in case of serine), which is a rearrangement that 
leads to a thioester (or ester in case of serine). This step is followed by nucleophilic 
attack of the thiol moiety of the intein flanking cysteine (transesterification; OH moiety in 
case of serine and threonine). Cyclization of the Asn/Gln residue results in the release of 
the intein domain. The reaction concludes with an S(O)-N acyl shift of Ser/Thr/Cys to 
form a peptide bond between the exteins. 
 Trans-splicing with split-inteins takes advantage of the protein splicing reaction 
(Scheme 1-10). The intein domain can be cut into two pieces. The splicing reaction is 
initiated by recombination of the split-inteins. This method can be utilized to label 
proteins.183 In theory the label can be attached to the N-extein or C-extein. Connecting 
the label with the N-extein domain is more feasible in case of generating the label-N-
extein-split-inteinN portion by synthetic means because the inteinN domain can be as little 
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as 11 amino acids.184 Long reaction times and reported yields of only about 30% are 
challenging downsides of this labeling method. 
 





 Scheme 1-10.   Mechanism of trans-splicing by split-inteins. 
 
1.2.8.3 Expressed Protein Ligation 
 Expressed Protein Ligation (EPL) is based on the native chemical ligation 
method, whereby two unprotected synthetic peptides are joined, forming a peptide 
bond.185 In native chemical ligation an α-thioester reacts with an N-terminal cysteine 
specifically even in the presence of internal cysteines. In case of in vivo EPL the protein 
of interest is fused to a modified intein domain (Scheme 1-8). Incubation with a cell-
permeable N-cysteine containing label leads to reaction with the expressed protein and 
displacement of the intein domain.186 Since N-terminal cysteines do not occur in 
biological systems naturally side-reactions by competition with N-cysteine containing 




1.2.8.4 Human Alkylguanine Transferase 
 Mutant Human O6-alkylguanine-DNA alkyltransferase (AGT) is a monomeric 
protein (≈ 177 amino acids) that can be labeled with substrates containing an 
alkylguanine moiety (Scheme 1-8).187,188 The labeling reaction occurs by reaction of 
cysteine moieties inside the active site with the substrate under release of 
benzylguanine. It usually proceeds quickly and irreversibly. AGT reacts with a wide 
variety of substrates (that have an alkylguanine moiety) rendering it a highly attractive 
labeling method. A possible obstacle is the observed slow but steady unfolding of the 
protein induced by labeling with certain substrates. 
 
1.2.8.5 Other Labeling Methods for In Vivo Cell Imaging Applications 
 The nonsense suppression technique allows the site-specific introduction of 
unnatural amino acids into the protein of interest by modified tRNAs.189 Other labeling 
methods include peptide labeling based on biotin ligase190 and Halo-tag (mutant 
dehalogenase that reacts with certain chloroalkane derivatives).191 A comprehensive 





1.3 Thesis Objective 
 The objective of this thesis was to develop semi-synthetic proteins for catalytic 
and analytical applications.  
 The replacement of organic solvents by environmentally benign solvents such as 
water is an imperative step towards achieving “green chemistry”. Platinum metals offer 
powerful catalysts with broad substrate tolerance but are not biologically available. 
Proteins catalyze a plethora of reactions with high turnover number and high 
stereoselectivity in their native solvent, which is water. One of the primary objectives of 
this thesis was to combine the advantages of “both worlds” by generating a semi-
synthetic protein. The semi-synthetic protein consists of a catalytically active achiral 
platinum metal cofactor embedded into a protein framework that induces chirality of the 
products. The first part of the semi-synthetic proteins for analytical applications section 
focused on the development and characterization of a synthetic platinum series metal 
cofactor that is able to catalyze a suitable model reaction in aqueous medium in the 
absence of the protein. The second part of this topic focused on the catalysis of the 
model reaction by the synthetic cofactor embedded in a protein. 
 The exploration of labile metal pools of the biologically relevant transition metals 
copper, iron and zinc in cells was the purpose of developing semi-synthetic proteins for 
analytical applications. Fusion proteins consisting of fluorescent proteins and a “reactive” 
domain that allows attachment of fluorescent or colored chelators (upon metal binding) 
offer an attractive platform for in vivo cell imaging. The genetically encoded fusion 
proteins are directed to different compartments of interest in the cell. Formation of 
FRET-pairs upon metal binding allows the detection of the desired transition metals by 
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changes in the fluorescence emission or lifetime. The exploration of labile metal pools by 
fluorescence lifetime measurements is an especially promising approach because the 
fluorescence lifetime is unaffected by the probe concentration or excitation intensity. The 
focus was on the development and in vitro characterization of such semi-synthetic 
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CHARACTERIZATION OF RUTHENIUM PORPHYRINS AS 
WATER-SOLUBLE ORGANOMETALLIC CATALYSTS 
 
2.1 Introduction and Concept 
 The replacement of organic solvents by environmentally benign solvents such as 
water is an imperative step towards achieving “green chemistry” (see chapter 1.1.1).1 
Utilizing semi-synthetic proteins for catalysis with a cofactor containing a platinum metal 
requires either thermodynamic or kinetic stability of the platinum metal catalyst and all 
reactants in the native solvent of the protein, which is water. Many organometallic 
catalysts are known to undergo reactions in water, which lead to their deactivation (see 
chapter 1.1.2).2 Therefore, the focus of this study was to explore, whether catalysis with 
a platinum metal porphyrin (without being attached to a protein) can be carried out 
successfully in aqueous medium. Properties such as turnover numbers, kinetics and the 
influence of axial ligands on the reactivity of the catalyst were studied. These 






2.1.1 Semi-Synthetic Protein Designs Based on Incor poration of Cofactors  
In order to choose a platinum metal cofactor that can be incorporated into a 
protein and exhibit catalytic activity, the methods of embedding a cofactor into a protein 
have to be considered.  The incorporation of an organometallic cofactor into a protein 
can in principle be accomplished by three basic approaches.3,4  
First, an appropriate metal binding site can be directly generated in the active site 
of the protein by site-directed mutagenesis utilizing naturally occurring amino acids as 
coordinating ligands. This type of design requires a very detailed understanding of the 
coordination chemistry of amino acid ligands bound to the non-biological metal center. 
Moreover, any influences of the metal on the conformation of the active site or the 
surrounding protein backbone upon incorporation are difficult to predict. Thus, simple 
reconstitution of a metalloprotein with a platinum series metal would probably yield a 
catalytically inactive enzyme.  
The second method to create a semi-synthetic protein containing a platinum 
metal series organometallic cofactor is by supramolecular attachment. This highly 
promising approach was greatly optimized for hydrogenation reactions with rhodium 
based catalysts, based on the streptavidin/avidin biotin technology,5 by Ward and 
coworkers;6-14 however, this viable design of artificial metalloenzymes utilizes poorly 
defined structures. Therefore supramolecular anchoring attempts by the 
streptavidin/avidin biotin non-covalent interactions were not pursued.    
Finally, an organometallic cofactor can be attached to a protein framework by the 
cofactor reconstitution method.15  In this method the metal cation is embedded as a 
prebuilt synthetic prosthetic group. The incorporation of either natural or modified 
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cofactors by this method was carried out successfully for several hemoproteins and 
flavoenzymes.16-18 An important benefit of this approach is that the organometallic 
cofactor is already catalytically active, even if it is not incorporated in a protein. Thus, the 
synthetic cofactor can already be tested and optimized for reactions in aqueous media. 
Moreover, the cofactor reconstitution method allows the incorporation of the cofactor into 
the structurally clearly defined (if structural information is available) active site. The 
active site pocket provides a chiral framework that induces stereoselectivity. Reaction 
properties of the resulting semi-synthetic enzyme, including turnover number, substrate 
selectivity and enantioselectivity, can be enhanced by site-directed mutagenesis of 
crucial active-site residues. 
 Heme proteins and enzymes contain heme groups, which are metalloporphyrins 
(usually Fe-porphyrins). Metalloporphyrins are ubiquitous organometallic cofactors that 
are involved in the binding of oxygen (e.g. hemoglobin and myoglobin) and catalyze a 
plethora of reactions, such as oxidations (e.g. peroxidases and cytochrome c oxidase) 
and electron transfer reactions (e.g. cytochrome c).16,19,20  The porphyrin prosthetic 
groups are mostly bound in the active site by hydrophobic interactions and hydrogen 
bonding. Due to the lack of covalent interactions they often can be readily extracted at 
acidic pH.15  Despite some losses by denaturation of the protein due to the low pH, the 
reconstitution of the protein with the cofactor usually leads to the recovery of the original 
enzyme activity. Consequently, the reconstitution of the apoprotein with a synthetically 
modified metalloporphyrin cofactor, containing a biologically not available platinum 




2.1.2 Selection of Platinum Metal in Cofactor 
 Ruthenium organometallic complexes facilitate the catalysis of myriad 
reactions.21 Ruthenium porphyrins catalyze the cyclopropanation of a variety of olefins, 
22-32 thus rendering this type of reaction an attractive starting point for the development of 
a catalytically active semi-synthetic protein. While iron porphyrins are efficient catalysts 
for the cyclopropanation of olefins this prosthetic group was originally evolved to bind 
dioxygen and would primarily function as oxidation catalyst or oxygen carrier.33,34  Many 
peroxidases, containing iron porphyrins as cofactor, can facilitate the enantioselective 
epoxidation of a broad range of olefins utilizing hydrogen peroxide as oxidizing agent.35-
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2.1.3 Selection of Model Reaction 
Epoxidation and cyclopropanation are closely related organic transformations of 
olefins (Figure 2-1). In case of the epoxidation reaction, an electrophilic iron-oxo or 
peroxo porphyrin species is attacked by the electron rich C=C double bond of the olefin 
to give an epoxide. In the cyclopropanation reaction a Fisher-type ruthenium porphyrin 
carbene intermediate is formed, which is electrophilic and reacts with the electron rich 
alkene double bond yielding a cyclopropane species. The carbene complex is only 
slightly larger than the iron-oxo intermediate rendering the active site of hemoproteins, 
capable of catalyzing epoxidation reactions, spacious enough to accommodate the 
carbene intermediates of the cyclopropanation reaction. 
Cyclopropanes are attractive synthetic targets because the reactivity of the three-
membered ring due to their high ring-strain renders them useful as synthetic building 
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blocks. Cyclopropane derivatives can be found in numerous natural products and 
biologically active compounds.  
 A key requirement for the creation of a “cyclopropanase” is that the cofactor is 
catalytically active under the conditions required by its protein-host. Since proteins 
require water as their natural solvent the ruthenium porphyrin catalyst, its carbene 
intermediate and all involved reagents have to be stable enough in aqueous medium to 
successfully catalyze the cyclopropanation reaction (Scheme 2-7). 
 





2.1.4 Selection of a Suitable Ruthenium Porphyrin f or Aqueous Cyclopropanation 
Model Reactions 
 In order to successfully carry out cyclopropanation reactions in aqueous media 
the catalyst needs to be water-soluble (in case of homogenous catalysis). The 
solubilization of chemical compounds for applications in water can be achieved by 
adding polar functional groups, such as the alcohol, amine, amide, carboxyl, phosphate 
and sulfonate groups.38  Moreover, the ruthenium porphyrin should contain bulky 
moieties to inhibit or reduce dimerization. Dimerization is a known feature of certain 
ruthenium porphyrins and can still result in catalytically active species (Figure 2-2).39 
Due to hydrophobic effects, dimerization of the ruthenium catalyst might even be more 
favorable in water than in organic solvents. However, a dimer is not representative as a 
model for possible reactions with reconstituted proteins because the active site pocket 
will most likely not be large enough to fit a dimer. Besides, the ruthenium porphyrin 
should have a relatively simple structure that does not require a laborious multi-step 
synthesis. A symmetric structure simplifies spectral studies, which is an important 
feature for mechanistic studies. Moreover, the synthesis should lead to sufficient 
quantities for detailed analytical studies. 
Ruthenium(II)carbonyl meso-tetrakis-(4-carboxyphenyl)porphyrin (Ru(CO)TPP-acid) 
encompasses all these requirements (Scheme 2-2). It has four carboxylic acids to 
increase the water-solubility, is highly symmetrical and can be synthesized in suitable 











 The synthesis of Ru(CO)TPP-acid commenced with the acid catalyzed reaction 
of the two commercially available starting materials methyl 4-formylbenzoate (2-1) and 
pyrrole (2-2), yielding meso-tetrakis-(4-carboxyphenyl)porphyrin tetramethyl ester (2-
3).40  The ruthenium carbonyl moiety was inserted into 2-3 by reaction with Ru3(CO)12 at 
high temperatures (190 °C) leading to ruthenium(II) carbonyl meso-tetrakis-(4-
carboxyphenyl)porphyrin tetramethyl ester (2-4).41 The water-soluble final ruthenium 





 Scheme 2-2.   
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2.3 Model Cyclopropanation Reactions in Aqueous Med ium 
2.3.1 Selection of Reaction Conditions  
 In choosing suitable reaction conditions, the most important parameters are the 
type of diazo compound acting as a “carbene-donor”, the olefin, buffer, pH and a 
cosolvent. Cyclopropanation reactions with ruthenium organometallic catalysts are most 
commonly carried out with either methyl diazoacetate or ethyl diazoacetate due to their 
commercial availability and relative stability (explosive only at elevated temperatures 
unlike diazomethane).43 Styrene is the simplest aromatic terminal alkene and most 
widely used for cyclopropanation reactions despite its tendency to polymerize. Styrene’s 
lipophilicity and subsequent insolubility in water can be overcome by the addition of a 
water-miscible cosolvent, such as acetone or acetonitrile. Common buffers such as 
phosphate and acetate buffers often are not suitable for organometallic transformations 
because the formed ions can bind to metal center and subsequently change the 
reactivity. An alternative non-coordinating buffer is 1,4-piperazinediethanesulfonic acid 
(PIPES), suitable for buffering around neutral the pH (pKa = 7.2).  
 Hence, the model cyclopropanation reactions were conducted with 2-5, EDA and 
styrene in a PIPES buffered solution with acetone as cosolvent (Scheme 2-3). 
 
Scheme 2-3.    
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2.3.2 Analysis of the Model Cyclopropanation by GC- MS 
 The cyclopropanation of styrene by slow addition of ethyl diazoacetate was 
catalyzed by Ru(CO)TPP-acid (2-5) in aqueous buffered solution at neutral pH (Scheme 
2-3). The reaction mixture was analyzed by coupled gas chromatography – mass 
spectrometry (GC-MS). Four compounds could be reliable identified (other compounds 
were either solvent additives or known impurities in the column): styrene, diethyl 
maleate, cis-1-carbethoxy-2-phenylcyclopropane (2-6a) and trans-1-carbethoxy-2-
phenylcyclopropane (2-6b) (Figure 2-2). The absence of the starting material ethyl 
diazoacetate despite unreacted styrene is either caused by decomposition during the 
reaction or by thermal decomposition in the GC column (due to the gas chromatography 
process), which is a well established property of diazo-compounds.44  The formation of 
diethyl maleate and diethyl fumarate is a common side-reaction for ruthenium-based 
catalysis with EDA.43 In fact, ruthenium porphyrins that are similar to 2-5 are efficient 





Figure 2-2.    GC-MS chromatogram of cyclopropanation reaction. An HP-5 column was used ((5%-Phenyl)-







Interestingly, the formation of the trans-sideproduct diethyl fumarate was not observed. 
The pathway for its formation is either not accessible in water or the small amount of 
fumarate, formed during the cyclopropanation reaction, is below the detection limit of the 
instrument. 
 
 Scheme 2-4.    
 
2.3.3 Quantitation by GC-FID 
 Several requirements have to be met in order to quantify the compound 
compostion accurately by GC-FID (FID = Flame Ionization Detection). The crucial 
requirement of volatility and mobility in the stationary phase has already been met 
(Chapter 2.3.1). Since it is desirable to use an internal standard, such as tetradecane or 
dodecane, to correct for the loss of analyte during sample preparation or sample inlet the 
measured ratios of analyte to internal standard have to be linear in the desired range. 
Therefore a series of solutions with varying analyte concentrations of styrene, diethyl 
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maleate and the trans-cyclopropanation product 2-6b with constant amounts of 









 Figure 2-4.  Standardization graphs of styrene, diethyl maleate and 2-6b. 
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Plotting of mass analyte to mass internal standard (dodecane) ratio against peak area 
analyte to peak area internal standard ratio provided standardization graphs. These 
showed exclusively linear behavior in the desired concentration region. Thus, all relevant 
analytes could be reliably quantified by GC-FID in the further studies. 
 
2.3.4 Influence of the pH on the Cyclopropanation R eaction in Aqueous Medium 
 The influence of the pH on the cyclopropanation was investigated because the 
stability of the catalytically active species and formation of the desired cyclopropanation 
products and potential side-products could be pH dependent (see Scheme 2-7). 
Therefore a series of cyclopropanation reactions of styrene with EDA, catalyzed by 
ruthenium porphyrin 2-5, was carried out in buffered solution in the pH range of 6.0 to 
8.0. The amounts of the reagent styrene, the side-product diethyl maleate and the 
desired cis- and trans cyclopropanation products 2-6a,b and their corresponding yields 
were determined by GC-FID (Figure 2-5; Table 2-1).  
Table 2-1.  Yields of the cyclopropanation reaction of styrene with EDA catalyzed by 2-5 
and unreacted starting material. 









6.0 26.31 28.08 0.78 16.22 
6.5 17.88 7.19 0.35 27.97 
7.0 19.53 7.69 0.38 37.15 
7.5 19.18 7.87 0.30 29.15 




 Ruthenium porphyrin 2-5 successfully catalyzed the cyclopropanation of styrene 
and afforded a fair yield of the trans-product 2-6b (about 33%) in the pH range of 6.5 to 
8.0. At pH 6.0 the catalyst precipitated during the reaction and this presumably led to the 
observed low yield of about 16%. The reaction did not go to completion because 
unreacted styrene was found in the reaction mixture. Over the pH range of 6.5 to 8.0 the 
product distribution remained essentially unchanged despite a 100-fold proton 
concentration difference (pH 6.0 compared to pH 8.0). Slightly lower yields at acidic pH 
may be caused by lower local concentrations of styrene due to polymerization. The 
polymerization of styrene in aqueous medium might even be accelerated by hydrophobic 
effects (see chapter 1.1.2). At pH 7.5 and 8.0 hydrolysis of the ester moiety of 2-6a,b 
could be the reason for slightly lower yields at pH 7.5 and 8.0. The yield of diethyl 
maleate, requiring the reaction of two molecules of EDA each, is low in the pH range of 

































 Figure 2-5.   Cyclopropanation of styrene in aqueous medium with varying pH. 
With regard to the formed trans-cyclopropanation product 2-6b the yield of the maleic 
ester ranged from 20% to 27%. At pH 6.0 much more diethyl maleate is probably formed 
due to precipitation of the ruthenium catalyst suggesting that the relative concentration of 
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catalyst compared to EDA has an impact on the formation of the maleic ester. This is 
consistent with findings that fast addition of EDA to ruthenium porphyrins yielded 
increased amounts of maleate.45 Diethyl maleate is considered to be the kinetic product 
while 2-6a,b are considered to be the thermodynamic products. 
 The successful cyclopropanation with the ruthenium porphyrin catalyst 2-5 in 
aqueous medium is remarkable. Water as a reaction medium did not deactivate the 
ruthenium metal center. The proposed catalytically active Fisher-carbene intermediate 
(Figure 2-1) is either thermodynamically or kinetically stable enough in water to facilitate 
the cyclopropanation reaction. Decomposition of the carbene intermediate by insertion in 
the O-H bond of water was not observed; however, other organometallic platinum series 
metal complexes show different behavior.46 The addition of ethyl diazoacetate to 
allylalcohol in the presence of a catalytic amount of platinum complexes afforded the 
corresponding OH insertion product without yielding any cyclopropanation product 
(Scheme 2-4a).47 Rhodium carbene complexes react readily with water by OH insertion. 
Particularly interesting is the formation of ethers catalyzed by rhodium porphyrins 
(Scheme 2-4b).48 Hence, if the ruthenium metal center of catalyst 2-5 was replaced with 
rhodium then transformation of the diazo moiety of EDA to a hydroxyl group instead of a 
cyclopropanation reaction would have most likely occurred. However, ruthenium 
complexes can also show this type of reactivity. Ruthenium complexes with N-(p-
toluenesulfonyl)diamine ligands are also efficient catalysts for the insertion of OH bonds 
into carbenes generated from diazo esters.49 On the other hand, organometallic 
ruthenium catalysts can facilitate cyclopropanation reactions in aqueous medium. Due to 
possible OH insertion it is not surprising that there are only few examples of aqueous 
cyclopropanation reactions. The first example of a successful cyclopropanation in 
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aqueous media was achieved by bis(hydroxymethyldihydrooxazolyl)pyridine-ruthenium 
catalysts (ruthenium-pybox) (Scheme 2-4c).50 In agreement with the results of the 
cyclopropanation catalyzed by Ru(CO)TPP-acid in aqueous medium are X-ray 
structures of ruthenium porphyrin carbenes having hydrophilic solvents like methanol 
and ethanol as ligands.26 This suggests that OH insertion is indeed not favorable for 
carbenes of ruthenium porphyrins. The yields of ruthenium-pybox catalyzed 
cyclopropanation reactions in water (biphasic) are similar to the obtained yields for the 
Ru(CO)TPP-acid catalyzed reaction; they usually are around 40 to 50 %. In contrast, 
Simmoneaux and coworkers catalyzed the cyclopropanation of styrene with EDA by the 
structurally related Ru(CO)TPP (Figure 2-1) in much higher yields in CH2Cl2 (85 %).
26  In 
summary, the successful cyclopropanation by 2-5 in water with acceptable yields 
represents an encouraging result for the utilization of ruthenium porphyrins as cofactors 




 Scheme 2-4. 47,48,50  
 
2.3.4.1 Mass Balance of Reaction 
 The sum of the molar equivalents of the products has to equal the sum of the 
molar equivalents of the starting materials. Summing up of the products and the educts 
revealed that about one third of the compounds could not be accounted for by GC-FID 
quantitation (Figure 2-6). The missing compounds are most likely styrene because of 





Figure 2-6.   Molar fractions of quantitated educts and products. 
 
2.3.4.2 Stereoselectivity of Reaction 
 The cyclopropanation reactions proceeded with high cis/trans selectivity in the 
pH range of 6.5 to 8.0 (pH 6.0 was omitted due to precipitation of the catalyst). The 
cis/trans ratio ranged from 1:80 up to 1:99 (Figure 2-7). This constitutes the highest 
stereoselectivity reported for the cyclopropanation of styrene with EDA that has been 
catalyzed by a ruthenium porphyrin. In comparison, Simmoneaux and coworkers 
catalyzed the same reaction with the structurally similar Ru(CO)TPP (Figure 2-1) in 
CH2Cl2 with a cis/trans ratio of only 1:14 (Figure 2-8).
26 Among organic solvents, such as 
benzene, toluene and dichloromethane, the product distribution of this kind of reaction 
varies only slightly. Apparently, the selection of water instead of organic solvents can 





Figure 2-7.   Stereoselectivity of cyclopropanation of styrene in aqueous medium 
with varying pH. 
 
 





2.3.5 Phase Transfer Catalysis 
 The catalytic cyclopropanation of styrene was carried out in a biphasic system 
consisting of an equal mixture of THF and aqueous HEPES buffer.51 Under these 
conditions the cyclopropanantion products 2-6a and 2-6b were obtained with only 14 % 
yield (Scheme 2-5). The yield was dramatically improved (83 %) by addition of 5 mol% of 












 Scheme 2-5.    
 
 Given the increase of yield, styrene was catalytically transformed to its 
cyclopropanation product with ruthenium porphyrin 2-5 in the presence of 2.2 mol% of 
the phase transfer catalyst cetyltrimethylammonium bromide (CTAB) (Scheme 2-6). 
Styrene only dissolves partially in an acetone/water mixture. The yield might increase 
through better solubility caused by the phase transfer catalyst. Unfortunately, the 
reaction proceeded in a sluggish way, with the generation of dark, decomposed and 




 Scheme 2-6 .   
 
2.3.6 Reagent Addition Time Studies 
 The catalytically active species of the cyclopropanation of styrene by ruthenium 
porphyrin 2-5 is presumably a carbene species, which is formed by reaction with EDA 
(Scheme 2-7). This carbene species can either react with styrene to yield the desired 
cyclopropanation product or react with EDA forming diethyl maleate. That is why the 
formation of diethyl maleate can be reduced or inhibited by keeping the concentration of 
EDA in the reaction mixture low (compared to styrene) through slow addition.52 
Consequently, several different addition times of ethyl diazoacetate were utilized to 
catalyze the cyclopropanation of styrene with ruthenium porphyrin 2-5 in order to 
optimize the reaction conditions (Figure 2-9). The previously arbitrarily chosen EDA 
addition time of eight hours (used for the pH influence studies) turned out to provide the 
best yields of cyclopropanation product. Shorter addition times resulted in decreased 
formation of the desired product and increased diethyl maleate. Longer addition times 
led to slightly lower yields and about the same amount of the maleic ester side-product 
(compared to eight hours addition time). Therefore the addition time of eight hours was 




Figure 2-9.   Yields of 2-6b of the cyclopropanation reaction of styrene with EDA 
catalyzed by 2-5 in comparison with the yields of diethyl maleate. The respective 
yields were obtained with varying addition times of EDA. 
 
2.3.7 Concentration Dependent Turnover Numbers 
 A series of cyclopropanations of styrene with EDA in aqueous medium catalyzed 
by varying amounts of ruthenium porphryin 2-5 were conducted. Catalytic 
cyclopropanation activity was obtained even at very low catalyst loads (7.6% yield with 
0.03 mol% 2-5) (Figure 2-10). The yield of cyclopropanation product 2-6b and the 
amount of utilized catalyst were not directly proportional to each other. Therefore the 
resulting catalyst load dependent turnover numbers were not constant (Figure 2-11). 
Lower catalyst loads led to higher turnover numbers. The difference in turnover numbers 
between the highest and lowest amount of ruthenium porphryin 2-5 was almost five-fold. 
The catalyst turnovers were in the range of cyclopropanations of styrene with ethyl 





Figure 2-10.   Yield dependence of 2-6b on catalyst load (2-5) of the 
cyclopropanation of styrene. 
 
 
Figure 2-11.   Dependence of turnover number on catalyst load (2-5) of the 




2.4 Reaction Kinetics  
2.4.1 Catalytic Cycle 
 In order to analyze potential reaction pathways of the cyclopropanation reaction 
in water the kinetic parameters of the catalytic pathways had to be determined. A 
catalytic cycle for the cyclopropanation of styrene with ruthenium porphyrins was 
designed based on the findings of Che, Collman and Simmoneaux et al. for this type of 
reaction in organic solvents and potential pathways occurring in aqueous medium 
added.23,26,45,53  The catalytic cycle commences with the reaction of the ruthenium 
carbonyl porphyrin (I) with ethyl diazoacetate, forming a carbene species (II) while 
undergoing decarbonylation. The supposedly electrophilic carbene intermediate is 
attacked by the electron rich olefin styrene yielding the cis/trans cyclopropanation 
product. In lieu of reacting with styrene carbene species II can also undergo reaction 
with another molecule of EDA producing the olefins diethyl maleate and diethyl fumarate 
(the formation of diethyl fumarate was never observed in aqueous medium; see chapter 
2.3.2). The resulting 6-coordinated ruthenium porphyrin species III, having only water as 
axial ligands, is an active cyclopropanation catalyst. It can react with a new molecule of 
EDA generating ruthenium porphyrin carbene II again, thus concluding the catalytic 
cycle. Ethyl diazoacetate itself can undergo hydrolysis forming the glycolic acid ester IV. 





 Scheme 2-7.    
 
2.4.2 Kinetics of Carbene Formation 
The formation of the carbene-complex for the reaction of 2-5 with ethyl diazoacetate in 
aqueous solution at neutral pH was monitored by UV-vis spectroscopy (Figure 2-12) 
(Scheme 2-7). Varying equivalents of EDA (1 to 4) were reacted to examine the kinetics 
of the reaction (Figure 2-13). Non-linear least squares fit of the UV-vis traces over the 
entire wavelength range revealed EDA dependent second order rate constants (Table 2-
2). The formed carbene species can react with another molecule of EDA yielding diethyl 
maleate. This reaction pathway causes an error for the observed rate constants for the 
generation of carbene complex II. The more equivalents of EDA are used the more 
diethyl maleate is formed. Therefore the most accurate rate constant for the formation of 




Figure 2-12.   UV-vis traces at the beginning (t=0) and after 2 h of the reaction of 
2-5 (40 µM) with EDA. The reaction was carried out at room temperature in 
PIPES buffer at pH 7.0. 
 
 
Figure 2-13.   Absorbance change at 530 nm as a function of time and added 
equivalents of EDA. The reaction of 2-5 (40 µM) with EDA was carried out at 
room temperature in PIPES buffer at pH 7.0. 
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Table 2-2.   EDA dependent rate constants for the aqueous cyclopropanation of styrene. 
Equiv. EDA 1 2 3 4 
k2 [M
-1s-1] 5.2426 4.7682 4.1965 3.4914 
Standard 
deviation 0.07234 0.04584 0.06883 0.071891 
 
 
2.4.3 Kinetics of Reaction of Carbene-Complex with Styrene 
 EDA was reacted with ruthenium porphyrin 2-5 and various equivalents of 
styrene. Spectral shifts in the visible range could also be observed, but the final 
absorbance was significantly higher after 2 hours than without styrene. Thus, the rate 
constant of the reaction of the carbene and styrene was determined by fitting to the 
following system: A+B⇒C; C+D⇒E+F. However, the data could be fitted to several 
kinetic systems and different starting values for the rate constant curve fit resulted in 
different values for k. Therefore no reliable rate constant for the reaction of the carbene 
with styrene could be obtained. This might be due to the error caused by the poor 
solubility of styrene in water.  
 
2.4.4 Kinetics of Decomposition of EDA in water 
 The rate of decomposition of EDA in water has to be determined in order to 
correct the rate constants for the formation of the carbene-complex and to examine all 
the kinetic pathways. Instability in the presence of acids is a characteristic property of 








decomposition (Scheme 2-8). After protonation the diazo compound can decompose 
irreversibly into several different products under release of nitrogen. Staudinger 




 Scheme 2-8.   Acid catalyzed decomposition of diazo compounds. 
Electron-withdrawing groups reduce the nucleophilicity of the diazo carbon (-I effect) and 
consequently its basicity. Therefore an ester moiety should significantly decrease the 
rate of decomposition of a diazo alkane. Thus, ethyl diazoacetate is predicted to be fairly 
stable in water. Roberts el al. studied the decomposition of ethyl diazoacetate in water in 
the presence of acids (Scheme 2-9).56  The formation of only the glycolic acid ester IV as 
decomposition product was observed. Ethyl diazoacetate exhibited remarkable stability. 
The decomposition proceeded quite slowly, even under high concentrations of acids. 
  
 
 Scheme 2-9.    
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 The decomposition of EDA in aqueous solution at neutral pH was monitored by 
UV-vis spectroscopy. Its strong absorption at 263 nm was used to follow the 
decomposition (Figure 2-14). After 12 h the change in the absorption spectrum was very 
small (decrease by ≈ 2 %). Therefore the decomposition of EDA in aqueous medium at 
neutral pH was considered negligible. However, many compounds can absorb in this 
range. Therefore, the stability of EDA was also tested by NMR spectroscopy in D2O and 
no decomposition was observed after 24 h (data not shown). These results are in 
agreement with Roberts et al. acid-catalyzed decomposition studies of EDA.56 
 




2.5 Examination of Reaction Mechanism 
2.5.1 Generation of Carbene-Complex in D 2O 
 It was previously assumed that a carbene-complex intermediate is formed in the 
reaction of ruthenium porphyrin 2-5 and EDA. In order to confirm this assumption 2-5 
was reacted with EDA in phosphate buffered D2O and the reaction analyzed by NMR 
spectroscopy (Figure 2-15-A-B). The measured spectra were aligned with the possible 
side-products ethyl glycolate (Fig. 2-15-C) and diethyl maleate (Fig. 2-16-D) and also 
with the starting material ethyl diazoacetate (Fig 2-15-E). The carbene-complexes of 
similar porphyrins, generated by reaction with EDA, were previously described.26,45,52   
The carbene moiety exhibited three signals in C6D6: 13.79 (s, C-H, 1H); 2.58 (q, CH3, 
3H); 0.01 (t, CH2, 3H). The chemical shifts in D2O and C6D6 are usually close to each 
other unless there are particular interactions between the solvent and the solute, such as 
hydrogen bonding or π-stacking. However, no peak around 13.8 ppm was found in the 
spectrum. This could be due to H-D exchange because of the acidity of the proton. The 
pKa values of many Fisher carbene complexes were determined by Bernasconi et al.
57 
Some of them are rather acidic, e.g. pentacarbonyl(methoxymethylcarbene)chromium(0) 
was estimated of having a pKa of 12.3 in water.
58 Unfortunately, the expected triplet and 
quartet of the carbene moiety (0.01 ppm and 2.58 ppm respectively) were not observed 
with the correct chemical shift either. The two quartets (q1 and q2) and triplets (t1 and 
t2) in the obtained spectrum do most likely not derive from a carbene complex because 
the chemical shifts are off by at least 1.2 ppm from the expected signals at 2.58 ppm and 
0.01 ppm. In fact, alignment with several compounds revealed a very good match of the 
quartet at 4.3 ppm and the triplet at 1.3 ppm with the corresponding peaks of diethyl 
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maleate. The assignment of the remaining quartet and triplet is not as obvious. The 
signals match ethyl diazoacetate best but are nevertheless slightly off, thus they cannot 
be assigned with absolute certainty. Analysis of the reaction mixture by mass 
spectrometry did not confirm the presence of a carbene complex (data not shown).  Due 
to these findings other reaction and catalyst deactivation pathways have to be taken into 
account. 
In theory, ruthenium complexes can react with diazo compounds in several 
different ways. The metal center could interact with the lone pair of the terminal nitrogen 
of the diazo group (Figure 2-16-A). Side-on bonding to the ruthenium metal center is 
another feasible possibility (Figure 2-16-B). Ruthenium organometallic complexes, which 
exhibit this type of interactions between the diazo moiety and the metal center, have 
been isolated and characterized.59,60 Cenini and coworkers examined the 
cyclopropanation of styrene with EDA by cobalt porphyrins, which is very similar to the 
ruthenium porphyrin catalysis.61 They were also not able to form a terminal catalytically 
active carbene complex in their NMR experiments. They suggested based on kinetic 
studies that a porphyrin complex, bound to ethyl diazoacetate with intact diazo moiety, is 
the actual intermediate that catalyzes the cyclopropanation and not a carbene species. 
Moreover, it was proposed that diethyl maleate is formed by an N-bridged carbene. It 
has been shown that iron porphyrin carbene complexes can reversibly isomerize from 
the terminal carbene form to the N-bridged form and vice versa.62 In addition, Tatsumi 
and Hoffmann’s theoretical studies of metalloporphyrin carbene complexes show that a 
decrease of the oxidation state stabilizes the N-bridged form with respect to the terminal 
one.63 Besides, ruthenium porphyrins and iron porphyrins are closely related to each 
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other due to their periodic relationship and can both catalyze the cyclopropanation 




























Figure 2-15.  1H-NMR spectra of reaction of EDA with 2-5. A + B. 2-5 with EDA (1 equiv.). C. ethyl glycolate. D. diethyl 






Figure 2-16.  Possible complexes formed by the reaction of 2-5 with EDA. A. lone 
pair of terminal nitrogen of the diazo group of EDA coordinating to the ruthenium 
porphyrin metal center. B. side-on coordination of the nitrogens of the diazo 
group to the ruthenium center. C. reversible isomerization of terminal carbene to 
its N-bridged form. 
 
Hence, ruthenium porphyrins might also be able to form an N-bridged species (Figure 2-
16-C); however, the NMR experiments did not confirm the involvement of a bridged 
carbene form. The ethyl group would be strongly shifted in the spectrum due to the 
magnetic anisotropy caused by the ring current. The side-on bound complex would show 
similar behavior and it can therefore be ruled out. If the signals at 1.2 and 3.9 ppm do 
indeed not belong to EDA then complex A (Figure 2-16) would be the most likely match 
because the ethyl group is probably far enough away from the ring current to exhibit only 
a small shift in the NMR spectrum. However, all of the discussed complexes might still 
be present in the reaction but react so fast that they cannot be seen in an NMR 
spectrum. Hence, the important question if the terminal carbene species is the 
catalytically active intermediate or simply an “artifact” could not be answered. Moreover, 
the NMR studies suggest that the measured rate constant for the formation of the 
carbene complex represents probably the formation of the ruthenium porphyrin species 
III instead of generation of II (Scheme 2-7). 
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2.5.2 Generation of carbene complex in C 6D6 
 The terminal carbene complex could not be observed in D2O in NMR titration 
experiments. Hence, it was attempted to form the ruthenium carbene species in other 
solvent systems in order to examine its properties. Collman and coworkers reported the 
formation of ruthenium carbene complexes with ruthenium porphyrins in C6D6.
39,45 That 
is why ruthenium carbonyl tetraphenyl porphyrin (2-7; Figure 2-1), which is structurally 
very closely related to 2-5, was reacted with EDA and monitored by NMR spectroscopy 
Figure 2-17). The carbene complex was successfully formed in C6D6 unlike in D2O 
(depicted by arrows in Figure 2-17). The signals in the aromatic region changed strongly 
upon addition of ethyl diazoacetate. Remarkable are the decrease of the signal at 8.9 
ppm and the corresponding appearance of a peak at 8.6 ppm. Interestingly, side-
products are already formed with one equivalent or less of ethyl diazoacetate. Similar to 
the reaction in D2O, comparison of the formed compounds with known side-products and 
the starting material EDA revealed the formation of diethyl maleate (Figure 2-18). 
Especially striking are a triplet at 0.75 ppm (with a small hidden triplet at 0.8 ppm) and a 
quartet at 3.7 ppm (and small quartet at 3.8 ppm probably coupling with the triplet at 0.8 
ppm). These signals could not be assigned to any likely compound, such as starting 
material or known side-products. A similar pattern could be seen in the reaction of 2-5 
with EDA in buffered D2O but it was not clear if the unknown peaks belonged to 
unreacted ethyl diazoacetate or a new species. Assuming similarities in the reactivities 
of these ruthenium porphyrins, it can be concluded that the unknown down-shifted triplet 
and quartet in the reaction in D2O is not unreacted “free” ethyl diazoacetate (Figure 2-










Figure 2-17.  1H-NMR spectrum of carbene formation in C6D6. A. Ru(CO)TPP (2-7) B. 2-7 + EDA (0.5 equiv.) C. 2-7 + EDA (1 



























Figure 2-18.  1H-NMR spectrum of carbene formation in C6D6. A. 2-7 + EDA (1 equiv) B. EDA C. diethyl maleate D. diethyl 
fumarate. Signals that could not be assigned to any likely compound, such as starting material or known side-products, were 
depicted with arrows. 
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2.5.3 Influence of Axial Ligands on Carbene Formati on 
The influence of axial ligands on the formation of the ruthenium porphyrin 
carbene complex was examined in order to attain a better understanding of important 
reaction parameters for the cyclopropanation with a semi-synthetic protein. Lewis bases 
such as imidazole, pyridine, N,N-dimethylamino-pyridine (DMAP) and mercaptoethanol 
were chosen as axial ligands because they show good resemblance to the axial ligand 
moieties of heme groups in heme proteins (histidine and cysteine). Thus, they are 
important models for the feasibility of cyclopropanation reactions by semi-synthetic 
proteins. The studies were carried out in the non-coordinating solvent C6D6 with 
ruthenium porphyrin 2-7 and monitored by 1H-NMR spectroscopy. The selected axial 
ligands are stronger π-donors than water and are therefore expected to bind tighter to 
the ruthenium metal center. Consequently, the opposing bond(s) of either the carbonyl 
or the carbene moiety should get more weakened (trans-effect). Unfortunately, imidazole 
could not be successfully used for the axial ligand experiments due to its surprisingly 
poor solubility in benzene. Ruthenium porphyrin 2-7 was reacted with several 
equivalents of pyridine (4 equivalents total) (Figure 2-19). Upon binding to the ruthenium 
metal center pyridine was expected to exhibit three new signals due to the symmetry of 
the formed complex; however, more than three new peaks appeared in the spectrum. 
Binding of the axial ligand can also be seen by the slight shift of the porphyrin signal at 
8.8 ppm. Interestingly, addition of ethyl diazoacetate did not result in the generation of 
the characteristic peaks of the carbene complex. Instead, comparison with likely 
compounds showed a perfect match for the starting material EDA. Apparently, pyridine 
as axial ligand completely inhibits the reaction of the ruthenium catalyst with ethyl 
diazoacetate. Reacting 2-7 with DMAP revealed a similar pattern (Figure 2-20). Addition 
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of DMAP yielded more than the expected amount of new signals and a slightly messy 
spectrum in the aliphatic region. Again, the carbene formation reaction was inhibited by 
the axial ligand because only unreacted EDA was found in the spectrum. 
Mercaptoethanol is a weaker binding ligand and led to completely different results 
(Figure 2-21). Addition of mercaptoethanol to the ruthenium porphyrin solution in 
benzene resulted in a fairly messy spectrum in the aliphatic region. Despite the broad 
peaks due to mercaptoethanol it could be observed that the addition of ethyl 
diazoacetate did not simply yield in an inert catalyst. Comparison with probable 
molecules demonstrated that EDA was converted to diethyl maleate. However, no 
signals of the terminal carbene species were found in the NMR spectrum. Interestingly, 
traces of the previously observed triplet and quartet (0.75 and 3.7 ppm respectively) of 
an unknown species were also observed. In summary, the results of the influence of the 
axial ligand on the formation of the carbene species present a possible obstacle for the 
development of a semi-synthetic “cyclopropanase” because axial ligands are usually 
bound to the porphyrin metal center in heme proteins. The limitation of this model is that 
an excess of ligand is required to ensure that ligand is bound to the metal center. This 
leads to the potential formation of complexes with a 2:1 binding stochiometry, which are 






















Figure 2-19.   1H-NMR spectrum of carbene formation with pyridine as axial ligand. A. Ru(CO)TPP (2-7) B. 2-7 + pyridine (4 
























Figure 2-20.   1H-NMR spectrum of carbene formation with DMAP as axial ligand. A. Ru(CO)TPP (2-7) B. 2-7 + DMAP (4 





























Figure 2-21.   1H-NMR spectrum of carbene formation with mercaptoethanol as axial ligand. A. Ru(CO)TPP (2-7) B. 2-7 + 




2.5.4 Examination of the Reaction of Lewis Bases wi th Ruthenium Carbonyl 
Porphyrins 
 It has been shown that the reaction with an excess of certain lewis bases and 
ruthenium porphyrin 2-7 in C6D6 resulted in the emergence of more new signals than 
expected (Figure 2-19). Therefore the reaction of pyridine with 2-7 was further 
investigated by electrospray mass spectrometry (MS-ESI), which is a mild ionization 
method that usually causes only little fragmentation. Ruthenium porphyrin 2-7 was 
reacted with an excess of pyridine (20 equivalents) at 50 °C for several hours (Figure 2-
22). Three different cone voltages were used to generate three different levels of 
ionization (low = 5V; medium = 20V; high = 60V). In all conditions the expected signal of 
a 1:1 pyridine-ruthenium carbonyl porphyrin complex (A) could be observed. However, 
another complex was also already formed under mild ionization conditions. The 
exhibited pattern matches the isotope distribution pattern of a 2:1 pyridine-porphyrin 
complex (C) well. The suggested structure of this unknown complex is depicted as a 
complex with one pyridine that is directly bound to the metal center and a pyridine 
moiety that is bound to the carbonyl carbon forming an amide-type bond. This complex 
was stable enough to be apparent at a high cone voltage. The actual ratio of formed A to 
C might be quiet different than illustrated in the mass spectrum because the proposed 
complex C is already charged and thus will already exhibit a signal without any 
additional ionization. It is possible that complex C was formed by the MS process and 
not during the previous reaction. However, the appearance of the signal for complex C 
already at a low cone voltage renders this assumption unlikely. It is noteworthy that the 
spectrum shows almost no signs of decarbonylation. Hence, pyridine does not bind 
strongly enough to the ruthenium metal center to induce the loss of the carbonyl group. 
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The strong signal at high cone voltage can be assigned to an acetonitrile-ruthenium 
carbonyl porphyrin species (B). The acetonitrile derived from the standard ESI mixture 
utilized (acetonitrile/formic acid) by the Georgia Tech Mass Spectrometry Facility. Only 
under fairly harsh conditions was the large excess of acetonitrile able to replace some of 
the axial ligands of 2-7. Complex A exhibited a much greater abundance with regard to 
complex C at high cone voltage. It is not clear if this originates from increased ionization 






Figure 2-22.   MS spectrum of 2-7 reacted with excess of pyridine. A,B and C represent the structures of the most abundant 
signals. 
Huettinger KH-181-II
Georgia Tech Mass Spec Lab 11-Mar-2005 15:52:22
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 This chapter represents the design, development and characterization of a 
suitable reaction, reaction conditions and catalytic system for later utilization in a semi-
synthetic protein. The chosen cyclopropanation reaction proceeded with fair yields and 
high stereoselectivity in the required aqueous medium. The successful cyclopropanation 
in aqueous medium constitutes a crucial requirement for a catalytically active semi-
synthetic protein. Mechanistically, it remains unclear what the actual catalytic species for 
the formation of diethyl maleate and the cyclopropanation product are; however, new 
insights were gained from the mechanistic studies. Moreover, the examination of the 
influence of the axial ligand on the carbene formation illustrated that Lewis bases, such 
as pyridine and DMAP, can inhibit the catalytic reactivity. This might be a major obstacle 
for the development of a catalytically active cyclopropanase because histidine or 










2.7 Experimental Section 
2.7.1 Materials and Reagents 
 Methyl 4-formyl benzoate (Aldrich, 99%), pyrrole (Aldrich, 98%), anhydrous 
decaline (Aldrich, 99% mixture cis + trans), styrene (Aldrich, 99%), ethyl diazoacetate 
(Aldrich, contains 10% CH2Cl2), diethyl maleate (Aldrich, 97%), Ru3CO12 (Acros, 98%). 
All chemicals, except pyrrole, were used without further purification. NMR: δ in ppm 
versus SiMe4 (0 ppm, 1H, 400 MHz). MS: selected peaks; m/z. Flash chromatography: 
Merck silica gel (240-400 mesh). TLC: 0.25 mm, Merck silica gel 60 F254, visualizing at 
254 nm or with permanganate solution (2 % KMnO4, 5 % K2CO3). 
 
2.7.2 Synthesis 
 Meso-tetrakis-(4-carboxyphenyl)porphyrin tetramethyl ester (2-3) was 
synthesized following the published procedure.40 
Ruthenium(II)carbonyl meso-tetrakis-(4-carboxyphenyl)porphyrin tetramethyl 
ester  (2-4). Modifications of the procedure of Rillema et al. were used:41  A mixture of 2-
3 (536 mg, 0.49 mmol) and Ru3CO12 (307 mg, 0.48 mmol) in 115 mL of decaline were 
heated for 5 hours under reflux and then allowed to cool to room temperature. The 
suspension was filtered and the remaining solid extracted several times with a 100 mL 
CH2Cl2-acetone mixture (96:4). The combined extracts were concentrated under 
reduced pressure and the crude product was purified by using flash chromatography on 
silica gel (CH2Cl2/acetone 96:4, gradually changed to CH2Cl2/acetone 9:1) providing 2-4 
as an orange powder (351 mg, 74%). 1H NMR (DMSO-d6, 400 MHz): δ 8.57 (s, 8H); 
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8.39-8.34 (m, 12H); 8.25-8.23 (m, 4H); 4.08 (s, 12H). 1H NMR (CDCl3, 400 MHz): δ 8.66 
(s, 8H); 8.41-8.36 (m, 12H); 8.28-8.24 (m, 4H); 4.07 (s, 12H). 
 
Ruthenium(II)carbonyl meso-tetrakis-(4-carboxyphenyl)porphyrin (2-5).  
Modifications of the procedure of Nimri et al. were used:42 Ruthenium porphyrin 2-4 (200 
mg, 0.31 mmol) was added to a 60 mL mixture of 3 M aqueous KOH and methanol (1:1) 
and refluxed for 4 h. The solution was acidified with acetic acid and extracted several 
times with EtOAc until the remaining solution was almost colorless. The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure to 
provide 2-5 as a dark red powder (177 mg, 95% yield). 1H NMR (DMSO-d6, 400 MHz): δ 
8.58 (s, 8H); 8.37-8.32 (m, 12H); 8.22-8.20 (m, 4H). 
 
trans-1-carbethoxy-2-phenylcyclopropane  (2-6b). Modifications of the procedure of 
Doyle et al. were used.64 Ethyl diazoacetate (2.70 mL, 26.0 mmol) was added at a 
controlled rate over 4 h via syringe pump to a stirred mixture of Pd(PPh3)4 (100 mg, and 
styrene (43.72 g, 420 mmol). The reaction mixture was filtered through a pad of celite 
and concentrated under reduced pressure. The crude product was purified via 
preparative thin layer chromatography (Chromatotron) on silica gel plates 
(hexanes/acetone 40:1) to provide a white solid. 1H NMR (CDCl3, 400 MHz): δ 7.33-7.08 
(m, 5H); 4.18 (q, J = 7.2 Hz, 2H); 2.52 (m, 1H); 1.90 (m, 1H); 1.60 (m, 1H); 1.31 (m, 1H); 




2.7.3 GC-FID and GC-MS 
 An HP 5890 GC equipped with a 6890 series autosampler was used for GC-FID 
analysis with an HP-5 capillary column ((5%-phenyl)-methylpolysiloxane). An Agilent GC 
Chemstation was utilized for peak integration and data analysis. Response factors were 
calculated for all of the major compounds according to chapter 2.7.5. GC-MS analysis 
was conducted on an HP 5973 MSD coupled with an HP 5890 GC, using an HP-5 
capillary column. Peak identifications were made using the Wiley Registry of Mass 
Spectral Data (6th edition). 
 
2.7.4 Model Cyclopropanation Reaction for Analysis by GC 
 Ethyl diazoacetate (90 µL, 0.86 mmol), dissolved in 500 µL acetone, was added 
at a controlled rate over 12 h via syringe pump to a stirred solution of ruthenium 
porphyrin 2-5 (5 mg, 5.44 µmol, 0.63 mol%) and styrene (100 µL, 0.87 mmol) in 9 mL 
PIPES buffer at ambient temperature. The solution was extracted twice with 5 mL 
diethylether. The GC-MS samples were taken by diluting with acetone and addition of 
dodecane. 
 
2.7.5 Standardization of Analytes with Internal Sta ndard by GC-FID and 
Quantitation 
A series of solutions with varying amounts of styrene, diethyl maleate and 2-6b in 
acetone was prepared in the concentration range of 0.1 mg/mL – 1.0 mg/mL. The 
internal standard dodecane was kept at a concentration of 0.5 mg/mL. The response 
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factor was determined as the slope of the linear regression line of the mass analyte (x) 
to mass internal standard ratio (dod = dodecane) against peak area analyte to peak area 
internal standard ratio (equation 1). The yield could then be calculated according to 

























Yield     (equation 2) 
 
2.7.6 Influence of pH on Cyclopropanation Reactions  
 Ethyl diazoacetate (90 µL, 0.86 mmol), dissolved in 500 µL acetone, was added 
at a controlled rate over 8 h via syringe pump to a stirred solution of ruthenium porphyrin 
2-5 (5 mg, 5.44 µmol, 0.63 mol%) and styrene (100 µL, 0.87 mmol) in 9 mL PIPES buffer 
(pH 6.0, 6.5, 7.0, 7.5, 8.0) and 3 mL acetone at ambient temperature. The solution was 
extracted five times with 5 mL diethylether. The GC-FID samples were taken by diluting 
with acetone and addition of n-dodecane. 
 
2.7.7 Phase Transfer Catalysis 
 The procedure of 2.7.6 was followed. The pH 7.0 was chosen and CTAB (7.0 
mg, 19 µmol, 2.2 mol%) added to reaction mixture before addition of ethyl diazoacetate. 
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2.7.8 Reagent Addition Time Studies 
 The procedure of 2.7.6 was followed at pH 7.0 with addition times of 4 h, 8 h and 
16 h of EDA. 
 
2.7.9 Concentration Dependent Turnover Numbers 
 The procedure of 2.7.6 was followed at pH 7.0 with catalyst loads (2-5) of 0.03, 
0.13, 0.31 and 0.62 mol%. 
 
2.7.10 Kinetics of Carbene Formation 
 Ruthenium porphyrin 2-5 (40 µM) was reacted with varying equivalents of EDA (1 
to 4) in 10 mM PIPES buffer (pH 7.0) at 25 °C for 2  h while stirring and the reaction 
monitored by UV-vis spectroscopy.  
  
2.7.11 Kinetics of Decomposition of EDA in water 
 Ethyl diazoacetate (5.31 µM) was stirred at 25 °C for 12 h in ddH2O and the 






2.7.12 Generation of Carbene Complex in D 2O 
  Ru(CO)TPP-acid (2-5) (2.72 mg; 2.96 µmol) was dissolved in 0.7 mL of 
deuterophosphate buffer in D2O (20 mM; pD =  7.44 = pH 7.0)
65 and small aliquots of 
EDA were added resulting in various equivalents and the reaction analyzed by 1H-NMR 
spectroscopy. 
 
2.7.13 Generation of Carbene Complex in C 6D6 
 Ru(CO)TPP (2-7) (1.41 mg; 1.90 µmol) was dissolved in 0.7 mL C6D6 and small 
aliquots of EDA were added resulting in 0.5, 1.0 and 3.0 equivalents and the reaction 
analyzed by 1H-NMR spectroscopy. 
 
2.7.14 Influence of Axial Ligands on Carbene Format ion 
 2-7 (0.73 mg; 0.98 µmol) was dissolved in 0.6 mL C6D6 and small aliquots of 
pyridine, DMAP or mercaptoethanol were added resulting in various equivalents and the 
reaction analyzed by 1H-NMR spectroscopy. Ethyl diazoacetate (1.0 equivalents) was 






2.7.15 Examination of the Reaction of Lewis Bases w ith Ruthenium Carbonyl 
Porphyrins 
2-7 (2.20 mg; 2.96 µmol) was dissolved in 2.1 mL C6H6, pyridine was added and 
the solution stirred at 50 °C for 3 h. The solution  was analyzed by ESI-MS. 
 
UV-vis spectroscopy:  UV-vis absorption spectra were recorded at 25 °C u sing a Varian 
Bio50 UV-vis spectrometer with constant-temperature accessory.  
 
NMR spectroscopy:  All NMR spectra (1H, 13C) were recorded on either a Bruker DRX 
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CHARACTERIZATION OF RECONSTITUTED SEMI-SYNTHETIC 
PROTEINS AS CYCLOPROPANATION CATALYSTS 
 
3.1 Introduction 
 A critical step in designing a semi-synthetic protein is the choice of a suitable 
protein scaffold that provides the desired environment for achieving high 
enantioselectivities. Among possible candidates heme proteins stand out as suitable 
scaffold because their natural cofactor (heme) can often be readily removed and 
reconstitution of the resulting apoprotein usually leads to catalytically active holoproteins 
that are able to catalyze reactions, such as sulfoxidations, stereoselectively (chapter 
1.1.6 and chapter 2.1.1).1,2 That is why a heme protein and its corresponding ruthenium 
organometallic cofactor had to be chosen that were suitable for reconstitution yielding a 
semi-synthetic cyclopropanation catalyst. 
 
3.1.1 Selection of Heme Protein 
The ideal heme protein for generating a catalytically active semi-synthetic protein 
has to fulfill several criteria. It should be cheap and readily available in order to carry out 
cyclopropanation reactions with catalyst loads and amounts of reactants similar to the 
model reactions with ruthenium porphyrin 2-5 (chapter 2.3.3). Furthermore, the protein 
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has to be expressable in E. coli with good yields in order to allow the optimization of the 
activity and stereoselectivity of the semi-synthetic protein by mutation of the active site 
amino acid residues. Moreover, the stability of the protein is a crucial parameter for its 
viability as a semi-synthetic cyclopropanase. The cofactor removal-reconstitution 
process requires harsh conditions (low pH, 50 % organic solvent for cofactor extraction). 
High losses caused by lack of stability under these conditions would render the protein 
unsuitable. Additionally, it has to be very stable under the chosen reaction conditions for 
the cyclopropanation reaction. Even partial unfolding could lead to the release of the 
cofactor, which is already catalytically active. This would result in the decrease or loss of 
enantioselectivity. The prosthetic group has to be readily exchangeable otherwise the 
ruthenium porphyrin cofactor cannot be inserted into the active site of the heme protein. 
Besides, the active-site pocket has to be accessible for the reactants styrene and ethyl 
diazoacetate. Another imperative requirement is the size of the active-site binding 
pocket. The binding pocket has to be large enough to accommodate the sterically 
demanding carbene complex and the olefin in order to facilitate the reaction. Due to the 
similarities between the epoxidation and cyclopropanation reaction (see chapter 2.1) a 
good protein expoxidation catalyst can more likely be converted to a good 
cyclopropanation catalyst.  
 The epoxidation of olefins in the presence of H2O2 is a difficult reaction. A lot of 
times peroxidase-catalyzed epoxidation reactions exhibited low yields and low 
enantioselectivity.3 By far the best heme protein epoxidation catalyst is chloroperoxidase 
(CPO) from Caldariomyces fumago. Styrene derivatives were oxidized to the 
corresponding (R)-styrene oxides with up to 96% ee.4,5 However, the reconstitution of 
CPO is very difficult and proceeds with low efficiency.6 On the other hand myoglobin is a 
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well-studied heme protein that was utilized for the generation of catalytically active semi-
synthetic proteins (chapter 1.1.6). Myoglobin is closely structurally related to peroxidases 
and can be converted into an efficient peroxidase with high epoxidation activity. Despite 
the low epoxidation activity in its native state myoglobin represents a good starting point 
for the development of a catalytically active cyclopropanase. It meets all important 
criteria and horse heart myoglobin is even available in gram quantities for a low price. 
Myoglobin has a fairly open topology, which might be a disadvantage for achieving high 
enantioselectivities (Figure 3-1).7 Cytochrome P450 BM3, a heme containing enzyme 
that was successfully overexpressed in E. coli, contains a less open-faced active site 
pocket and represents therefore a promising candidate for conversion to an active 
cyclopropanase.8-11 Moreover, the open side is above the porphyrin ring, thus guiding 
the approach of the reactant to the reactive metal center in a different fashion. This 











Figure 3-2.  Active site topology of cytochrome P450 BM3 (protein 
crystallographic database entry 1BU7) 
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3.1.2 Selection of Synthetic Cofactor 
 Ru(CO)TPP-acid (2-5) was used in the studies of cyclopropanation reactions in 
water due to its simplicity and bulky structure that inhibits dimerization. The active site of 
myoglobin and cytochrome P450 was evolutionary developed to accommodate its native 
prosthetic group, which is heme b (iron protoporphyrin IX). Consequently, the ruthenium 
porphyrin prosthetic group has to be as structurally close to heme b as possible. The 
obvious choice is ruthenium carbonyl protoporphyrin IX (Ru(CO)PPIX) (Figure 3-3). 
 
Figure 3-3.   A. heme b B. Ru(CO)PPIX 
 
3.2 Synthesis of Cofactor 
 The synthesis of the ruthenium porphyrin cofactor commenced with the 
dehydration of the commercially available haematoporphyrin (3-1) by p-toluenesulfonic 
acid forming two new double bonds (Scheme 3-1). This reaction was followed by 
esterification of the carboxylic acid moieties yielding protoporphyrin IX dimethylester (3-
2).12 The insertion of the ruthenium carbonyl moiety into 3-2 by reaction with Ru3(CO)12 
failed probably due to the required harsh conditions of the reaction (high temperatures of 
about 190 °C). 13 Ruthenium probably reacted with the two double bonds that are not part 
of the aromatic system under these conditions, thus leading to the decomposition of 
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protoporphyrin IX rather than “clean” insertion of the ruthenium metal center. These 
results are in agreement with Morishima et al. who were also not able to obtain 
ruthenium carbonyl porphyrin 3-3.14 Due to the instability of protoporphyrin IX under the 
harsh conditions required for the synthesis of many heme analogues, the closely 
structurally related mesoporphyrin IX complexes were traditionally utilized for studies of 
reconstituted heme proteins and heme enzymes.15-20 Therefore 3-2 was partially 
hydrogenated to give dimethyl mesoporphyrin IX (3-4) with palladium on carbon as 
catalyst.21 Some over-reduction occurred, which is typical for this type of reaction, 
yielding a chlorine-type compound (porphyrin with aromatic double bonds, which were 
partially reduced) that exhibits a UV-vis absorption band at 650 nm. Recently, a 
straightforward and superior way to hydrogenate 3-2 without the formation of chlorine-
type derivatives was reported (after the studies had been finished).22 Ruthenium 
porphyrin 3-5 was obtained by insertion of the ruthenium carbonyl moiety into 3-4 with 
Ru3(CO)12 under high temperatures (190 °C).
13 Very recently a new synthetic method to 
produce 3-5 with higher yields was reported (after the studies had been finished), which 
utilized a ruthenium-DMF complex instead of Ru3(CO)12.
23 The ruthenium porphyrin ester 












3.3 Characterization of Native Myoglobin Reconstitu ted with 
Ru(CO)MPIX 
3.3.1 Reconstitution of Native Myoglobin 
 In order to incorporate the synthetic cofactor the previously described cofactor 
reconstitution method based on non-covalent attachment (chapter 1.1.6) was utilized 
(Figure 3-4).1 The heme group of myoglobin can be readily removed by the acido-
butanone method.24,25 Acidification (pH ≈ 2) leads to protonation of amino acid residues 
in the active site and thus interrupts stabilizing salt bridges to the carboxylic acids of the 
heme. This results in the loss of the heme group, which can then be extracted with 
butanone. The decrease of helix content due to the loss of heme is only 20%, as 
determined by circular dichroism (CD), which means that backbone conformation and 
basic folding features are well preserved.26,27 Reconstitution and full recovery of the helix 
content and activity is achieved simply by changing the pH to around neutral and 
addition of the cofactor. The reconstitution of apomyoglobin with the natural heme b is 
surprisingly fast. It has been shown by ESI-MS that the reconstitution of myoglobin can 
be complete in as little as 9 s.28 Since reconstitution is mostly governed by hydrophobic 
interactions and hydrogen-bonding and not interactions with the metal center, the 
reconstitution with the structurally very similar ruthenium mesoporphyrin was expected to 
proceed in a similar fashion. Indeed, addition of apomyglobin to 3-6 resulted quickly in 
spectral shifts that are characteristic for reconstituted myoglobin (Figure 3-5).18,19 The 
absorption maximum (soret band) is red-shifted by 10 nm compared to “free” 3-6. The 
splitting of one of the bands (548 nm) in the visible range of 3-6 into two bands (554 nm 
and 546 nm) of the reconstituted myoglobin (Ru(CO)Mb) supposedly derives from 
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Figure 3-5.  UV-vis spectra of myoglobin reconstituted with 3-6 (lilac) in 
comparison with wild-type myoglobin (yellow) and free cofactor 3-6 (blue) 
(spectra normalized to soret band). 
 
 
Figure 3-6.   UV-vis spectra of myoglobin reconstituted with 3-6 (lilac) in 
comparison with wild-type myoglobin (yellow) and free cofactor 3-6 (blue) with 
focus on the visible range (spectra normalized to soret band). 
126 
 
3.3.2 Cyclopropanation Using Myoglobin Reconstitute d with Ru(CO)MPIX as 
Catalyst 
 The cyclopropanation reaction of styrene with ethyldiazoacetate catalyzed by the 
semi-synthetic protein Ru(CO)Mb (apomyoglobin reconstituted with 3-6) was carried out 
in aqueous medium (Scheme 3-2). Unfortunately, the yield was very low (about 1 %) and 
racemic. Due to the very high optical activity of the expected cyclopropanation products 
even small enantiomeric excess would have been detected by polarimetry.29,30 The 
cyclopropanation products were proably formed by small amounts of released 3-6 











Scheme 3-2.    
 
The difference between the cyclopropanation reaction with 3-6 and Ru(CO)Mb is that in 
case of Ru(CO)Mb, 3-6 is embedded in the active site of the protein. Since 3-6 shows 
catalytic activity in the absence of protein, the inhibition of the catalyst should be due to 
active site. Steric crowdedness or binding of axial ligands to the embedded cofactor may 
be the reason for the inhibition of the cyclopropanation reaction (Figure 3-7). The 
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proximal histidine 93 (beneath the porphyrin) binds to the metal center of the prosthetic 
group. It has been previously shown (NMR studies chapter 2.5.3) that Lewis base axial 
ligands can deactivate the ruthenium porphyrin catalyst. Histidine contains an imidazole 
moiety that might inhibit the reaction with EDA.  
 
 
Figure 3-7.  Cartoon representation of active site of horse heart myoglobin (entry 
1AZI from protein crystallographic database) 
 
3.3.3 The Influence of Imidazole on the Catalyst Ac tivity of Ru(CO)MPIX 
3.3.3.1 Analysis by UV-vis Spectroscopy 
 The reaction of Ru(CO)MPIX (3-6) with EDA in aqueous medium in the presence 
and absence of imidazole were conducted in order to model the influence of the axially 
bound histidine in Ru(CO)Mb. First, the reactivity of 3-6 with regard to EDA was tested 
and monitored by UV-vis spectroscopy (Figure 3-8). The UV-vis spectrum, which is 
almost identical to the spectrum of the reaction of Ru(CO)TPP-acid (2-5) with EDA 
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(chapter 2.4.2; Figure 2-12), confirmed rapid reaction with EDA. However, basically no 
spectral changes could be observed upon addition of EDA if imidazole is present in the 
reaction mixture. These results suggest that the imidazole moiety of histidine 93 that is 
bound to the metal center of the cofactor (Figure 3-7) could indeed inhibit the 











Figure 3-9.   UV-vis spectrum of the reaction of 3-6 with EDA in presence of 
imidazole (30 mM) in PIPES buffer at pH 7.0 
 
3.3.3.2 Analysis by Gas Chromatography 
 The cyclopropanation of styrene with EDA by Ru(CO)MPIX (3-6) in aqueous 
medium in the presence and absence of imidazole were carried out to confirm the 
deactivating effect of imidazole suggested by reactions monitored by UV-vis 
spectroscopy (Figure 3-8 & 3-9). Analysis by GC-FID illustrated the inhibitory effects of 
an axially bound ligand such as imidazole (Figure 3-10). Only minuscule amounts of 
cyclopropanation products were found in case of imidazole in the reaction mixture, in 





Figure 3-10.   Analysis (GC-FID) of cyclopropanation of styrene by 3-6 with or 
without imidazole 
 
3.4 Cobalt Porphyrins as Alternatives to Ruthenium Porphyrins 
3.4.1 Selection of Cobalt Porphyrins as Cyclopropan ation Catalysts 
 Cobalt porphyrins are able to catalyze the cyclopropanation of styrene with EDA 
in pyridine as a solvent (Scheme 3-3).31 Due to the similarities of pyridine and imidazole 
in the deactivation behavior cobalt porphyrins might not get deactivated by imidazole, 




 Scheme 3-3.    
 
3.4.2 Synthesis of a Water-Soluble Cobalt Porphyrin  
A water-soluble cobalt porphyrin was synthesized utilizing the same strategies as 
for the synthesis of the water-soluble ruthenium porphyrin 2-5 (chapter 2.2) (Scheme 3-
4). The cobalt metal center was inserted into 3-7 via reaction with cobalt(II) acetate in 
DMF.32 The synthesis was concluded by the hydrolysis of the four ester moieties yielding 




 Scheme 3-4.    
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3.4.3 Cyclopropanation of Styrene by Cobalt Porphyr ins in the Presence of 
Imidazole 
 The cyclopropanation of styrene with EDA by cobalt porphyrin 3-9 was carried 
out in aqueous medium with and without imidazole in order to examine the impact of this 
axial ligand on the activity of the catalyst. Unfortunately, the overall results of the cobalt 
porphyrin catalyzed reactions were disappointing (Figure 3-11). Examination of the 
reaction by GC-FID revealed that the yield of the cyclopropanation with 3-9 was only a 
fraction of the yield of the same reaction with ruthenium porphyrin 3-6 (in the absence of 
imidazole). Most importantly, imidazole also deactivated cobalt porphyrin 3-9. The 
excess of imidazole in the reaction mixture probably led to the formation of a 1:2 
complex (3-9 : imidazole) because both axial positions can be occupied by a ligand 
resulting in a six coordinated species. A 1:1 complex might still be catalytically active. 
However, it is very difficult to carry out the experiments with a 1:1 complex, even if it 
could be generated reliably.  The cobalt porphyrin imidazole complex can dissociate 
yielding an already catalytically active species. Since no dissociation constants are 
known it would be very challenging to ensure catalysis with exclusively a 1:1 complex. 
Besides, cobalt porphyrins are harder to handle than ruthenium carbonyl porphyrins. 
Cobalt porphyrins bind oxygen tightly, thus inhibiting cyclopropanation reactions. That is 
why the reactions had to be carried out strictly under argon atmosphere. All in all, cobalt 
porphyrins were inferior catalysts for the cyclopropanation of styrene in aqueous 
medium, which also get deactivated by imidazole. Hence, they do not constitute a viable 





Figure 3-11.   Analysis (GC-FID) of cyclopropanation of styrene by 3-6 compared 
to 3-9 with or without imidazole. 
 
3.5 Characterization of Myoglobin Mutants Reconstit uted with 
Ru(CO)MPIX 
3.5.1 Generation of Myoglobin Mutants 
 Due to failure of ruthenium and cobalt porphyrins to catalyze the 
cyclopropanation of styrene with imidazole as axial ligands the histidine moieties of the 
active site of myoglobin had to be mutated (Figure 3-7). Histidine 93 binds directly to the 
porphyrin metal center and histidine 64 represents a bulky group within the binding 
pocket that might obstruct the reaction. Glycine is the smallest amino acid and cannot 
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bind to the ruthenium metal center. Therefore the myoglobin mutants H64G, H93G and 
H64G/H93G were generated for over-expression in E.coli (molecular cloning performed 
by Dr. Javier Chaparro-Riggers). The myoglobin H93G mutant and the H64D/H93G 
double mutant have been previously described in the literature.33,34 The new double 
mutant H64G/H93G is probably stable and expressable in E. coli due to the similarity to 
myoglobin H64D/H93G.  
 
3.5.2 Properties of Myoglobin Mutants 
 His-tagged horse-heart myoglobin and myoglobin mutants were overexpressed 
in E.coli and purified (standard His-tag purification) (Figure 3-12). Porphyrins usually 
show a significant shift of the soret band upon binding of axial ligands. The shift shown 
by binding of imidazole is very similar to the shift after reconstitution of myoglobin.  
Interestingly, the mutants did not exhibit any shift at the soret band despite different axial 
ligands. This is in agreement with published UV-vis spectra of myoglobin mutants in the 
literature. The purity of the expressed proteins was confirmed by SDS-PAGE and the 
ratio of the protein concentrations (determined by Bradford assay) to absorption maxima 
at the soret band were determined. These ratios indicate the relative level of heme 
incorporation, assuming 100 % incorporation in case of native myoglobin (Figure 3-13). 
The myoglobin mutant H93G (proximal histidine replaced by glycine) had nearly the 
same level of heme incorporation as the wild-type, thus showing a remarkable stability 
despite the absence of anchoring of the heme-group by direct binding of the histidine 
residue to the porphyrin metal center. In contrast, H64G (distal histidine replaced by 
glycine) exhibited a lower level of heme incorporation (it also has by far the lowest 
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expression yield of all myoglobin mutants). The myoglobin double mutant H64G/H93G 
showed the lowest level of incorporation. However, it was still stable enough to retain 
more than half of the embedded heme group. This trend of stability is consistent with 










Figure 3-13.   The relative level of heme incorporation of myoglobin mutants. 
 
3.5.3 Cyclopropanation with Myoglobin H64G/H93G Rec onstituted with 
Ru(CO)MPIX 
 The cyclopropanation reaction of styrene with ethyldiazoacetate was catalyzed 
by the semi-synthetic protein Ru(CO)Mb H64G/H93G (apoprotein reconstituted with 3-
6). Unfortunately, the results of the reaction catalyzed by the ruthenium porphyrin 
reconstituted double mutant are as those for the myoglobin wild type catalyzed reaction 
(low yield, racemic mixture of products). These results were confirmed by the reaction of 
Ru(CO)Mb H64G/H93G with EDA, monitored by UV-vis spectroscopy (Figure 3-14). 
Almost no change could be observed upon addition of EDA; neither the strong 
absorption band of EDA at 250 nm nor the soret band showed any signs of reaction. The 
reason for the slight initial change of the spectrum in the visible range is probably only 
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due to solvent effects (EDA stock solution was not dissolved in the reaction buffer but in 
DMF) because the spectrum did not continue to change (Figure 3-15).  
 
Figure 3-14.   UV-vis spectra of reaction of Ru(CO)Mb 64/93G with EDA 
 
 
Figure 3-15.   UV-vis spectra of reaction of Ru(CO)Mb 64/93G with EDA 
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3.5.4 Cyclopropanation with Myoglobin H64G/H93G Rec onstituted with RuMPIX 
 Cyclopropanation attempts with myoglobin or myoglobin mutants reconstituted 
with Ru(CO)MPIX had failed. The initial reaction of ethyl diazoacetate with ruthenium 
carbonyl porphyrins might occur on the axial position of the metal center opposite of the 
carbonyl moiety. Since this position is most likely obstructed by the protein backbone the 
carbonyl moiety was removed before reconstitution, simply by reacting 3-6 with EDA and 
styrene. Utilizing this method did again not lead to any cyclopropanation products with 
enantiomeric excess. The failure of this method is illustrated by UV-vis spectra of this 
reaction (Figure 3-16 + Figure 3-17). Ru(CO)MPIX (A) was reacted with EDA and 
styrene in a mixture of PIPES buffer and acetone for one hour (B) in order to remove the 
carbonyl functionality of 3-6. Significant spectral changes could be seen despite the lack 
of clearly defined isosbestic points. Upon addition of apomyoglobin 64/93G immediate 
characteristic spectral shifts occurred confirming the generation of the semi-synthetic 
protein (C). However, all spectral changes ceased suggesting the inhibition of the 
catalytic activity (D). This clearly shows the inability of ruthenium porpohyrin 









Figure 3-16.   Cyclopropanation of styrene by 3-6 and RuMb. (A). 3-6 (B). 3-6 + 




Figure 3-17.  Cyclopropanation of styrene by 3-6 and RuMb. (A). 3-6 (B). 3-6 + 





3.6 Non-Specific Binding of Synthetic Prosthetic Gr oup 
Generally, either equimolar amounts or a slight excess of apomyoglobin was 
used for reconstitution with 3-6 followed by purification with size-exclusion 
chromatograpy (gel-filtration). No relative change of the UV-vis spectrum of the semi-
synthetic protein solution before and after gel filtration was observed (data not shown). 
In the literature no significant excess of the cofactor was used for reconstitution. If a 
significant excess of the cofactor is used then the UV-vis spectrum before and after gel 
filtration still remains the same (after normalization of the spectra based on protein 
concentration). Hence, the size-exclusion chromatography did not successfully separate 
excess unincorporated ruthenium porphyrin. In the absence of protein Ru(CO)MPIX 
stays on top of the column, which is the expected behavior of a small molecule in size-
exclusion chromatography. In the presence of protein even a 20 fold excess of 
Ru(CO)MPIX was eluted together with the protein. This suggests that non-specific 
binding is the cause of the failure to separate excess 3-6. Non-specific interactions are 
usually reduced by an increase of the ionic strength. However, even a buffered solution 
with one molar NaCl did not inhibit the “sticking” of Ru(CO)MPIX to the protein. The 
change of other conditions, such as pH, column loading, column length, etc. did not 
result in an improvement of the separation. 
 Ruthenium porphyrin 3-6 contains a carbonyl functionality that exhibits a 
characteristic C=O stretch in an IR spectrum. This feature can be utilized to study non-
specific interactions between 3-6 and myoglobin because binding to the surface would 
probably cause a shift of the carbonyl stretch. Water very strongly absorbs light in the 
frequency range of interest for studying proteins. This problem can be circumvented by 
using Attenuated Total Reflection Infrared Spectroscopy (ATR-IR).36 Ru(CO)MPIX  was 
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added to solutions of green fluorescent protein (GFP), horse heart myoglobin wild type 
and expressed (E.coli) His-tagged wild-type myoglobin (Figure 3-18). Both types of 
myoglobin were in the holo-form; therefore no incorporation of 3-6 into the active site 
should have been possible. GFP has no heme binding sites and was selected as a 
“control protein”. Mixing GFP with Ru(CO)MPIX resulted in a shift compared to “free” 
Ru(CO)MPIX (see black line in spectrum) suggesting non-specific binding to be origin of 
this spectral change. Unfortunately, the myoglobin ruthenium carbonyl mixtures could 
not be resolved enough to clearly compare the IR stretches with each other. 


















 GFP + Ru(CO)MPIX
 Myo-His + Ru(CO)MPIX
 Myo + Ru(CO)MPIX
 
Figure 3-18.   ATR-IR spectra of mixtures of 3-6 with myoglobin and GFP. 
 
3.7 Cyclopropanation by Cytochrome P450 154C1  
 The CYP154C1 C355A mutant (proximal anchoring cysteine replaced by alanine) 
was overexpressed in E. coli. Unfortunately, no heme group was found in purified protein 
(lack of the typical strong red color; confirmed by UV-vis spectroscopy) suggesting that 
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the cysteine moiety is crucial for the stability of the heme group in the active site. All 
attempts to “reconstitute” this protein with Ru(CO)MPIX failed. The cofactor does not get 
incorporated into the active site and slowly precipitates overtime. Therefore 
cyclopropanation reactions could not be carried out. 
 
3.8 Cyclopropanation by Anchored Ruthenium Porphyri n - BSA 
Conjugates 
 Komatsu et al. reported on the formation of iron tetraphenylporphyrin serum 
albumin conjugates.37 Therefore Ru(CO)TPP-acid (2-5) was reacted with bovine serum 
albumin in order to provide a chiral framework for cyclopropanation reactions (Figure 3-
19). Ruthenium porphyrin 2-5 exhibited a shift similar to 3-6 after incorporation into 
myoglobin (B). BSA has two porphyrin binding sites, therefore addition of another 
equivalent of 2-5 did not result in a change of the soret band (C-D). Unfortunately, 
cyclopropanation reactions with ruthenium porphyrin – BSA conjugates proceeded in a 
similar way like myoglobin reconstituted with 3-6; small amounts of formed 





Figure 3-19.   Generation of ruthenium porphyrin – BSA attachment. (A) 2-5. (B) 
A + BSA (1 equiv). (C) B + 2-5 (1 equiv) t = 0. (D) C t = 2 h. 
 
3.9 Conclusion 
 Myoglobin and myoglobin mutants were successfully reconstituted with the 
heme-like ruthenium carbonyl porphyrin 3-6. None of the generated semi-synthetic 
proteins were catalytically active “cyclopropanases”. Deactivation of the catalytic activity 
by axial histidine ligands represented a big obstacle for this project. The origin of the lack 
of activity in case of missing histidine ligands in the active site is not known. Non-specific 
binding of the ruthenium cofactor to the protein and the resulting purification problems 
were obstacles that could never be overcome. Many reactions have been catalyzed by 
semi-synthetic proteins but never cyclopropanation reactions. This is an indication for 
the difficulty of the reaction with semi-synthetic proteins. Apparently, converting 
myoglobin into an active cyclopropanase requires more drastic changes then a few 
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3.10 Experimental Section 
3.10.1 Materials and Reagents and General Technique s 
 All starting materials, reagents and solvents were purchased from Aldrich 
(Milwaukee, WI), Fisher Scientific (Pittsburgh, PA) or VWR (West Chester, PA). NMR: δ 
in ppm versus SiMe4 (0 ppm, 1H, 400 MHz). MS: selected peaks; m/z. Flash 
chromatography: Merck silica gel (240-400 mesh). TLC: 0.25 mm, Merck silica gel 60 
F254, visualizing at 254 nm or with permanganate solution (2 % KMnO4, 5 % K2CO3). 
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
Ampicillin was used at 50 µg/mL and Kanamycin at 30 µg/mL concentration. Unless 
otherwise stated, standard protocols were used. All plasmids were verified by DNA 
sequencing. Mutated sites are in indicated in bold and red. 
 
3.10.2 Synthesis 
 Protoporphyrin IX dimethylester (3-2) was synthesized following the published 
procedure.12 
Attempted synthesis of ruthenium(II)carbonyl protop orphyrin IX dimethylester (3-
3). Modifications of the procedure of Rillema et al. were used.13 A mixture of 3-2 (50 mg, 
84.6 µmol) and Ru3CO12 (54 mg, 84.5 µmol) in 10 mL of decaline were heated for 24 
hours under reflux and then allowed to cool to room temperature. No starting material or 




Mesoporphyrin IX dimethylester (3-4).  Modifications of the procedure of Muir et al. 
were used.21 A solution of protoporphyrin IX dimethylester 3-2 (750 mg, 1.27 mmol) in 
1,2-dichloroethane (32 mL) and ethanol (50 mL) was hydrogenated at room temperature 
and ambient pressure in the presence of Pd on activated carbon as catalyst (78 mg, 5 wt 
% Pd, 3 mol %) for three days. The crude product was purified by using flash 
chromatography on silica gel (CHCl3/EtOAc 50:1) providing 3-4 as a purple powder (310 
mg, 41 %). 1H NMR (CDCl3, 400 MHz): δ 10.10, 10.09 (2s, 4H); 4.42 (t, J = 7.6 Hz, 4H); 
4.09 (q, J = 7.6, 4H); 3.67, 3.65 (2s, 6H); 3.64, 3.63 (2s, 12H); 3.28 (t, J = 7.6, 4H); 1.85 
(t, J = 7.62, 6H); -3.76 (brs, 2H). Spectroscopic data are in agreement with those 
reported.22 
 
Ruthenium(II)carbonyl mesoporphyrin IX dimethyleste r (3-5). Modifications of the 
procedure of Rillema et al. were used.13 A mixture of 3-4 (285 mg, 0.48 mmol) and 
Ru3CO12 (291.4 mg, 0.46 mmol) in 50 mL of decaline were heated for 5 hours under 
reflux and then allowed to cool to room temperature. The suspension was filtered and 
the remaining solid extracted several times with a 100 mL CH2Cl2-acetone mixture 
(95:5). The combined extracts were concentrated under reduced pressure and the crude 
product was purified by using flash chromatography on silica gel (CHCl3/EtOAc 50:1, 
gradually changed to CHCl3/EtOAc 15:1) providing 3-5 as a purple powder (190 mg, 55 
%). 1H NMR (CDCl3, 400 MHz): δ 9.96, 9.95, 9.94 (3s, 3H); 9.85 (s, 1H); 4.33-4.26 (m, 
4H); 4.02 (q, J = 7.6 Hz, 4H); 3.65, 3.62 (2s, 6H); 3.59, 3.58, 3.57, 3.56 (4s, 12H); 3.27-
3.20 (m, 4H); 1.88 (t, J = 7.6 Hz, 6H). FAB-MS: m/z 723.2 [M+H+]. FAB-HRMS 
calculated for [M+H+] C37 H41 N4 O5 723.2120, found 774.2063. 
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Ruthenium(II)carbonyl mesoporphyrin IX (3-6).  Modifications of the procedure of 
Nimri et al. were used.38  Ruthenium porphyrin 3-5 (43 mg, 59 µmol) was added to a 40 
mL mixture of 3 M aqueous NaOH and methanol (1:1) and refluxed for 12 h. The 
solution was acidified with acetic acid and extracted several times with EtOAc until the 
remaining solution was almost colorless. The combined organic extracts were dried over 
MgSO4 and concentrated under reduced pressure to provide 3-6 as a purple powder (40 
mg, 98% yield). 1H NMR (CD3OD, 400 MHz): δ 9.99, 9.93, 9.92, 9.91 (4s, 4H); 4.35 (t, J 
= 7.5 Hz, 4H); 4.03 (q, J = 7.6 Hz, 4H); 3.56, 3.55 (2s, 12H); 3.27 (t, J = 7.5 Hz, 4H); 
1.88 (t, J = 7.6 Hz, 6H). 
 
Meso-tetrakis-(4-carboxyphenyl)porphyrin tetramethyl ester (2-3 or 3-7) was synthesized 
following the published procedure.39 
Cobalt(II) meso-tetrakis-(4-carboxyphenyl)porphyrin tetramethyl es ter  (3-8). The 
procedure for the synthesis of the structurally related Co(TPP) was applied.32   
Yield: (384 mg, 90 %). MALDI-MS: m/z 903.3 [M+].   
 
Cobalt(II) meso-tetrakis-(4-carboxyphenyl)porphyrin (3-9).  Cobalt porphyrin 3-8 (70 
mg, 77.5 µmol) was added to a 100 mL mixture of 3 M aqueous NaOH and methanol 
(1:1) and refluxed for 4 h. The solution was acidified with acetic acid and extracted 
several times with EtOAc until the remaining solution was almost colorless. The 
combined organic extracts were dried over MgSO4 and concentrated under reduced 
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pressure to provide 3-9 as a red powder (63 mg, 96 % yield). MALDI-MS: m/z 847.1 
[M+]. MALDI-HRMS calculated for [M+] C48H28CoN4O8 847.1239, found 847.1249. 
 
3.10.3 Reconstitution of Heme Proteins 
 The procedure for removal of the heme group of Teale was used to generate 
apoprotein (e.g. myoglobin).25 The apoprotein was dialyzed against the desired buffer. 
Generally, about 50 % of the protein survived the harsh treatment. Reconstitution with 
the selected cofactor was achieved by mixing of the apoprotein with the cofactor (usually 
0.9 – 1.0 equivalents).24 
 
3.10.4 Reconstitution of Wild Type Myoglobin Monito red by UV-vis Spectroscopy 
 To ruthenium porphyrin 3-6 (5.8 µmol, 11.6 µM) in PIPES buffer (30 mM, pH 7.0, 
0.5 mL) was added one equivalent of apomyoglobin while stirring. 
 
3.10.5 Attempted Cyclopropanation with Myoglobin an d Myoglobin Mutants 
Reconstituted with Ru(CO)MPIX 
 The procedure of chapter 2.7.6 at pH 7.0 was followed. A typical 





3.10.6 The Influence of Imidazole on the Catalyst A ctivity of Ru(CO)MPIX  
 Ruthenium porphyrin 3-6 (129 nmol, 86 µM) was reacted with an equimolar 
amount of ethyl diazoacetate in 1.5 mL PIPES buffer (100 mM, pH 7.5) in the presence 
of 3 mM, 30 mM and 300 mM imidazole and the reaction monitored by UV-vis 
spectroscopy. 
 The cyclopropanation of styrene with 3-6 was carried out according to chapter 
2.7.6 with and without 37.5 mM imidazole and analyzed by GC-FID (chapter 2.7.5). 
 
3.10.7 Cyclopropanation by Cobalt Porphyrins 
 The cyclopropanation of styrene with 3-9 was carried out according to chapter 
2.7.6 under argon atmosphere with and without 37.5 mM imidazole and analyzed by GC-
FID (chapter 2.7.5). 
 
3.10.8 Construction of Expression Plasmids of Horse  Heart Myoglobin 
Myoglobin H64G. The bacterial expression vector pGYM-myoglobin (kind gift from 
Mauk research group)40,41 was used as a template for site-directed mutagenesis using 







AACCCAGTTCTTTGTACTTAGC-3’ and inserted into the NcoI and HindIII sites of pET 
28a to give pET 28 Myo H64G. 
 
Myoglobin H93G.  The bacterial expression vector pGYM-myoglobin was used as a 
template for site-directed mutagenesis using overlap extension PCR with 




AACCCAGTTCTTTGTACTTAGC-3’ and inserted into the NcoI and HindIII sites of pET 
28a to give pET 28 Myo H93G. 
 
Myoglobin H64G/H93G.  The bacterial expression vector pET 28 Myo H93G was used 
as template for site-directed mutagenesis using overlap extension PCR with 




AACCCAGTTCTTTGTACTTAGC-3’ and inserted into the NcoI and HindIII sites of pET 
28a to give pET 28 Myo H64G/H93G. 
 
3.10.11 Construction of Expression Plasmids of Cyto chrome P450 (CYP154C1) 
CYP154C1 C355A. The bacterial expression vector pet 17-CYP154C1 (kind gift from 
Waterman research group)42 was used as a template for site-directed mutagenesis using 
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overlap extension PCR with oligonucleotides 5’-
AGGAGATATACATATGACGACCGGCACCGAAGAAGC-3’, 
5’- CCTTCGGCCACGGCCCGCACGTGGCGCCCGGTGCGGCCCTGTCCCGG-3’, 5’- 
CAGGGCCGCACCGGGCGCCACGTGCGGGCCGTGGCCGAAGGAGATGTGC-3’ and 
5’- CACGTGCGGGCCGTGGCCGAAGG-3’ and inserted into the BamHI and PmlI sites. 
 
3.10.9 Expression of Myoglobin and Cytochrome P450  
 The published procedures were followed.41,42 
3.10.10 Reactions of Myoglobin H64G/H93G Reconstitu ted with Ru(CO)MPIX 
Monitored by UV-Vis Spectroscopy 
Reaction with EDA. A Ru(CO)Mb 64/93G (purified by size exclusion chromatography) 
solution (17.5 µM) in PIPES buffer (30 mM, pH 7.5, 530 µL) was reacted with ethyl 
diazoacetate (2 equivalents) for 2 h. 
Reaction with EDA and Styrene.  A Ru(CO)MPIX solution (36.6 nmol, 24.4 µM) in 
PIPES buffer (30 mM, pH 7.5, 1.5 mL) was reacted with EDA (1 equivalent) and styrene 
(1 equivalent) for one hour. Apomyoglobin 64/93G (1 equivalent) was added to the 







3.10.11 Purification of Myoglobin Reconstituted wit h 3-6 
 Generally size-exclusion chromatography was attempted with sephadex G-25 as 
stationary phase. Cation-exchange chromatography with carboxy methyl cellulose led to 
precipitation of the protein on the column. 
 
3.10.12 Examination of Non-Specific Binding by ATR- IR 
 Several mixtures of Ru(CO)MPIX and proteins were measured in phosphate 
buffer (10 mM; pH 8.0) with the following concentrations: Ru(CO)MPIX (230.7 µM); 
Ru(CO)MPIX (230.7 µM) – GFP (57.6 µM); Ru(CO)MPIX (420 µM) – myoglobin (210 
µM); Ru(CO)MPIX (230 µM) – myoglobin-His (165 µM). The IR-ATR spectra were 
recorded from 4000 - 400 cm-1 using a Bruker Equinox 55 FT-IR spectrometer (Bruker 
Optics Inc., Billerica, MA) equipped with a liquid nitrogen (LN2) cooled MCT detector 
(Infrared Associates, Stuart, FL) and a Specac Gateway in-compartment horizontal ATR 
unit (Specac Inc., Woodstock, GA). Each sample was directly deposited onto a 
trapezoidal ZnSe (nD = 2.43 at λ = 5 µm) ATR crystal (MacroOptica, Moscow, Russia) 
with 6 effective reflection regions (72 × 10 × 6 mm; 45 °).  
 
Purification of expressed proteins:  The proteins were purified either by a Ni2+-NTA 
superflow column or by Ni2+-NTA superflow batch purification according to the Quiagen 




UV-vis spectroscopy:  UV-vis absorption spectra were recorded at 25 °C u sing a Varian 
Bio50 UV-vis spectrometer with constant-temperature accessory.  
 
NMR spectroscopy:  All NMR spectra (1H, 13C) were recorded on either a Bruker DRX 
500 or Mercury VX 400. 
 
GC-FID and GC-MS:   An HP 5890 GC equipped with a 6890 series autosampler was 
used for GC-FID analysis with a DB-5 capillary column. An Agilent GC Chemstation was 
utilized for peak integration and data analysis. Response factors were calculated for all 
of the major compounds according to chapter 2.7.5. GC-MS analysis was conducted on 
an HP 5973 MSD coupled with an HP 5890 GC, using a DB-5 capillary column. Peak 
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DESIGN OF SEMI-SYNTHETIC PROTEINS FOR THE STUDY OF 
LABILE POOLS OF COPPER, IRON AND ZINC IN 
INTRACELLULAR COMPARTMENTS 
 
4.1 Introduction and Concept 
 Green fluorescent protein (GFP) has revolutionized cellular imaging and 
cell biology (see chapter 1.2.5). It offers a non-invasive method for imaging virtually any 
protein of interest within live cells based on fluorescence microscopy. The fluorophore of 
GFP is buried inside of a cylindrical β-barrel, which renders the fluorescence emission 
mostly insensitive towards environmental changes, in particular solvent polarity. At the 
same time, this insensitivity poses significant challenges for the design of GFP based 
biosensors that will respond through the fluorescence intensity shift towards analyte 
binding. The binding of metals to the surface of the protective protein framework results 
in only small changes of the fluorescence emission due to the strong distance 
dependence of the energy transfer efficiency (see chapter 1.2.7).1 That is why GFP 
cannot be converted to an efficient fluorescent metal sensor for in vivo applications. In 
contrast small molecule fluorescent probes can be used that exhibit a change of 
fluorescence upon metal binding, which subsequently allows the determination of the 
presence or concentration of metals; however, small molecule fluorescent probes 
usually have no anticipated specificity for any proteins or intracellular locations. A classic 
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example for their “mind of their own” is rhodamine B, which tends to accumulate in the 
mitochondria.2 On the other hand, proteins such as GFP can be directed to intracellular 
compartments by signal peptides (see chapter 1.2.6) or by fusion to a protein with 
specific subcellular localization. One of the biggest challenges in metal sensing based 
on small molecule fluorescent dyes is that open d-shell cations from transition metals, 
such as copper and iron, quench the fluorophore fluorescence efficiently. Colorimetric 
and complexometric methods for the qualitative and quantitative determination of 
transition metals were widely used before the emergence of modern analytical 
instrumental techniques such as atomic absorption spectroscopy (AAS) or inductively 
coupled plasma mass spectrometry (ICPMS).3,4 The formation of colored chelator-metal 
charge transfer complexes, with spectral properties that are highly dependent on the 
bound metal, allows the analytical determination of metal ions by colorimetry. Therefore, 
metal chelators were developed that form colored charge transfer complexes for the 
metals copper and iron, both of which are typically strong fluorescence quenchers 
(Figure 4-1). Unfortunately, these charge transfer complexes cannot be used for live cell 
imaging applications because they do not emit any light.  
Nevertheless, the combination of colored charge transfer complexes with a signal 
peptide carrying fluorescent protein or the combination of a signal peptide carrying 
protein with a small molecule fluorescent chelator by generating semi-synthetic proteins 
may take advantage of beneficial properties of each species while bypassing their 
downsides. Our design of the semi-synthetic protein for the study of labile metal pools is 
based on a genetically encoded fluorescent protein that is modified at the N- and C-
terminus (Figure 4-2). A signal peptide directs the protein and therefore the attached 
metal sensor to intracellular compartments of interest; thus, the problem of non-existing 
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or unwanted specificity of small molecule fluorescent sensors can be circumvented. A 
number of organelles, including nucleus, mitochondria and the Golgi apparatus (and the 
trans Golgi network) are likely locations of labile metal pools and therefore were chosen 
as target locations (Figure 4-3).5-7 The fluorescent protein is expressed as a fusion 
protein; the fusion domain allows labeling of the protein. Labeling of the protein with the 
metal chelator by AGT and by trans-splicing with split-inteins was chosen (see chapter 
1.2.8) because both labeling methods are fairly general with high substrate tolerance 
and are also suitable for in vivo studies.8-11 The protein has to be labeled with a metal 
chelator that either exhibits a suitable change of fluorescence or color upon binding of 
the desired metal. This change results in the formation of a Förster resonance energy 
transfer (FRET) pair in which the fluorescent protein acts as the donor fluorophore and 
the colored species as acceptor (in case of a fluorescent metal chelator complex this 
relationship can also be the other way around). The FRET pair can then be analyzed by 
fluorescence emission of the donor-acceptor pair or fluorescence lifetime of the donor 
(the fluorescence lifetime of the acceptor does not change). Thus, the local metal 
concentrations can be determined while circumventing the notorious fluorescence 
quenching of copper and iron (for mechanism see chapter 4.1.1). In case of sensing 
Zn(II) (which does not quench the fluorescence efficiently), the design can be slightly 
changed if the metal chelator exhibits fluorescence upon metal binding; the fluorescent 
protein domain can be omitted since another fluorophore is not required. The fusion 
protein can be expressed inside of the target mammalian cells after transfection with 
generated plasmids encoding the protein. Incubation of the cells with the precursor metal 
chelator (contains moiety that allows attachment to protein) should lead to the in vivo 
labeling of the protein, thus forming the metal sensor.  
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Many metal chelators form complexes with 2:1 or even 3:1 ligand-metal 
stochiometry (Figure 4-1). For sensing applications a 1:1 binding stochiometry is 
preferable because a variety of lewis bases in the cytoplasm (e.g. amines and thiols) can 
coordinate to the metal center. The resulting heteroleptic metal complexes would distort 
live cell measurements. Utilizing semi-synthetic proteins labeled with 2:1 or 3:1 binding 
ligands would always lead to potential coordination sites for intracellular Lewis bases 
because the steric hindrance of the protein domain does not allow the required 
movement of two or three semi-synthetic proteins around one metal cation to form a 
complex. Hence, 1:1 binding chelators are required for intracellular measurements. A 
crucial property of the metal chelator for the goal of in vivo cell imaging of the labile 
metal pools of copper, iron and zinc is the appropriate binding affinity for the desired 
metal. Too weak binding would lead to a low signal while too tight binding would simply 
strip metals from metalloproteins instead of binding metals of the targeted labile metal 
pool. A binding affinity in the µM range is suitable because it is a compromise between 




Figure 4-1.   Strongly colored metal charge transfer complexes of copper and 
iron. A. free ligands. B. metal complexes, which almost exclusively exhibit 2:1 or 






Figure 4-2.   Design concept of a genetically encoded, semi-synthetic metal 
sensor. A fusion protein containing a signal peptide and fluorescent protein 
domain is expressed in mammalian cells. This fusion protein is labeled with a 
metal chelator that exhibits color or fluorescence upon metal chelation. Thus, 
binding of a metal-ion results in the formation of a FRET pair. Analysis of the 
FRET pair (fluorescence emission and fluorescence lifetime) allows the 

















4.1.1 Mechanism of Fluorescence Quenching by Charge  Transfer States 
 The design of the metal sensor is based on FRET of the donor fluorophore to the 
colored species that forms upon metal binding. Upon absorption of photons with suitable 
energy the donor fluorophore is excited from the ground state S0 into the excited state S1 
(Figure 4-4). In the absence of a metal ligand charge transfer (MLCT) state the excited 
state decays to the ground state either by radiative deactivation under emission of a 
photon or by non-radiative deactivation through vibrational relaxation. Hence, the 
quantum yield (Q) and fluorescence lifetime (TF) of the donor are determined by the rate 
of radiative (kr) and non-radiative (knr) deactivation (equation 4-1).
12 In case of the 
presence of a low-lying MLCT state there is an additional pathway for the non-radiative 
deactivation of the excited state. Upon energy transfer (for requirements of energy 
transfer see chapter 1.2.7) of the excited state of the donor to the MLCT state of the 
acceptor the excited acceptor state is subsequently deactivated by non-radiative 
deactivation to the ground state of the acceptor. Thus, the quantum yield and 
fluorescence lifetime of the donor is dependent on the FRET efficiency. The more 
efficient the energy transfer to the colored acceptor the shorter is the fluorescence 







































Figure 4-4.   Jablonski diagram of fluorescence quenching by FRET. Upon 
excitation to the excited state S1 radiative or non-radiative deactivation to the 
ground state S0 occurs. In case of the presence of a FRET pair, an additional 
non-radiative pathway is available. This pathway allows the transfer of energy 
from the donor (FP) to the acceptor (synthetic probe), thus competing with the 
deactivation pathways of S1 to S0 of the donor. This results in the quenching of 
the donor fluorescence emission. The efficiencies of the quenching depends on 
the individual rate constants of the pathways (kr = rate constant of radiative 
deactivation; knr = rate constant of non-radiative deactivation; kFRET = rate 





















4.2 Design and Generation of Fusion Proteins 
 Plasmids are circular extra-chromosomal DNA molecules that are self-replicating 
and can be transferred from one organism to another.13  They can be found in both pro- 
and eukaryotic cells and are essential in genetic engineering as vectors of genes. 
Therefore plasmids encoding the desired fusion proteins were generated utilizing 
methods and techniques of molecular cloning, such as transformation, restriction 
digestions, PCR (polymerase chain reaction) techniques and ligations. The generated 
plasmids usually contain a localization sequence and a fusion domain enabling protein 
labeling. The plasmids are designed for the expression of the genes in either eukaryotic 
or prokaryotic hosts. All of the following depicted plasmids are selected “final” plasmids. 
 
4.2.1 Plasmids for Eukaryotic Expression Targeting Mitochondria Based on 
Labeling by AGT 
 The generated plasmids contain a CMV (cytomegalovirus) promoter for efficient 
eukaryotic expression (Figure 4-5). Plasmid A encodes a fusion protein with the genes 
for AcGFP (a monomeric GFP mutant) and AGT (commercial name SNAP-tag). The 
genes are connected by a linker encoding 10 amino acids (ALAAADIKLT). The 
mitochondrial targeting sequence (MTS) is located at the N-terminus of the fusion 
protein and cannot be placed at the C-terminus. The FRET efficiency is dependent on 
the overlap integral between donor and acceptor (see chapter 4.3). In order to achieve 
better spectral overlap with certain compounds, such as bicinchoninic acid derivatives, 
plasmid B was generated that contains a cerulean gene (mutant of cyan fluorescent 
protein) in place of AcGFP. Theoretically, the order of AcGFP and AGT can be reversed; 
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however, no obvious advantage of this strategy could be inferred from the crystal 
structures of the proteins. Successful localization in the mitochondria upon transfection 





Figure 4-5.  Circular and linear representation of plasmids for eukaryotic 


























Figure 4-6.  Light micrographs of 3T3 cells transfected with plasmid A expressing 
MTS-AcGFP-AGT. Localization in the mitochondria was observed (left panel) 
and confirmed by staining with mitochondria specific antibodies (center panel) 
and overlay of the resulting images (right panel). 
 
4.2.2 Plasmids for Eukaryotic Expression Targeting the Nucleus Based on 
Labeling by AGT 
 Plasmid E is similar to A because it encodes AcGFP-AGT with the same linker 
but has some key differences (Figure 4-7). The leader sequence (sequence between 
CMV promoter and first start codon) is a Kozak consensus sequence for enhanced 
expression. The nuclear localization signal is at the C-terminus but may have also been 
placed at the N-terminus.14 Localization in the nucleus was confirmed by transfection of 
mammalian cells with plasmid E and subsequent microscopy (Figure 4-8).  
 
 
Figure 4-7.   Linear representation of plasmids for eukaryotic expression targeting 




Figure 4-8.  Light micrographs of 3T3 cells transfected with plasmid E expressing 
AcGFP-AGT-NLS. Localization in the mitochondria was observed. 
 
4.2.3 Plasmids for Eukaryotic Expression Targeting the Trans-Golgi Network 
Proteins can be directed to the trans-Golgi network (TGN) by expression as 
fusion protein with TGN38, a membrane protein of the TGN.15 The advantage of utilizing 
TGN38 is that the N-terminal domain of this membrane protein is located in the lumen.16 
Therefore the metal ions of the intracellular compartments instead of the cytosol would 
be analyzed; however, utilizing this strategy would require expressing a triple fusion 
protein. TGN38 is about the size of the whole AcGFP-AGT domain and could therefore 
lead to perturbations of the folding process, instability of the fusion protein, etc. 
Moreover, TGN38 is heavily glycosylated and the impact of this feature on the fusion 
protein and analyte sensing is hard to determine.17 Due to the complexity of biological 
systems a simpler approach to direct the protein to the TGN is preferable. Deletion 
analysis has revealed that an 11 amino acid segment of TGN38 is sufficient for TGN 
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localization.16 Hence, several plasmids encoding AcGFP were generated that contained 
short TGN localization sequences (TGN-LS) at the C-terminus. 
 The 11-amino acid encoding sequence was inserted into pAcGFP1-C1 with 
either an immediate stop codon or additional 20 amino acids before termination of 
translation with a 5 amino acid linker (SGLRS) (Figure 4-9). Unfortunately, upon 
transfection of mammalian cells (HeLa cells) no specific localization of the expressed 
AcGFP in the TGN was observed (Figure 4-10).18 
 
Figure 4-9.   Linear representation of plasmids encoding AcGFP with 11 amino 
acid TGN localization sequences. 
 
 
Figure 4-10.  Light micrographs of 3T3 cells transfected with F expressing 
AcGFP. Localization in the TGN was not observed. 
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 Due to the failed localization of AcGFP in the TGN the design was modified 
(Figure 4-11). The first approach was to insert more than 11 amino acids of the TGN38 
“tail” assuming that interactions of the localization sequence with the original neighboring 
amino acids could play a role with regard to the recognition of the signal (I). The second 
approach focused on the generation of repeat localization sequences to increase the 
probability of being recognized (H). This is a common strategy for other localization 
signals (e.g. nuclear localization sequence).14 Unfortunately, these designs also failed to 
localize AcGFP in the TGN. Pap and coworkers have reported on the successful 
targeting of fluorophores to the TGN utilizing short peptides by the truncated TGN38 
localization sequence (TGN38-LS) SDYQRL.19 The net charge of the localization signal 
plays an important role in targeting of intracellular compartments. In case of TGN38-LS 
and adjacent amino acids should be around 0. The basic amino acids, such as arginine 
in the 11-amino acid localization sequence result in an increase of the net charge. 
Therefore a SDYQRL double repeat was inserted at the C-terminus of AcGFP1-C1 (J). 
Unfortunately, upon transfection of 3T3 mammalian cells with plasmid J localization of 
AcGFP at the trans-Golgi network was not observed either. 
 




 As a consequence of the failures to direct AcGFP to the TGN by short 
localization signals, plasmids had to be generated that encode AcGFP and the 
membrane protein TGN38 as fusion protein or even triple fusion protein (in combination 
with AGT or inteinC) (Figure 4-12 and Figure 4-13). This strategy led to the localization of 
expressed proteins in the TGN (Figure 4-14). Plasmids K and L only differ from each 
other with regard to the fluorescent protein (AcGFP in case of K and cerulean in case of 
L). They both have a CMV promoter and a chimeric intron and encode inteinC-FP-
TGN38. It has been shown that the combination of CMV promoter and chimeric introns 
usually lead to significantly higher levels of expression.20 The split-inteinC (from Ssp DNA 
B intein) design is based on an investigation of suitable split-intein sites, which revealed 
that an inteinN fragment of only 11 amino acids and its 143 amino acid inteinC 
counterpart were capable of protein trans-splicing in vivo.9 Mootz et al. adapted this 
strategy in order to ligate synthetic peptides to the N-terminus of a recombinant protein.8 
This design constitutes an excellent starting point for attaching metal chelators to the 
protein, thus generating semi-synthetic proteins for metal sensing. Since the inteinC 
fragment is required to be N-terminal only signal sequences that are functional at the C-
terminus, which is a minority of the localization signals, can be utilized. 
Plasmid M contains a CMV promoter with Kozak consensus sequence and the 
genes for AcGFP-AGT-TGN38. The AGT based labeling method allows more flexibility 










Figure 4-13.   Linear representation of AGT based plasmids targeting TGN. 
 
 
Figure 4-14.  Light micrographs of 3T3 cells transfected with plasmids encoding 
AcGFP-TGN38. Localization in the TGN was observed. 
 
4.2.4 Plasmids for Prokaryotic Expression 
 The genes of several generated eukaryotic expression plasmids (section 4.2.1 – 
4.2.3) were transferred to prokaryotic expression vectors (Novagen pET vector series) 
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containing T7 promoters for efficient overexpression in bacteria yielding plasmids N to T. 
Overexpression in E. coli is necessary in order to obtain suitable amounts of protein for 
in vitro studies. The His-tag that is usually encoded to enable facile purification of the 
expressed protein might interfere with the in vitro metal sensing experiments due to its 
ability to strongly bind divalent cations such as nickel, zinc, etc. Therefore plasmid N 
does not encode a His-tag while plasmids O to T encode either an N-or C-terminal His-
tag. In addition plasmid O and P encode Thrombin protease sites that allow the cleavage 
of the His-tag. Plasmids N to P encode AGT (Figure 4-15) while plasmids Q to T contain 
split-intein inteinC as labeling method (Figure 4-16 and Figure 4-17). 
 
Figure 4-15.   Linear representation of bacterial expression plasmids based on 
labeling by AGT. 
 
 
Figure 4-16.  Linear representation of bacterial expression plasmids based on 





Figure 4-17.  Linear representation of bacterial expression plasmids based on 
labeling by split-inteins. 
 
4.3 In Vitro Studies of Labeling Expressed Fusion Proteins with  
Model Compounds  
4.3.1 Labeling of AGT Based Fusion Proteins 
4.3.1.1 Expression and Isolation of AGT Based Fusion Proteins 
 E. coli bacteria were transformed with plasmids for bacterial expression encoding 
MTS-AcGFP-AGT (plasmids N and O). The formation of the fusion proteins (MW ≈ 54 
kDa) was observed after induction of expression followed by lysis of the bacterial cells 
(Figure 4-18). However, the desired protein was only present in the insoluble fractions of 
the cell lysate. Expression of soluble protein was achieved by modification of the 
standard overexpression conditions to significantly lower temperatures and longer 
expression times (see experimental section). The desired pure protein was obtained by 
Ni-NTA (Quiagen) based His-tag purification (Figure 4-19). Expression of the untagged 
protein was not necessary anymore because the potentially problematic His-tag could be 
easily removed by proteolysis with thrombine (Figure 4-20). Complete cleavage was 
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observed at all dilution levels of thrombin (even with 200 fold dilution of the 




Figure 4-18.  SDS-PAGE gel of expression of AGT based fusion proteins (cell 





Figure 4-19.   SDS-PAGE gel of purified protein MTS-AcGFP-AGT.  
 
 
Figure 4-20.   Thrombin cleavage of His-tag of MTS-AcGFP-AGT. All utilized 




4.3.1.2 Synthesis of Model Compound 
 Labeling of AGT based fusion proteins requires an alkyl guanine or benzyl 
guanine moiety. Therefore the model compound rhodamine was linked to a benzyl 
guanine group (Scheme 4-1 and Figure 4-18). The synthesis commenced with the 
reduction of 4-cyanobenzaldehyde (4-1) by LiAlH4 to the corresponding alcohol and 
amine yielding 4-2.21 The amino group was protected as a trifluoroacetamide (4-3) and 
reacted with guanine derivative 4-5 to obtain 4-6.11 The resulting O6-guanine derivative 
was deprotected in order to obtain 4-7. Benzyl guanine (4-7) was coupled with 
rhodamine derivative 4-822 affording the desired benzyl guanine rhodamine 4-9 (BGRH). 
 
 Scheme 4-1. 
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4.3.1.3 Labeling of AGT Based Proteins with Rhodamine Derivatives 
 Isolated protein MTS-AcGFP-AGT was incubated with rhodamine derivative 4-9 
(BGRH) and the labeling reaction monitored by fluorescence spectroscopy (Figure 4-21). 
The comparison of the emission ([M]) and excitation ([X]) spectra of MTS-AcGFP-AGT 
before and after reaction with BGRH shows the formation of a FRET pair, thus indicating 
a successful labeling reaction (Figure 4-22 and Figure 4-23). Spectrum D shows the 
decrease of the fluorescence of the GFP domain and an energy transfer to the 
rhodamine label and subsequent emission of light. The best indicator for the generation 
of a FRET pair is the excitation spectrum F (Figure 4-24). A strong GFP component (see 
spectrum B) can now be observed at the far-red emission wavelength of 600 nm. Based 
on the observed changes of the fluorescence spectra the estimated FRET efficiency was 
about 44 % (for calculations see chapter 4.8.4). The Foerster radius (distance of 50 % 
FRET efficiency) was 60 Ǻ. Therefore the distance between donor and acceptor was 64 
Ǻ. The distance of the fluorophore of GFP to its C-terminus is about 26 Ǻ and the 
distance from the active site of AGT to its N-terminus is approximately 17 Ǻ (based on 
the protein crystal structures). Adding 5 Ǻ due to the size of the rhodamine label sums 
up to approximately 50 Ǻ (the linker also has to be taken into account but its exact size 
is unknown). This estimation is in agreement with the determined donor - acceptor (DA) 
distance derived from the spectral data. Due to the strong distance dependence of the 
energy transfer efficiency the DA distance has to be in the narrow range of 0.5 R0 and 
2R0 (R0 = Foerster radius) for meaningful measurements. Distances below 0.5 R0 lead to 
almost complete donor quenching while distances of more than 2R0 result in inefficient 
energy transfer. The fusion protein MTS-AcGFP-AGT, labeled with rhodamine, has a DA 
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distance close to R0 and hence represents an excellent starting point for attaching 
colored metal chelators. 
 
 






Figure 4-22.  Fluorescence spectrum of unreacted MTS-AcGFP-AGT (0.29 µM 
in 50 mM phosphate buffer, pH 8.0). A. [M] MTS-AcGFP-AGT (exc.: 475 nm). B. 
[X] MTS-AcGFP-AGT (emm.: 505 nm). C. [X] MTS-AcGFP-AGT (emm.: 470 nm).  
 
 
Figure 4-23.  Fluorescence spectrum of the labeling reaction of MTS-AcGFP-
AGT with BGRH (0.29 µM each in 50 mM phosphate buffer, pH 8.0). D. [M] MTS-






Figure 4-24.   Fluorescence spectrum of the labeling reaction of MTS-AcGFP-
AGT with BGRH (0.29 µM each in 50 mM phosphate buffer, pH 8.0). F. [X] MTS-
AcGFP-AGT + BGRH (emm.: 600 nm). G. [M] MTS-AcGFP-AGT + BGRH (exc.: 
554 nm). 
 
 The formation of a FRET pair was consistent with the observed change of 
fluorescent lifetimes (Figure 4-25). The change of the fluorescence intensities of the 
donor in case of energy transfer is directly proportional to the change of fluorescence 
lifetimes. The FRET efficiency was 44 % therefore the fluorescence lifetime should also 
decrease by 44 %. Indeed, the fluorescence lifetime dropped from approximately 2.7 ns 
to 1.5 ns, which is a decrease of 45 % and close to the measured decrease of 44 % of 






Figure 4-25.  Fluorescence decay of labeled and unlabeled MTS-AcGFP-AGT. 
 
4.3.2 Labeling of Split-Intein Based Fusion Protein s 
4.3.2.1 Expression and Isolation of Split-Intein Based Fusion Proteins 
 E. coli bacteria were transformed with plasmids for bacterial expression encoding 
inteinC-AcGFP-TGN38 and inteinC-Cerulean-TGN38 (plasmids Q and R). No formation of 
the fusion proteins was observed after induction of expression followed by lysis of the 
bacterial cells (data not shown). The expression of TGN38 in bacteria has not been 
reported. Eukaryotic membrane and glycosylated proteins usually are difficult to express 
in bacteria because bacteria do not glycosylate proteins. Glycosylation is important for 
protein folding and stability in mammalian cells. Hence, the failure to express these 
heavily glycosylated membrane proteins in E. coli was not surprising. It was attempted to 
circumvent this problem by exporting the fusion protein to the periplasm by inserting an 
export signal sequence to periplasm (plasmids not shown). This strategy often leads to 
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the successful expression of eukaryotic because the periplasmic medium is much more 
similar to the eukaryotic intracellular medium than the bacterial cytoplasmic medium; 
however, this strategy did not lead to the desired fusion proteins either (data not shown). 
Since TGN38 is only required to direct the fusion protein to the TGN the design was 
simplified to inteinC-AcGFP and inteinC-Cerulean (plasmids S and T), which is sufficient 
to examine trans-splicing reactions in vitro. The encoded His-tagged protein was 
successfully expressed and purified (Mw ≈ 47 kDa) (Figure 4-27 control); however, the 
purified protein solution contained a significant amount of a protein with a molecular 
weight of about 32 kDa. This was probably His-tagged AcGFP, generated by ribosomes 
initiating translation at the remaining start codon of AcGFP instead of at inteinC, and was 
not expected to interfere with the trans-splicing reaction. 
 
4.3.2.2 Design and Synthesis of Split-InteinN Containing Model Compound 
 Labeling of split-intein based fusion proteins requires a split-intein moiety. Hence, 
the model compound rhodamine was linked to an 11 amino acid split-inteinN moiety 
(Scheme 4-2 and Figure 4-26). The polypeptide also contains the necessary N-extein. 
The synthesis commenced with the formation of the lactone 4-11 by the reaction of 
rhodamine B (4-10) with NaOH.23 Lactone 4-11 was transformed to the tertiary amide 4-
12 by piperazine and Al(Me)3. The secondary amine of the piperazyl moiety (4-11) was 
reacted with succinic anhydride, yielding carboxylic acid 4-13. Amide coupling with the 
synthesized 4-14 (synthesis not shown in Scheme 4-2), catalyzed by EDCI and HOBT, 
led to the rhodamine thioester 4-15. The final rhodamine derivative 4-16 was obtained by 
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native chemical ligation with the polypeptide, containing an N-terminal cysteine, and a 
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 Scheme 4-2.  
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4.3.2.3 Labeling of Split-Intein Based Fusion Proteins with Rhodamine Derivatives 
 It was attempted to label the protein inteinC-AcGFP by trans splicing with split-
inteins utilizing rhodamine derivative 4-16 (Figure 4-26). This method was based on the 
labeling of the protein thioredoxin with fluorescein by Mootz et al.8 Successful labeling 
should generate a FRET pair similar to MTS-AcGFP-AGT-rhodamine (chapter 4.3.1); 
however no change was observed by fluorescence spectroscopy (data not shown). This 
was confirmed by SDS-PAGE (Figure 4-27). Trans-splicing should result in the formation 
of spliced out inteinC (Mw ≈ 17 kDa). The missing band at 17 kDa clearly showed that no 
splicing reaction occurred. 
 
Figure 4-26.  Labeling of AcGFP with rhodamine by trans splicing with split-
inteins. The splicing reaction is induced by recombination of the split-inteins and 






Figure 4-27.  SDS-PAGE gel of the trans-splicing reaction with split inteins. 
InteinC-AcGFP can be seen at 47 kDa and an impurity at 32 KDa that is most 
likely His-tagged AcGFP. No band of excised inteinC was observed at 17 kDa 
suggesting that trans-splicing did not occur. 
 
4.4 Labeling of Proteins with Zinc Chelators 
 In order to generate semi-synthetic proteins for the sensing of Zn-ions suitable 
colored or fluorescent Zn-chelators needed to be synthesized (for requirements of the 




4.4.1 Synthesis of Benzyl Guanine Zinquin 
 Benzyl guanine zinquin 4-18 was synthesized by HOBT and EDCI catalyzed 
coupling of zinquin (4-17) with benzyl guaine (4-7) (Scheme 4-3). 
 
 Scheme 4-3.  
 
4.4.2 Labeling of Proteins with Benzyl Guanine Zinq uin 
Benzyl guanine zinquin showed excellent solubility in CH2Cl2 (which is somewhat 
surprising because zinquin and benzyl guanine are poorly soluble in CH2Cl2); however, 
4-18 exhibited poor solubility in water and only fair solubility in DMF and DMSO. The 
poor solubility in water probably derived from aggregation due to hydrophobic effects 
(see chapter 1.1.2) and prevented the examination of properties such as binding 
affinities and binding kinetics of the zinc chelator. The labeling of AGT based fusion 
proteins was sluggish because precipitation occurred quickly after addition of benzyl 
guanine zinquin to the reaction mixture despite adding 10 % of DMF (v/v) to the reaction 
mixture. Hence, 4-18 was not suitable as a zinc chelator for labeling proteins with the 




4.4.3 Labeling of Proteins with Alternative Zinc Ch elators 
 Due to the unsatisfying properties of benzyl guanine zinquin 4-18 alternative 
benzyl guanine zinc chelators were developed. The Fahrni research group developed a 
fluorescent, selective and ratiometric Zn(II) chelator that is suitable for metal sensing in 
methanol (Figure 4-28).24 This dye, designed for two-photon absorption (also suitable for 
one photon absorption), has attractive properties such as a binding affinity in the µM 
range but is not suitable for metal sensing in aqueous medium. Ratiometric behavior 
was not observed in aqueous medium, probably due to processes such as aggregation, 
dimerization or excimer formation (data not shown). Attachment to a protein would solve 
these problems because these processes cannot occur if the molecules are separated 
from each other. That is why a benzyl guanine derivative of this type of dye was 
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Figure 4-28.  Emission ratiometric Zn(II) sensor. The sensor contains a 






















Figure 4-29.  Benzyl guanine modified Zn(II) emission ratiometric sensor (see 
Figure 4-25). 24 
 
 The fluorescence properties of 4-19 in methanol and in aqueous buffered 
solution differ significantly (Figure 4-30). In methanol 4-19 shows basically the same 
behavior as the Zn(II) chelator without the benzyl guanine moiety. Upon excitation (at 
350 nm) of 4-19 in methanol in the absence of Zn(II) (TPEN was added to remove trace 
amounts of Zn(II)) fluorescence emission was observed with an intensity maximum at 
418 nm (A). Saturation of the zinc chelator 4-19 with Zn(II) resulted in a large spectral 
shift and fluorescence enhancement (B).  In contrast the fluorescence intensity of 4-19 is 
much weaker in aqueous buffer (in the absence of Zn(II)) and the shape of the curve is 
not Gaussian (bell-shaped) suggesting the presence of more than one emissive state 
(C). Saturation of the zinc chelator 4-19 with Zn(II) in aqueous buffer exhibited a 
fluorescence spectrum (D) similar to Zn(II) saturated 4-19 in methanol.  
The expressed and purified protein MTS-AGT was labeled with 4-19 and the 
reaction monitored by fluorescence spectroscopy (Figure 4-31). Reaction of 4-19 with 
MTS-AGT led to a considerable change of the fluorescence emission (compared to C) 
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already after five minutes (E). The intensity of the fluorescence emission kept increasing 
and reached its maximum after about one hour (F). The resulting spectrum illustrated a 
remarkable similarity to the “zinc-free” fluorescence spectrum of 4-19 in methanol (A). 
This suggests that the protein was labeled with the zinc(II)-chelator, thus inhibiting 
processes such as aggregation, dimerization or excimer formation. Upon saturation of 
the zinc-chelator domain of the formed semi-synthetic protein with Zn2+ a fluorescence 
emission was exhibited (G) similar to Zn(II)-saturated 4-19 in aqueous buffer (D); 
however, the emission maximum (474 nm (G) and 484 nm (D)) was shifted by 10 nm. 
This shift is another indication for the successful labeling of the protein MTS-AGT. The 
semi-synthetic protein formed by the in vitro reaction of MTS-AGT and 4-19 represents, 
due to its fluorescence properties in the presence and absence of Zn2+, a very useful 
platform for the goal of in vivo cell imaging of zinc-ions. Therefore the focus shifted on 






Figure 4-30.  Fluorescence emission spectra (excitation at 350 nm) of 4-19 (4 
µM) in methanol or aqueous buffered solution (10 mM PIPES, 10 mM HEDTA, 
pH 7.06, 0.1 M KCl). A. 4-19 + TPEN in MeOH. B. 4-19 + Zn2+ in MeOH. C. 4-19 




Figure 4-31.  Fluorescence emission spectra (excitation at 350 nm) of 4-19 (6 
µM) reacted with MTS-AGT (6 µM) in aqueous buffered solution (10 mM PIPES, 
10 mM HEDTA, pH 7.06, 0.1 M KCl, 1 mM DTT). E. reaction time = 5 min. F. 
reaction time = 1 h. G. F + Zn2+. 
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4.5 Labeling of Proteins with Iron Chelators  
 In order to generate semi-synthetic proteins for the sensing of Fe-ions suitable 
colored or fluorescent Fe-chelators needed to be synthesized. Kikkeri et al. have 
recently reported on the synthesis of a tripodal phenol-oxazoline based Fe(III) chelator 
that exhibits a red color upon metal binding (4-20 in Scheme 4-4).26 Therefore it was 
attempted to synthesize a benzyl guanine derivative in the same fashion as for the 
Zn(II)-chelators (see chapter 4.4). Unfortunately, all efforts to synthesize benzyl guanine 
derivative 4-21 failed. Consequently, AGT based fusion proteins could not be labeled 
with any iron chelators. 
 




4.6 Labeling of Proteins with Copper Chelators  
 In order to generate semi-synthetic proteins for the sensing of Cu(I)-ions suitable 
colored or fluorescent Cu(I)-chelators needed to be synthesized. The copper chelator 
has to form 1:1 complexes; however, no colored or fluorescent chelators have been 
reported that bind Cu(I) in a 1:1 fashion. Therefore it was attempted to synthesize 1:1 
binding Cu(I)-chelators based on the known copper chelators bicinchoninic acid and 
bathocuproine, which bind Cu(I) in a 2:1 fashion (Figure 4-32 and 4-33). Based on 
molecular modeling a diethanolamine or resorcinol (1,3-benzenediol) based linker would 
allow the ligands to rotate to tetrahedral metal binding position, thus forming a complex 












Figure 4-32.  Tetrahedral 2:1 Cu(I) complexes of bicinchoninic acid (A) and 






Figure 4-33.  Structures of Cu(I) complexes of bicinchoninic acid and 
bathocuproine (generated by molecular modeling with MM2 force field 
calculations).28 A. Dimethylbicinchoninic acid complex with 2:1 ligand-metal 
stochiometry. B. Dimethylbicinchoninic acid complex connected by a linker with 
1:1 ligand-metal stochiometry. C. Bathocuproine complex connected by a linker 
with 1:1 ligand-metal stochiometry. 
 
4.6.1 Synthesis of Bicinchoninic Acid Based Derivat ives 
 The possibly 1:1 binding Cu(I) chelator 4-25 was attempted to synthesize starting 
with the formation of isonitrosoacetanilide 4-22 by the reaction of m-toluidine and 2,2,2-
trichloro-1-ethoxy ethanol (Scheme 4-5).29 Reaction to the corresponding isatin 
derivative by concentrated sulfuric acid resulted in the formation of a mixture of 4-methyl 
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isatin 4-24 and the desired 6-methyl isatin 4-23.30 The purification of 4-23 requires 
several laborious crystallization and precipitation steps,31-33 therefore the target molecule 
and consequently the reactants and intermediates were altered (Scheme 4-6). Utilizing 
p-toluidine as starting material resulted avoided the formation of mixtures of isatin 
isomers; thus, 5-methyl isatin 4-27 was obtained in good yield (after synthesis of 
isonitrosoacetanilide 4-26). The reaction of 4-26 with KOH and acetoin (Pfitzinger 
reaction), followed by acidification, yielded the dimethyl bicinchoninic acid derivative 4-
28.34  Acid catalyzed acidification did not result in the formation of the ethyl ester 4-30. 
That is why 4-28 was transformed to an acyl chloride (4-29) and reacted with sodium 
ethoxide in order to obtain the ethyl ester 4-30. Radical bromination by a stochiometric 
amount of NBS provided the monobromo derivative 4-31. Attempts to couple two 
molecules of bicinchoninic acid ester 4-31 with the t-boc protected diethanolamine 
through the formation of alkyl oxides by NaH failed (Scheme 4-7).  
Since small amounts of water can lead to the formation of NaOH, which can 
hydrolyze the ester moiety, the more base-stable t-butyl ester derivatives of 
bicinchoninic acid were synthesized (Scheme 4-8). Esterification of acyl chloride 4-29 
with K-tBuO did not succeed. Hence, dimethyl bicinchoninic acid 4-28 was transformed 
to the corresponding tert-butyl ester (4-34) with DMAP and EDCI. Radical bromination 
with NBS provided the monobromo derivative 4-35; however, coupling of two 
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 Scheme 4-8. 
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4.6.2 Synthesis of Bathocuproine Based Derivatives 
 Due to the failure to form a 1:1 binding Cu(I) chelator based on bicinchoninic acid 
the focus shifted to utilizing bathocuproine derivatives (Scheme 4-9). Bromination of 
bathocuproine (4-37) was achieved by radical bromination with NBS yielding 4-38. 
Similar to the bicinchoninic acid, the coupling of two molecules of bathocuproine in order 
to obtain 4-39 failed. Therefore, a different linker was utilized (4-41). The benzyl 
protected linker 4-41 did not result in the formation of the desired connected 
bathocuproine derivative 4-42.  
 Aromatic alcohols usually require milder reaction conditions than alkyl alcohols 
for reactions with halides. That is why monobromo bathocuproine 4-38 was reacted with 
resorcinol (Scheme 4-10). The yield of the reaction was insufficient (< 1 % based on 
mass spectrometry); however, the reaction proceeded in a “clean” fashion, producing 
mostly unreacted starting material, bathocuproine linked to one alcohol of resorcinol, and 
the desired product 4-43 (determined by mass spectrometry and NMR spectroscopy). 
Therefore this approach is a good starting point for future attempts to synthesize 
bicinchoninic acid or bathocuproine based 1:1 binding Cu(I)-chelators. 
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 Scheme 4-10. 
 
4.7 Conclusion 
 Plasmids encoding fluorescent proteins, targeting sequences and AGT or intein 
fusion domains for eukaryotic and prokaryotic expression were generated. Successful 
targeting of intracellular compartments (mitochondria, nucleus and TGN) was confirmed 
by light microscopy experiments with transfected mammalian cells. The encoded 
proteins were overexpressed in E.coli and purified. In vitro labeling experiments of the 
fusion proteins with rhodamine derivatives succeeded with AGT based fusion proteins 
resulting in the formation of a FRET-pair; however, labeling of fusion proteins by trans-
splicing with split-inteins failed. Zinc(II)-chelator 4-19 was attached to an AGT based 
protein and the resulting semi-synthetic protein exhibited strong changes of fluorescence 
in the presence of zinc(II). This represents an important step towards the goal of in vivo 
cell imaging of labile zinc(II) pools. Iron chelators suitable for protein-labeling could not 
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4.8 Experimental Section 
4.8.1 Materials and Reagents and General Techniques  
 All starting materials, reagents and solvents were purchased from Aldrich 
(Milwaukee, WI), Fisher Scientific (Pittsburgh, PA) or VWR (West Chester, PA). NMR: δ 
in ppm versus SiMe4 (0 ppm, 1H, 400 MHz). MS: selected peaks; m/z. Flash 
chromatography: Merck silica gel (240-400 mesh). TLC: 0.25 mm, Merck silica gel 60 
F254, visualizing at 254 nm or with permanganate solution (2 % KMnO4, 5 % K2CO3). 
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
Ampicillin was used at 50 µg/mL and Kanamycin at 30 µg/mL concentration. Unless 
otherwise stated, standard protocols were used. All plasmids were verified by DNA 
sequencing. Mutated sites are in indicated in bold and red. 
 
4.8.2 Generation of Plasmids 
CMV-MTS-AcGFP1-AGT  (A). The host or template vectors were the commercially 
available plasmids pSEMXT-26m (Covalys) containing AGT and pAcGFP1-Mito 
(Clontech) containing AcGFP1 and a mitochondrial targeting sequence. PAcGFP1-mito 
was digested by NheI and NotI and the isolated gene encoding MTS-AcGFP1 was 
cloned into the NheI and NotI sites of pSEMXT-26m. The resulting plasmid (pMito-
AcGFP1-SNAP) contained an opal stop codon (TGA). Therefore pMito-AcGFP1-SNAP 
was used as a template for site-directed mutagenesis according to the QuickChange 
protocol (Stratagene) with the oligonucleotides 5’- 
GGCATGGATGAGCTGTACAAGGCTCTAGCCGCGATATCAAGCTTAC-3’ and 5’- 
GTAAGCTTGATATCGCGGCTAGAGCCTTGTACAGCTCATCCATGCC-3’ to give 
intermediate plasmid pre-A-1 .  
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A second BsrgI restriction site, within the AcGFP1 gene of pre-A-1 , was removed 
by the introduction of a silent mutation by site-directed mutagenesis according to the 
QuickQhange protocol (Stratagene) with the oligonucleotides 5’- 
CTACAACGCCCACAATGTGTATATCATGACCGACAAGGCC-3’ and 5’- 
GGCCTTGTCGGTCATGATATACACATTGTGGGCGTTGTAG-3’ to yield intermediate 
plasmid pre-A-2 . The obtained unique BsrgI site allows straightforward replacement of 
the AcGFP gene by common GFP-derivatives like ECFP, EYFP, and etc. by cloning into 
the NheI and BsrgI sites without the change of any amino acid of the linker between 
AcGFP1 and AGT. 
The linker between AcGFP and the SNAP-tag (AGT) was modified by 
QuickChange (site-directed mutagenesis) with the oligonucleotides 5’- 
CTGTACAAGGCTCTAGCCGCTGCAGATATCAAGCTTACCATGGACAAAG-3’ and 5’- 
CTTTGTCCATGGTAAGCTTGATATCTGCAGCGGCTAGAGCCTTGTACAG-3’ to yield 
A. The resulting 10 amino acid linker was Ala-Leu-Ala-Ala-Ala-Asp-Ile-Lys-Leu-Thr.  
 
CMV-MTS-Cer-AGT  (B). Cerulean was amplified from pmscvcerulean (generous gift of 
doyle group) with the oligonucleotides 5’-
CTAATTGCTAGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAG-3’ and 5’-
CTAGTGCTTGTACAGCTCGTCCATGCC-3’ and inserted into the NheI and BsrgI sites 
of pAcGFP1-C1 (clontech) yielding pCer-C1.  PCer-C1 was digested with AgeI and BsrgI 
and the resulting fragment inserted into the corresponding restriction sites of A to obtain 
B. 
 




and 5’-TGAACATCCGGAACCCAGCCCAGGCTTGC-3’ and ligated into the Kpn2I and NheI sites 
of pECFP-nuc (clontech) resulting in E. 
 
CMV-AcGFP-TGN38-LS-1 (F).  The 5’-phosphorylated oligonucleotides 5’- 
GATCTCGACGGCCGAAAGCGAGCGATTATCAGCGCCTGTGAA and 5’- 
AGCTTTCACAGGCGCTGATAATCGCTCGCTTTCGGCCGTCGA encoding 
RRPKASDYQRL-stop were annealed to each other and inserted into the BglII and 
HindIII sites of pAcGFP1-C1 (clontech) to give F. 
 
CMV-AcGFP-TGN38-LS-2 (G).  The 5’-phosphorylated oligonucleotides 5’- 
GATCTCGACGGCCGAAAGCGAGCGATTATCAGCGCCTGA and 5’- 
AGCTTCAGGCGCTGATAATCGCTCGCTTTCGGCCGTCGA encoding 
RRPKASDYQRL were annealed to each other and inserted into the BglII and HindIII 
sites of pAcGFP1-C1 (clontech) to give G. 
 
CMV-AcGFP-TGN38-LS-3 (H).  F was digested by BglII and blunted by the exonuclease 
Mung Bean Nuclease. The 5’-phosphorylated oligonucleotides 5’- 
TACCATCGCGACGACCGAAAGCGAGCGATTATCAGCGCCT and 5’- 
AGGCGCTGATAATCGCTCGCTTTCGGTCGTCGCGATGGTA encoding 
RRPKASDYQRL were annealed to each other and ligated into the blunted F to give H. 
 
CMV-AcGFP-TGN38-LS-4 (I).  F was digested by BglII and blunted by the exonuclease 
Mung Bean Nuclease. The 5’-phosphorylated oligonucleotides 5’- 




KRKIIAFALEGKRSKVT were annealed to each other and ligated into the blunted F to 
give I. 
 
CMV-AcGFP-TGN38-LS-5 (J).  PAcGFP1-C1 was digested by BglII and blunted by the 
exonuclease Mung Bean Nuclease. The 5’-phosphorylated oligonucleotides 5’-
GCGACTACCAGCGCCTGAGCGACTACCAGCGCCTGTAAA-3’ and 5’-
AGCTTTTACAGGCGCTGGTAGTCGCTCAGGCGCTGGTAGTCGC-3’ were annealed 
to each other and ligated into the blunted pAcGFP1-C1 to give J. 
 
CMV-Intron-Intein C-AcGFP-TGN38 (K).  An InteinC-AcGFP-TGN38 fragment was 
amplified from Q with oligonucleotides 5’-
ATATGACTCGAGCATGGGCACTAGTAGCACAGG-3’ and 5’-
TATACGTCTAGATTAAAGCTTTAGGTTCAAACGTTGG-3’ and inserted into the XhoI and XbaI 
of pCI (Promega). 
 
CMV-Intron-Intein C-Cer-TGN38 (L). An InteinC-Cer-TGN38 fragment was amplified from 
R with oligonucleotides 5’-ATATGACTCGAGCATGGGCACTAGTAGCACAGG-3’ and 5’-
TATACGTCTAGATTAAAGCTTTAGGTTCAAACGTTGG-3’ and inserted into the XhoI and XbaI 
of pCI (Promega). 
 





TGAACAACCGGTACCCAGCCCAGGCTTGC-3’ and cloned into the AgeI site of CMV-
AcGFP-TGN38 . 
 
T7-MTS-AcGFP-AGT (N).  PET 11a was modified by PCR according to the Quickchange 
protocol with the oligonucleotides 5’-
GGTGGCAGCAGCCAACTCGAGCTTCCTTTCGGGCTTTG-3’ and 5’-
CAAAGCCCGAAAGGAAGCTCGAGTTGGCTGCTGCCACC-3’ to give pET 11a’ . An 
MTS-AcGFP-AGT fragment was obtained by digestion of A with NheI and XhoI and 
inserted into the corresponding restriction sites of pET 28a. 
 
T7-His-MTS-AcGFP-AGT (O).  An MTS-AcGFP-AGT fragment was obtained by 
digestion of A with NheI and XhoI and inserted into the corresponding restriction sites of 
pET 28a. 
 
T7-His-MTS-Cer-AGT (P).  A cerulean fragment was obtained by digestion of pCer-C1  
with AgeI and BsrgI and inserted into the corresponding restriction sites of O. 
 
T7-Intein C-AcGFP-TGN38-His (Q). An InteinC fragment was amplified from pTwin1 
(NEB) with oligonucleotides 5’-
ATACCATGGGCACTAGTAGCACAGGAAAAAGAGTTTC-3’ and 5’-
GGTGAAGCTAGCGCTGTTGTGTACAATGATGTCATTCGC-3’ and cloned into the 
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NheI and NcoI sites of pET 28a affording pET 28a-Intein C. A second BsrgI restriction 
site, within the AcGFP1 gene of pAcGFP1-C1, was removed by silent mutation via site-
directed mutagenesis according to the QuickQhange protocol (Stratagene) with the 
oligonucleotides 5’- CTACAACGCCCACAATGTGTATATCATGACCGACAAGGCC-3’ 
and 5’- GGCCTTGTCGGTCATGATATACACATTGTGGGCGTTGTAG-3’ to yield 
plasmid pAcGFP1-C1’ . A TGN38 fragment was amplified from TGN38-pHluorin 
(generous gift from Terry E Machen; originally generated in the Miesenbock group) with 
oligonucleotides 5’-AGCTTATGTACAAAACCGGTGGAAGCG-3’ and 5’-
CTTATCATGTCTGCTCGAAGCG-3’ and inserted into the BsrgI and SalI sites of 
pAcGFP1-C1’  affording CMV-AcGFP-TGN38 . An AcGFP-TGN38 fragment was 
amplified from CMV-AcGFP-TGN38  with 5’-
TTACTAACTAGTATGGTGAGCAAGGGCGC-3’ and 5’-
CCTCTACAAATGTGGTATGGCTG-3’, digested with SpeI and HindIII and cloned into 
the NheI and HindIII sites of pET 28a-Intein C in order to obtain Q. 
 
T7-Intein C-Cer-TGN38-His (R).  Cerulean was amplified from pmscvcerulean (generous 
gift of doyle group) with the oligonucleotides 5’-
CTAATTGCTAGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAG-3’ and 5’-
CTAGTGCTTGTACAGCTCGTCCATGCC-3’ and inserted into the NheI and BsrgI sites 
of CMV-AcGFP-TGN38  yielding CMV-Cer-TGN38. A Cer-TGN38 fragment was 
amplified from CMV-Cer-TGN38 with 5’-TTACTAACTAGTATGGTGAGCAAGGGCGC-3’ 
and 5’-CCTCTACAAATGTGGTATGGCTG-3’, digested with SpeI and HindIII and cloned 




T7-Intein C-AcGFP-His (S).  An AcGFP fragment was amplified from pAcGFP1-C1’  with 
the oligonucleotides 5’-TTACTAACTAGTATGGTGAGCAAGGGCGC-3’ and 5’-
CCTCTACAAATGTGGTATGGCTG-3’, digested with SpeI and SalI and inserted into the 
NheI and SalI sites of pET 28a-intein C. 
 
T7-Intein C-Cer-His (T). A cerulean fragment was amplified from pCer-C1  with the 
oligonucleotides 5’-TTACTAACTAGTATGGTGAGCAAGGGCGC-3’ and 5’-
CCTCTACAAATGTGGTATGGCTG-3’, digested with SpeI and SalI and inserted into the 
NheI and SalI sites of pET 28a-intein C. 
 
4.8.3 Synthesis 
 4-(Aminomethyl)-benzyl alcohol21 4-2, 2,2,2-Trifluoro-N-(4-hydroxymethyl-
benzyl)-acetamide11 4-3, 1-(2-Amino-7H-purin-6-yl)-1-methyl-pyrrolidinium chloride11 4-5 
and 3’,6’-Dipyrrolidino-6-carboxyrhodamine35,22 4-8, were synthesized following the 
published procedures. 
N-[4-(2-Amino- 9H-purin-6-yloxymethyl)-benzyl]-2,2,2-trifluoro-aceta mide (4-6). 11 
NaH (95 %) (36 mg; 1.5 mmol) was added to a stirred solution of 4-3 (90.1 mg; 0.386 
mmol) in 1 mL anhydrous DMF under argon atmosphere. Guanine derivative 4-5 (99.4 
mg; 0.415 mmol) and DMAP (6.0 mg; 49 µmol) were added and the solution stirred at 
room temperature for 2 h. Water (0.1 mL) was added to quench the reaction and the 
solvent removed in vacuo. The crude product was purified by flash chromatography on 
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silica gel (CH2Cl2/MeOH 10:1; Rf = 0.26) providing 4-6 as white powder (100 mg, 68 %). 
1H NMR (DMSO-d6, 400 MHz): δ 12.40 (s, 1H); 10.00 (s, 1H); 7.80 (s, 1H); 7.48 (d, J = 
8.2 Hz, 2H); 7.29 (d, J = 8.2 Hz, 2H); 6.29 (s, 2H); 5.45 (s, 2H); 4.39 (d, J = 6.0 Hz, 2H). 
 
O6-(4-Aminomethyl-benzyl)guanine 4-7. 11 Methylamine (3 mL; 33 % in EtOH) was 
added to a suspension of 4-6 in 1.5 mL methanol. The resulting solution was stirred at 
room temperature for 24 h. Concentration under reduced pressure yielded the product 
as white powder (93 mg, 100 %). 1H NMR (DMSO-d6, 400 MHz): δ 7.81 (s, 1H); 7.42 (d, 
J = 8.2 Hz, 2H); 7.33 (d, J = 8.2 Hz, 2H); 6.27 (s, 2H); 5.44 (s, 2H); 3.71 (s, 2H). 
 
3’,6’-Dipyrrolidino-6-amidobenzylguanine rhodamine (BGRH) 4-9.36 HOBT (3.0 mg, 
22 µmol) and DCC (13.0 mg, 63.0 µmol) were added to a solution of 4-8 (5.0 mg, 10 
µmol) in 0.5 mL anhydrous DMF at 0 °C and stirred f or 30 minutes. Benzyl guanine 4-7 
(4.0 mg, 15 µmol) was added to the solution and stirred for 30 minutes. The solution was 
allowed to reach room temperature and stirred for 24 h. The organic solvent was 
removed under reduced pressure and the residue purified by flash chromatography on 
silica gel (CH2Cl2/MeOH 10:1) providing 4-9 as red powder (5.2 mg, 68 %).  
 
 Rhodamine B base23 4-11, rhodamine B piperazine amide23 4-12 and rhodamine 
B 4-(3-carboxypropionyl)piperazine amide23  4-13 and glycine S-benzyl ester, 
hydrochloride salt37 4-14 were synthesized following the published procedure. 
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Rhodamine B 4-(3-amidopropionyl, 4-glycine S-benzyl  ester)piperazine amide 4-
15. HOBT (25.0 mg, 0.185 mmol) and EDCI (31.2 mg, 0.163 mmol) were added to a 
solution of 4-13 (100 mg, 0.163 mmol) in 2 mL DMF at 0 °C and stirr ed for 30 minutes. 
NaHCO3 (12.0 mg, 0.141 mmol) and 4-14 (35.6 mg, 0.163 mmol) were added and the 
solution stirred for 1 h. The solution was allowed to reach room temperature and stirred 
for 24 h. The organic solvent was removed under reduced pressure and the residue 
purified by flash chromatography on silica gel (CH2Cl2/MeOH 10:1) providing 4-15 as red 
powder (85 mg, 67 %). 1H NMR (CD3OD, 400 MHz): δ 7.79-7.76 (m, 2H); 7.71-7.69 (m, 
1H);  7.53-7.50 (m, 1H); 7.28 (d, J = 9.6 Hz, 2H); 7.25-7.19 (m, 5H); 7.08-7.05 (m, 2H); 
6.95 (d, J = 2.2 Hz; 2H); 4.07 (s, 2H); 4.05 (s, 2H); 3.67 (q, J = 7.2 Hz, 8H); 3.41 (br s, 
8H); 2.60 (br s, 2H); 2.55 (br s, 2H), 1.30 (t, J =7.2 Hz, 12H). ESI-MS: m/z 774.4 [M+]. 
ESI-HRMS calculated for [M+] C45 H52 N5 O5 S1 774.3689, found 774.3694. 
 
Rhodamine B split-intein N 4-16.38 A 20 mM solution of Rhodamine derivative 4-15 (161 
µL, 3.23 µmol) in DMF was added to a solution of the polypeptide CISGDSLISLASR 
(3.23 µmol) in 2.15 mL aqueous buffered solution (6 M guanidinium hydrochloride, 100 
mM Na-phosphate pH 7.60, 4 % thiophenol) and stirred at room temperature for 24 h. 
The crude product was purified by reversed phase HPLC (5.1 mg, 80 %). MALDI-MS: 
m/z 1971.0 [M+]. MALDI-HRMS calculated for [M+] C92 H140 N21 O25 S1 1971.0044, found 
1971.0170. 
 
Benzyl guanine zinquin 4-18. HOBT (11.0 mg, 81.4 µmol) and EDCI (16.0 mg, 83.5 
µmol) were added to a solution of 4-17 (27.3 mg, 70.6 µmol) in 2 mL anhydrous THF at 
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0 °C and stirred for 30 minutes. Benzyl guanine 4-7 (18.8 mg, 69.6 µmol) was dissolved 
in 2 mL anhydrous DMF and added dropwise to the solution and stirred for 30 minutes. 
The solution was allowed to reach room temperature and stirred for 24 h. The organic 
solvent was removed under reduced pressure and the residue purified by flash 
chromatography on silica gel (CH2Cl2/MeOH 10:1) providing 4-17 as off-white powder 




4-carboxypropionamide 4-20 was synthesized following the published procedures.26 
 
3-methyl isonitrosoacetanilide29 4-22, 6-methyl isatin30 4-23, 4-methyl isatin30 4-24, 4-
methyl isonitrosoacetanilide29 4-26, 5-methyl isatin30 4-27 and 6,6’-dimethyl-2,2’-
bicinchoninic acid 4-28 were synthesized following the published procedures. 
 
6,6’-Dimethyl-2,2’-bicinchoninic acid 4-28. 34 A mixture of 4-27 (4.02 g, 24.8 mmol), 
acetoin (1.15 g, 13.0 mmol) and 20 g of 33 % KOH-solution (w/w) was heated at 100 °C 
for 24 h. The suspension was allowed to cool, the K-salt filtered and dissolved in hot 
water. The product was precipitated by acidification with acetic acid, filtered and dried 
obtaining 4-28 as white powder (1.74 g, 38 %). 1H NMR (DMSO-d6, 400 MHz): δ 8.69 (s, 
2H); 8.49 (s, 2H); 7.98 (d, J = 8.6 Hz, 2H); 7.54 (d, J = 8.6 Hz, 2H); 3.32 (s, 6H). EI-




6,6’-Dimethyl-2,2’-bicinchoninic acid dichloride 4- 29. Bicinchoninic acid derivative 4-
28 (250 mg, 0.672 mmol) was dissolved in 5 mL SOCl2 and heated under reflux 
overnight. Thionyl chloride was removed under reduced pressure to yield 4-29 (325 mg, 
100 %). The product was used without any further purification. 
 
6,6’-Dimethyl-2,2’-bicinchoninic acid diethylester 4-30. To a solution of NaOEt (3.04 
mmol) in 10 mL ethanol 4-29 (250 mg, 0.611 mmol) was added and the solution stirred 
at room temperature for 24 h. After concentration of the solution water (20 mL) was 
added and the solution extracted three times with 30 mL CHCl2. The organic layers were 
combined and the solvent removed under reduced pressure to yield 4-30 as white 
powder (130 mg, 50 %). 1H NMR (CDCl3, 400 MHz): δ 9.24 (s, 2H); 8.56 (s, 2H); 8.21 (d, 
J = 8.6 Hz, 2H); 7.65 (d, J = 8.6 Hz, 2H); 4.59 (q, J = 7.2 Hz, 4H); 2.62 (s, 6H); 1.55 (t, J 
= 7.2 Hz, 6H). EI-HRMS calculated for [M+] C26 H24 N2 O4 428.17361, found 428.17078. 
 
6-Methyl-6’-bromomethyl-2,2’-bicinchoninic acid die thylester 4-31.  To a 10 mL CCl4 
solution of 4-30 (113 mg, 263 µmol) was added NBS (46.7 mg, 263 µmol) and a catalytic 
amount of benzoyl peroxide (≈ 3 mg). The mixture was heated under reflux for 24 h and 
concentrated under reduced pressure. The crude product was purified by 
chromatography on silica gel (Hexanes/EtOAc 20:1) providing 4-31 as white powder 
(39.9 mg, 30 %). 1H NMR (CDCl3, 400 MHz): δ 9.31 (s, 1H); 9.23 (s, 1H); 8.85 (s, 1H); 
8.56 (s, 1H); 8.30 (d, J = 8.6 Hz, 1H); (8.22 (d, J = 8.6 Hz, 1H); 7.85 (d, J = 8.6 Hz, 1H); 
218 
 
7.66 (d, J = 8.6 Hz, 1H); 4.73 (s, 2H); 4.59 (q, J = 7.2 Hz, 4H); 2.62 (s, 3H); 1.55 (t, J = 
7.2 Hz, 6H). EI-HRMS calculated for [M+] C26 H23 Br N2 O4 506.08412, found 506.07996. 
 
6,6’-Dimethyl-2,2’-bicinchoninic acid di- tert-butylester 4-34.  EDCI (1.567 g, 8.12 
mmol) was added to a solution of 4-28 (1.375 g, 3.69 mmol), DMAP (0.451 g, 3.69 
mmol) and t-BuOH (0.629 g, 8.49 mmol) in 50 mL CH2Cl2 at 0 °C and stirred for 2 h. The 
solution was allowed to reach room temperature and stirred for 24 h. The organic solvent 
was removed under reduced pressure and the residue purified by flash chromatography 
on silica gel (Hexanes/EtOAc 7:3) providing 4-34 as white powder (492 mg, 28 %). 1H 
NMR (CDCl3, 400 MHz): δ 9.14 (s, 2H); 8.51 (s, 2H); 8.19 (d, J = 8.6 Hz, 2H); 7.53 (d, J 
= 8.6 Hz, 2H); 2.61 (s, 6H); 1.75 (s, 18H). EI-HRMS calculated for [M+] C30 H32 N2 O4 
484.23621, found 484.23364. 
 
6-Methyl-6-bromomethyl-2,2’-bicinchoninic acid di- tert-butylester 4-35.  To a 30 mL 
CCl4 solution of 4-34 (480 mg, 990 µmol) was added NBS (176 mg, 991 µmol) and a 
catalytic amount of benzoyl peroxide (≈ 10 mg). The mixture was heated under reflux for 
24 h and concentrated under reduced pressure. The crude product was purified by 
chromatography on silica gel (Hexanes/EtOAc 30:1) providing 4-35 as white powder 
(124 mg, 28 %). 1H NMR (CDCl3, 400 MHz): δ 9.21 (s, 1H); 9.13 (s, 1H); 8.81 (s, 1H); 
8.51 (s, 1H); 8.28 (d, J = 8.6 Hz, 1H); 8.19 (d, J = 8.6 Hz, 1H); 7.82 (d, J = 8.6 Hz, 1H); 
7.53 (d, J = 8.6 Hz, 1H); 4.73 (s, 2H); 2.62 (s, 3H); 1.76 (s, 18H). EI-HRMS calculated for 




2-Bromomethyl-9-methyl-4,7-diphenyl-1,10-phenanthro line 4-38. To a 10 mL CCl4 
solution of 4-37 (100 mg, 277 µmol) was added NBS (49.4 mg, 277 µmol) and a catalytic 
amount of benzoyl peroxide (≈ 3 mg). The mixture was heated under reflux for 24 h and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (Hexanes/EtOAc 7:3; Rf = 0.24) providing 4-38 as white 
powder (49.3 mg, 41 %). 1H NMR (CDCl3, 400 MHz): δ 7.85-7.78 (m, 4H); 7.55-7.49 (m, 
10H); 5.03 (s, 2H); 3.01 (s, 3H). 13C NMR (CDCl3, 400 MHz): δ 159.0; 156.4; 149.6; 
148.6; 145.9; 145.3; 137.8; 137.7; 129.58; 129.53; 128.53; 128.51; 128.48; 128.4; 125.8; 
124.8; 124.4; 124.2; 123.6; 122.7; 35.1; 25.92. EI-HRMS calculated for [M+] C26 H19 Br 
N2 438.07316, found 438.07348. 
 
4.8.4 Analysis of FRET Pair MTS-AcGFP-AGT-Rhodamine  
 The properties of the FRET pair were calculated utilizing equations 1-5.39 The 
molar extinction coefficient of the acceptor rhodamine was derived from the absorption 
spectrum by the Lambert-Beer equation, in which A is the absorption intensity, c the 
concentration and l the path length (equation 1). The overlap integral J (λ) was 
determined via the integrals of the fluorescence intensities of the donor FD (equation 2). 
The Foerster radius R0 was calculated with the parameters κ
2 (orientation of the 
transition dipoles in space = 2/3 for the assumed dynamic random averaging of donor 
and acceptor), n (refractive index = 1.4), QD (quantum yield) and overlap integral J (λ) (in 
units of M-1 cm-1 (nm)4) (equation 3). The quantum yield of AcGFP (MTS-AcGFP-AGT) 
was determined by comparison of the integrated intensity of the unknown AcGFP with a 
220 
 
fluorescein standard solution in 0.1 M NaOH (resulting quantum yield of AcGFP QD = 
57.3 %).40,41 Equation 4 was used to calculate the energy transfer efficiency (FRET 
efficiency) E from the fluorescence intensity of the donor in the presence (FDA) and 
absence (FD) of energy transfer. The distance between donor and acceptor r was 
derived with the previously calculated parameters E and R0 by equation 5.  
 
 
  (equation 1) 
 
    (equation 2) 
 
 
    (equation 3) 
 
















































Purification of expressed proteins:  The proteins were purified either by a Ni2+-NTA 
superflow column or by Ni2+-NTA superflow batch purification according to the Quiagen 
protocol (The Quiagen expressionist volume 6). 
 
UV-vis spectroscopy:  UV-vis absorption spectra were recorded at 25 °C u sing a Varian 
Bio50 UV-vis spectrometer with constant-temperature accessory.  
 
Fluorescence spectroscopy: Emission and excitation spectra were recorded with a 
PTI fluorimeter utilizing FELIX software. All fluorescence spectra have been corrected 
for the spectral response of the detection system (emission correction parameters 
provided by the manufacturer) and for the spectral irradiance of the excitation channel by 
a calibrated photodiode. 
 
NMR spectroscopy:  All NMR spectra (1H, 13C) were recorded on either a Bruker DRX 










 (1) Richmond, T. A.; Takahashi, T. T.; Shimkhada, R.; Bernsdorf, J. 
Biochemical and Biophysical Research Communications 2000, 268, 462-465. 
 (2) Petrat, F.; Weisheit, D.; Lensen, M.; de Groot, H.; Sustmann, R.; Rauen, 
U. Biochemical Journal 2002, 362, 137-147. 
 (3) Sandell, E. B. Colorimetric determination of traces of metals; Interscience 
Publishers, inc.: New York, N.Y.,, 1944. 
 (4) Stokes, H. N.; Cain, J. R.; United States. Bureau of standards. On the 
colorimetric determination of iron with special reference to chemical reagents; Gov't 
print. off.: Washington,, 1907. 
 (5) Herd, S. M.; Camakaris, J.; Christofferson, R.; Wookey, P.; Danks, D. M. 
Biochemical Journal 1987, 247, 341-347. 
 (6) Williams, R. J. P.; da Silva, J. Coordination Chemistry Reviews 2000, 
200, 247-348. 
 (7) Breuer, W.; Shvartsman, M.; Cabantchik, Z. I. International Journal of 
Biochemistry & Cell Biology 2008, 40, 350-354. 
 (8) Ludwig, C.; Pfeiff, M.; Linne, U.; Mootz, H. D. Angewandte Chemie-
International Edition 2006, 45, 5218-5221. 
 (9) Sun, W. C.; Yang, J.; Liu, X. Q. Journal of Biological Chemistry 2004, 
279, 35281-35286. 
 (10) Keppler, A.; Pick, H.; Arrivoli, C.; Vogel, H.; Johnsson, K. Proceedings of 
the National Academy of Sciences of the United States of America 2004, 101, 9955-
9959. 
 (11) Keppler, A.; Gendreizig, S.; Gronemeyer, T.; Pick, H.; Vogel, H.; 
Johnsson, K. Nature Biotechnology 2003, 21, 86-89. 
223 
 
 (12) Valeur, B. Molecular fluorescence : principles and applications; Wiley-
VCH: Weinheim ; New York, 2002. 
 (13) Lackie, J. M.; Dow, J. A. T.; Blackshaw, S. E. The dictionary of cell 
biology; 2nd ed.; Academic Press: London ; San Diego, 1995. 
 (14) Hicks, G. R.; Raikhel, N. V. Annual Review of Cell and Developmental 
Biology 1995, 11, 155-188. 
 (15) Miesenbock, G.; De Angelis, D. A.; Rothman, J. E. Nature 1998, 394, 
192-195. 
 (16) Humphrey, J. S.; Peters, P. J.; Yuan, L. C.; Bonifacino, J. S. Journal of 
Cell Biology 1993, 120, 1123-1135. 
 (17) Luzio, J. P.; Brake, B.; Banting, G.; Howell, K. E.; Braghetta, P.; Stanley, 
K. K. Biochemical Journal 1990, 270, 97-102. 
 (18) The transfections and microscopy was carried out by Reagan McRae 
 (19) Pap, E. H. W.; Dansen, T. B.; van Summeren, R.; Wirtz, K. W. A. 
Experimental Cell Research 2001, 265, 288-293. 
 (20) Buchman, A. R.; Berg, P. Molecular and Cellular Biology 1988, 8, 4395-
4405. 
 (21) Lee, J.; Kang, M.; Shin, M.; Kim, J. M.; Kang, S. U.; Lim, J. O.; Choi, H. 
K.; Suh, Y. G.; Park, H. G.; Oh, U.; Kim, H. D.; Park, Y. H.; Ha, H. J.; Kim, Y. H.; Toth, 
A.; Wang, Y.; Tran, R.; Pearce, L. V.; Lundberg, D. J.; Blumberg, P. M. Journal of 
Medicinal Chemistry 2003, 46, 3116-3126. 
 (22) Woodroofe, C. C.; Lim, M. H.; Bu, W. M.; Lippard, S. J. Tetrahedron 
2005, 61, 3097-3105. 
 (23) Nguyen, T.; Francis, M. B. Organic Letters 2003, 5, 3245-3248. 
224 
 
 (24) Sumalekshmy, S.; Henary, M. M.; Siegel, N.; Lawson, P. V.; Wu, Y.; 
Schmidt, K.; Bredas, J. L.; Perry, J. W.; Fahrni, C. J. Journal of the American Chemical 
Society 2007, 129, 11888-+. 
 (25) The synthesis was carried out by Dr. S. Sumalekshmy 
 (26) Kikkeri, R.; Traboulsi, H.; Humbert, N.; Gumienna-Kontecka, E.; Arad-
Yellin, R.; Melman, G.; Elhabiri, M.; Albrecht-Gary, A. M.; Shanzer, A. Inorganic 
Chemistry 2007, 46, 2485-2497. 
 (27) The synthesis was carried out by Dr. Jing Li 
 (28) The calculations were carried out by Dr. Christoph Fahrni. 
 (29) Su, W. K.; Zhong, W. H.; Bian, G. F.; Shi, X. J.; Zhang, J. P. Organic 
Preparations and Procedures International 2004, 36, 499-547. 
 (30) Marvel, C. S.; Hiers, G. S. Organic Syntheses 1925, 5, 71-74. 
 (31) Grimshaw, J.; Begley, W. J. Synthesis-Stuttgart 1974, 496-498. 
 (32) Sadler, P. W. Journal of Organic Chemistry 1956, 21, 169-170. 
 (33) Sandmeyer, T. Helvetica Chimica Acta 1919, 2, 234-242. 
 (34) Lesesne, S. D.; Henze, H. R. Journal of the American Chemical Society 
1942, 64, 1897-1900. 
 (35) The synthesis was carried out by Dr. Jing Li 
 (36) The synthesis was carried out by Dr. Jing Li 
 (37) Alsina, J.; Yokum, T. S.; Albericio, F.; Barany, G. Journal of Organic 
Chemistry 1999, 64, 8761-8769. 
225 
 
 (38) Schuler, B.; Pannell, L. K. Bioconjugate Chemistry 2002, 13, 1039-1043. 
 (39) Lakowicz, J. R. Principles of fluorescence spectroscopy; 3rd ed.; 
Springer: New York, 2006. 
 (40) Demas, J. N.; Crosby, G. A. Journal of Physical Chemistry 1971, 75, 991-
&. 
 (41) Magde, D.; Wong, R.; Seybold, P. G. Photochemistry and Photobiology 



















 The enantioselective catalysis of the cyclopropanation of styrene with EDA by 
semi-synthetic proteins, based on myoglobin reconstituted with ruthenium porphyrins, 
failed (see chapter II and chapter III). The catalytic activity of ruthenium porphyrin 
ceased upon reconstitution of the apoprotein. Therefore the deactivation of the catalyst 
has to be due to the interaction of the synthetic cofactor with the residues of the active 
site. The successful reconstitution of myoglobin with a synthetic cofactor was confirmed 
by UV-Vis spectroscopy; however, no structural information, such as orientation of the 
cofactor in the active site pocket, can be gained from spectral shifts in UV-Vis spectra. 
The orientation of the synthetic cofactor that is different from the orientation of native 
heme cofactor may have led to the inhibition of the cyclopropanation reaction. Therefore 
the structure of the cofactor embedded in the active site pocket data can be obtained by 
X-ray crystallography and reveal any differences to the native heme pocket. Differences 
from the native myoglobin active site are expected to be more pronounced in case of the 
myoglobin single mutants (H64, H93) and especially the double mutant (H64G/H93G) 
due to the removal of hydrogen bond donors and the increase of the size of the active 
site pocket. Besides, flaws in the architecture of the active site, such as a partial collapse 
of the active site pocket caused by the mutations, can be detected by the X-ray 
structures. Hence, X-ray structures can direct future efforts to convert myoglobin, 
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reconstituted with ruthenium porphyrins, to an active cyclopropanase. Activity may be 
induced by site-directed mutagenesis based on the X-ray crystallography data. 
 A 1:1 stochiometry (ligand:metal) of the metal-chelator domain is required for the 
successful sensing of labile metal pools of copper, iron, and zinc by semi-synthetic 
proteins (see chapter IV). All attempts to failed to generate a chelator that forms Cu(I)-
complexes with the necessary 1:1 stochiometry. The design of the desired copper 
chelator was based on the linking of bathocuproine or bicinchoninic acid derivatives with 
a diethanolamine linker by the formation of an alkoxide and subsequent reaction with a 
halide. Other methods to connect these copper(I) chelators may be more successful. 
Alternative reaction designs should be based on established coupling reactions (usually 
palladium based reactions), such as the Heck or Sonogashira reaction.  
 A ratiometric zinc(II)-chelator (with a 1:1 stochiometry) was attached to an AGT 
based protein and the resulting semi-synthetic protein exhibited strong changes in 
fluorescence in the presence of zinc(II). These in vitro studies represent an imperative 
step towards the goal of in vivo cell imaging of labile zinc(II) pools. The protein-chelator 
conjugate will be used to study labile zinc(II) pools in mitochondria, the endoplasmatic 
reticulum, the Golgi apparatus, and the nucleus. Consequently, mammalian cells have to 
be transfected with plasmids encoding the AGT with the appropriate localization 
sequences. These cells are subsequently incubated with the zinc(II) chelator upon which 
the semi-synthetic protein is formed in vivo and the conjugate directed to the subcellular 
location. The semi-synthetic protein can also be generated in vitro by over-expressing 
the protein domain in bacteria and reacting the purified protein with the zinc(II) chelator. 
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The formed fluorescent chelator-protein conjugate can be introduced into the cell via 
microinjection. 
  
 
 
